Compositions and methods for inducing and enhancing Anti-cancer immune responses
A multi-specific binding protein with TAA and immune modulatory domains addresses the limitations of checkpoint inhibitors by selectively targeting cancer cells and enhancing immune responses, providing a more effective and less toxic treatment for cancer.
Patent Information
- Application Number
- PCT/US2026/027381
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-07-18
- Filing Date
- 2026-05-08
- Publication Date
- 2026-11-12
AI Technical Summary
Existing cancer treatments using checkpoint inhibitors like PD-1, PD-L1, and CTLA-4 are only effective when there is a pre-existing immune response and can lead to autoimmune diseases due to systemic targeting, necessitating more targeted and less toxic approaches to stimulate and enhance anti-tumor immune responses.
Development of a multi-specific binding protein comprising Fc regions linked to tumor-associated antigen (TAA) binding domains and immune modulatory domains, which can selectively target cancer cells and immune cells, enhancing immune activation while minimizing systemic toxicity.
The multi-specific binding protein effectively stimulates the immune system to target cancer cells, enhancing anti-tumor responses and reducing systemic toxicity, making it a more targeted and effective treatment option.
Smart Images

Figure US2026027381_12112026_PF_FP_ABST
Abstract
Description
Attorney Docket No.: 115631-000220PC-1549288COMPOSITIONS AND METHODS FOR INDUCING AND ENHANCING ANTI-CANCER IMMUNE RESPONSES CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to U.S. Provisional Application No. 63 / 803,333, filed May 9, 2025, and U.S. Provisional Application No. 63 / 846,547, filed July 18, 2025, the disclosures of which are herein incorporated by reference in their entirety for all purposes.BACKGROUND
[0002] Cancer is often accompanied by immunosuppression, where the tumor suppresses the immune response. This can result in two scenarios: tumors with no detectable immune response, or tumors with tumor-infiltrating lymphocytes (TILs), which indicate an anti-tumor immune response that is insufficient to control tumor growth and metastasis. Recent research has demonstrated that, in certain patients and for specific tumors, an anti-tumor immune response can exist and be amplified using checkpoint inhibitors, such as antibodies targeting programmed cell death protein 1 (PD-1), programmed cell death ligand 1 (PD-L1, PDL1), or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4, CTLA4). However, these agents are typically effective only when there is a pre-existing immune response to the tumor. Moreover, since these agents act broadly on the immune system rather than targeting the cancer-specific immune response, they can lead to autoimmune diseases with significant morbidity and mortality. Consequently, there is a critical need for innovative approaches to i) stimulate the immune system to target cancer; ii) enhance the efficacy of checkpoint inhibitors while minimizing additional toxicity, and iii) more selectively inhibit tumor-induced immunosuppression to reduce systemic toxicity.SUMMARY
[0003] In one aspect, the present disclosure provides a multi-specific binding protein comprising (a) a first polypeptide comprising a first Fc region that is linked to a first domain at the N-terminus and a second domain at the C-terminus; and (b) a second polypeptide comprising a second Fc region that is linked to a third domain at the N-terminus and a fourth domain at the C-terminus, wherein each of the first, second, third, and fourth domains independently comprises a tumor-associated antigen (TAA) binding domain (TAA-BD) or an immune modulatory domain (IMD); wherein the multi-specific binding protein comprises atleast one TAA-BD and at least one IMD; and wherein the first Fc region and the second Fc region form an Fc dimer.
[0004] In some embodiments, each domain comprises an active domain (AD) capable of binding to a cell surface protein. In some embodiments, each AD comprises an antibody, a cytokine, a receptor, a ligand for a receptor, or any derivative, fragment or fusion thereof. In some embodiments, the antibody comprises a single-chain variable fragment (scFv).
[0005] In some embodiments, each AD of the one or more TAA-BDs binds to a cancer cell surface protein. In some embodiments, the cancer cell surface protein is selected from the group consisting of STEAP1, B7-H3, EpCAM, ABCC4, ANO7, CEACAM1, FOLH1, OR51E1, OR51E2, PSCA, SLC30A4, SLC45A3, SPON2, STEAP2, TARP, TMEFF2, TMPR8, TMPRSS2, VEGF, CD274 (PD-L1), CD273 (PD-L2), CTLA4, and V domain immunoglobulin suppressor of T-cell activation (VISTA, VSIR), HER2 (ERBB2), HER3, Trop2 (TACSTD2), B7-H4 (VTCN1), MUC1, EGFRvIII, BCMA, CD19, CD20, CD22, CD33, CD123, CD138, CD171, PSMA, Ig-kappa, LeY, ROR1, FAP, FR, Glypican-3, IL13Ralpha2, mesothelin, and an NKG2D ligand. In some embodiments, the cancer cell surface protein comprises STEAP1, B7-H3, EpCAM, or any derivative, fragment or fusion thereof.
[0006] In some embodiments, each AD of the one or more TAA-BDs comprises an anti-STEAP1 antibody, an anti-B7-H3 antibody, and / or an anti -EpCAM antibody. In some embodiments, the anti-STEAPl antibody comprises a VH amino acid sequence having at least 80% identity to SEQ ID NO: 6 and a VL amino acid sequence having at least 80% identity to SEQ ID NO: 7. In some embodiments, the anti-B7-H3 antibody comprises a VH amino acid sequence having at least 80% identity to SEQ ID NO: 4 and a VL amino acid sequence having at least 80% identity to SEQ ID NO: 5. In some embodiments, the anti -EpCAM antibody comprises a VH amino acid sequence having at least 80% identity to SEQ ID NO: 109 or 111 and a VL amino acid sequence having at least 80% identity to SEQ ID NO: 110 or 112.
[0007] In some embodiments, each AD of the one or more IMDs binds to an immune cell surface protein. In some embodiments, the immune cell surface protein is selected from the group consisting of CD3y (CD3 gamma chain), CD36 (CD3 delta chain), CD3s (CD3 epsilon chain), CD3i (CD3 zeta chain, CD247), CD2, CD27, CD28, CD69, ICOS, IL-2RB, PTPRC (CD45), CD48, SELL, CD137 (4-1BB, TNFRSF9), CD134 (0X40, TNFRSF4), IL-7R, IL-15R, IL-21R, CTLA4, PD-L1, PD-L2, PD-1 (PDCD-1, CD279), TIGIT, and HAVCR2(TIM3). In some embodiments, the immune cell surface protein comprises CD3, IL-21R, IL-2R, CD28, PD-L1, PD-L2, PD-1, or any derivative, fragment or fusion thereof.
[0008] In some embodiments, each AD of the one or more IMDs comprises an anti-CD3 antibody, an anti-PD-Ll antibody, IL-21, IL-2, an CD80 extracellular domain (ECD), CD86 ECD, PD-1 ECD, PD-L1 ECD, and / or any derivative, fragment or fusion thereof. In some embodiments, the anti-CD3 antibody comprises a VH amino acid sequence having at least 80% identity to SEQ ID NO: 8 and a VL amino acid sequence having at least 80% identity to SEQ ID NO: 9. In some embodiments, the PD-L1 ECD or a fragment thereof comprises an amino acid sequence having at least 80% identity to SEQ ID NO: 117. In some embodiments, the IL-21 or a fragment thereof comprises an amino acid sequence having at least 80% identity to SEQ ID NO: 1. In some embodiments, the CD80 ECD or a fragment thereof comprises an amino acid sequence having at least 80% identity to SEQ ID NO: 2. In some embodiments, the CD80 ECD or a fragment thereof is a CD80 ECD variant with increased binding affinity for PD-L1. In some embodiments, the CD80 ECD variant comprises one or more substitutions at amino acid positions 8, 9, 10, 11, 13, 35, 47, 54, 55, 56, 57, 58, 60, 62, 63, 68, 70, 71, 107, 158, 159, 160, and 161, and wherein the substitutions and the positions are determined with reference to SEQ ID NO: 2. In some embodiments, the one or more substitutions are selected from Table 16. In some embodiments, the CD80 ECD or a fragment thereof is a CD80 ECD variant with reduced binding affinity for CD28. In some embodiments, the CD80 ECD variant comprises one or more substitutions at amino acid positions 29, 31, 33, 36, 38, 50, 81, 83, 85, 88, 90, 91, 92, 93, 94, and 97, and wherein the substitutions and the positions are determined with reference to SEQ ID NO: 2. In some embodiments, the one or more substitutions are selected from Table 17. In some embodiments, the CD80 ECD or a fragment thereof is a CD80 ECD variant with increased binding affinity for PD-L1 and reduced binding affinity for CD28, wherein the CD80 ECD variant comprises (i) one or more substitutions at amino acid positions 8, 9, 10, 11, 13, 35, 47, 54, 55, 56, 57, 58, 60, 62, 63, 68, 70, 71, 107, 158, 159, 160, and 161, and (ii) one or more substitutions at amino acid positions 29, 31, 33, 36, 38, 50, 81, 83, 85, 88, 90, 91, 92, 93, 94, and 97, and wherein the substitutions and the positions are determined with reference to SEQ ID NO: 2. In some embodiments, the CD86 ECD or a fragment thereof comprises an amino acid sequence having at least 80% identity to SEQ ID NO: 3. In some embodiments, the PD-1 ECD or a fragment thereof comprises an amino acid sequence having at least 80% identity to SEQ ID NO: 116.
[0009] In some embodiments, one or more ADs each binds to an inhibitory domain (ID) that prevents the AD from binding to the cell surface protein. In some embodiments, the ID comprises an IL- lb pro-peptide, PAS peptide, and / or any derivative, fragment or fusion thereof. In some embodiments, the IL- lb pro-peptide comprises an amino acid sequence having at least 80% identity to SEQ ID NO: 12. In some embodiments, the PAS peptide comprises an amino acid sequence having at least 80% identity to SEQ ID NO: 13.
[0010] In some embodiments, the ID is linked to the AD through a domain linker. In some embodiments, the domain linker comprises an amino acid sequence selected from the group consisting of (GS)n, (GGS)n, (GGGS)n and (GGGGS)n, where n is an integer from 1 to 10. In some embodiments, the domain linker comprises an amino acid sequence having at least 80% identity to any one of SEQ ID NOs: 65-71. In some embodiments, the domain linker comprises a protease cleavage site (PCS), and wherein cleavage at the PCS by a protease releases the ID from the AD, thereby allowing the AD to bind to the cell surface protein. In some embodiments, the protease is selected from the group consisting of matrix metalloprotease 1 (MMP-1), MMP-2, MMP-3, MMP-8, MMP-9, MMP-13, MMP-14, plasmin, prostate-specific antigen (PSA), prostate-specific membrane antigen (PSMA), cathepsin D, cathepsin K, cathepsin S, a disintegrin and metalloprotease 10 (AD M10), AD M12, AD M17 (TACE), ADAM with Thrombospondin motifs (ADAMTS), caspase-1, caspase-2, caspase-3, caspase-4, caspase-5, caspase-6, caspase-7, caspase-8, caspase-9, caspase-10, caspase-11, caspase-12, caspase-13, caspase-14, tissue plasminogen activator (tPA), and urokinase plasminogen activator (uPA). In some embodiments, the PCS comprises an amino acid sequence having at least 80% identity to any one of SEQ ID NOs: 73-87.
[0011] In some embodiments, the first and / or second Fc regions are from IgG, IgM, IgA, IgD, and / or IgE. In some embodiments, the first and second Fc regions each comprises a hinge region, and wherein the Fc dimer is formed via one or more disulfide bonds in the hinge regions of the first and second Fc regions. In some embodiments, the first and / or second Fc regions comprise one or more mutations to promote heterodimerization.
[0012] In some embodiments, the first Fc region comprises a knob mutation and the second Fc region comprises a hole mutation. In some embodiments, the first Fc region comprises an amino acid sequence having at least 80% identity to SEQ ID NO: 10.
[0013] In some embodiments, the second Fc region comprises an amino acid sequence having at least 80% identity to SEQ ID NO: 11. In some embodiments, the multi-specificbinding protein described herein further comprises one or more regional linkers between the first and / or second Fc regions and the domains.
[0014] In some embodiments, each of the one or more regional linkers comprises an amino acid sequence selected from the group consisting of (GS)n, (GGS)n, (GGGS)n, and (GGGGS)n, where n is an integer from 1 to 10. In some embodiments, each of the one or more regional linkers comprises an amino acid sequence selected from any one of SEQ ID NOs: 65-71.
[0015] In some embodiments, one or more of the regional linkers are cleavable linkers comprising one or more protease cleavage sites (PCSs), and wherein cleavage at the PCS by a protease releases the domain from the first or second Fc region. In some embodiments, the protease is selected from the group consisting of matrix metalloprotease 1 (MMP-1), MMP-2, MMP-3, MMP-8, MMP-9, MMP-13, MMP-14, plasmin, prostate-specific antigen (PSA), prostate-specific membrane antigen (PSMA), cathepsin D, cathepsin K, cathepsin S, a disintegrin and metalloprotease 10 (ADAM10), ADAM12, ADAM17 (TACE), ADAM with Thrombospondin motifs (ADAMTS), caspase-1, caspase-2, caspase-3, caspase-4, caspase-5, caspase-6, caspase-7, caspase-8, caspase-9, caspase- 10, caspase-11, caspase- 12, caspase-13, caspase-14, tissue plasminogen activator (tPA), and urokinase plasminogen activator (uPA). In some embodiments, each of the one or more PCSs comprises an amino acid sequence having at least 80% identity to any one of SEQ ID NOs: 73-87. In some embodiments, the one or more cleavable regional linkers comprise an amino acid sequence having at least 80% identity to any one of SEQ ID NOs: 88-108.
[0016] In some embodiments, the first polypeptide of the multi-specific binding protein, in either N- to C- terminal direction or C- to N-terminal direction, comprises a first TAA-BD, the first Fc region, and a first IMD. In some embodiments, the second polypeptide of the multispecific binding protein, in either N- to C- terminal direction or C- to N-terminal direction, comprises a second TAA-BD, the second Fc region, and a second IMD. In some embodiments, the second polypeptide, in either N- to C- terminal direction or C- to N-terminal direction, comprises a second IMD, the second Fc region, and a third IMD. In some embodiments, the second polypeptide, in either N- to C- terminal direction or C- to N-terminal direction, comprises a second TAA-BD, the second Fc region, and a third TAA-BD. In some embodiments, the first, second, and third TAA-BDs and / or the first second, and third IMDs are the same. As disclosed herein, in some embodiments, the first, second, and third TAA-BDsand / or the first second, and third IMDs are different. In some embodiments, the first Fc region comprises a knob mutation and the second Fc region comprises a hole mutation.
[0017] As disclosed herein, in some embodiments, the first polypeptide of the multi-specific binding protein comprises an amino acid sequence having at least 80% identity to any one of SEQ ID NOs: 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, and 62. In some embodiments, the second polypeptide of the multi-specific binding protein comprises an amino acid sequence having at least 80% identity to any one of SEQ ID NOs: 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, and 63.
[0018] In some embodiments, the multi-specific binding protein binds to the cancer cell surface protein STEAP1 and the immune cell surface proteins CD3 and IL-21R. In some embodiments, the first domain comprises an anti-STEAPl antibody, the second domain comprises IL-21, the third domain comprises an anti-CD3 antibody, and the fourth domain comprises an anti-STEAPl antibody, IL-21, or an anti-CD3 antibody. In some embodiments, the IL-21 is linked to the first or second Fc region through a cleavable regional linker comprising one or more PCSs, and wherein cleavage at the one or more PCSs by a protease releases the IL-21 from the first or second Fc region. In some embodiments, the first polypeptide comprises an amino acid sequence having at least 80% identity to SEQ ID NOs: 14 or 18, and wherein the second polypeptide comprises an amino acid sequence having at least 80% identity to SEQ ID NO: 15 or 19.
[0019] In some embodiments, the multi-specific binding protein binds to the cancer cell surface protein B7-H3 and the immune cell surface proteins CD3 and IL-21R. In some embodiments, the first domain comprises an anti-B7-H3 antibody, the second domain comprises IL-21, the third domain comprises an anti-CD3 antibody, and the fourth domain comprises an anti-B7-H3 antibody, IL-21, or an anti-CD3 antibody. In some embodiments, the IL-21 is linked to the first or second Fc region through a cleavable regional linker comprising one or more PCSs, and wherein cleavage at the one or more PCSs by a protease releases the IL-21 from the first or second Fc region. In some embodiments, the first polypeptide comprises an amino acid sequence having at least 80% identity to SEQ ID NOs: 16 or 20, and wherein the second polypeptide comprises an amino acid sequence having at least 80% identity to SEQ ID NO: 17 or 21.
[0020] In some embodiments, the multi-specific binding protein binds to the cancer cell surface protein STEAP1 and the immune cell surface proteins CD3 and CD28. In some embodiments, the first domain comprises an anti-STEAPl antibody, the second domain comprises an anti-CD3 antibody, the third domain comprises CD80 or CD86, and the fourth domain comprises an anti-STEAPl antibody, CD80, CD86, or an anti-CD3 antibody. In some embodiments, the anti-CD3 antibody binds to an inhibitory domain (ID), thereby inhibiting the anti-CD3 antibody from binding to CD3 present on an immune cell. In some embodiments, the ID is linked to the anti-CD3 antibody through a cleavable domain linker comprising one or more PCSs, and wherein cleavage at the one or more PCSs by a protease releases the ID from the anti-CD3 antibody, thereby allowing the anti-CD3 antibody to bind to the CD3 present on the immune cell. In some embodiments, the ID comprises an IL-lb pro-peptide fragment comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 12 or a PAS fragment comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 13. In some embodiments, the first polypeptide comprises an amino acid sequence having at least 80% identity to any one of SEQ ID NOs: 22, 26, 30 and 34, and wherein the second polypeptide comprises an amino acid sequence having at least 80% identity to any one of SEQ ID NO: 23, 27, 31, and 35.
[0021] In some embodiments, the multi-specific binding protein binds to the cancer cell surface protein B7-H3 and the immune cell surface proteins CD3 and CD28. In some embodiments, the first domain comprises an anti-B7-H3 antibody, the second domain comprises an anti-CD3 antibody, the third domain comprises CD80 or CD86, and the fourth domain comprises an anti-B7-H3 antibody, CD80, CD86, or an anti-CD3 antibody. In some embodiments, the first polypeptide comprises an amino acid sequence having at least 80% identity to any one of SEQ ID NOs: 24, 28, 32 and 36, and wherein the second polypeptide comprises an amino acid sequence having at least 80% identity to any one of SEQ ID NO: 25, 29, 33, and 37. In some embodiments, the multi-specific binding protein binds to the cancer cell surface protein STEAP1 and the immune cell surface proteins CD28 and IL-21R. In some embodiments, the first domain comprises an anti-STEAPl antibody, the second domain comprises IL-21, the third domain comprises CD80 or CD86, and the fourth domain comprises an anti-STEAPl antibody, IL-21, CD80, or CD86. In some embodiments, the first polypeptide comprises an amino acid sequence having at least 80% identity to SEQ ID NOs: 38 or 42, and wherein the second polypeptide comprises an amino acid sequence having at least 80% identity to SEQ ID NO: 39 or 43.
[0022] In some embodiments, the multi-specific binding protein binds to the cancer cell surface protein B7-H3 and the immune cell surface proteins CD28 and IL-21R. In some embodiments, the first domain comprises an anti-B7-H3 antibody, the second domain comprises IL-21, the third domain comprises CD80 or CD86, and the fourth domain comprises an anti-B7-H3 antibody, IL-21, CD80, or CD86. In some embodiments, the first polypeptide comprises an amino acid sequence having at least 80% identity to SEQ ID NOs: 40 or 44, and wherein the second polypeptide comprises an amino acid sequence having at least 80% identity to SEQ ID NO: 41 or 45.
[0023] In some embodiments, the multi-specific binding protein binds to the cancer cell surface protein STEAP1 and the immune cell surface protein CD28. In some embodiments, the first and third domains each comprises an anti-STEAPl antibody, and the second and fourth domains each comprises CD80 or CD86. In some embodiments, the first polypeptide comprises an amino acid sequence having at least 80% identity to SEQ ID NOs: 46 or 50, and wherein the second polypeptide comprises an amino acid sequence having at least 80% identity to SEQ ID NO: 47 or 51. In some embodiments, the multi-specific binding protein binds to the cancer cell surface protein B7-H3 and the immune cell surface protein CD28. In some embodiments, the first and third domains each comprises an anti-B7-H3 antibody, and the second and fourth domains each comprises CD80 or CD86. In some embodiments, the first polypeptide comprises an amino acid sequence having at least 80% identity to SEQ ID NOs: 48 or 52, and wherein the second polypeptide comprises an amino acid sequence having at least 80% identity to SEQ ID NO: 49 or 53.
[0024] In some embodiments, the multi-specific binding protein binds to the cancer cell surface proteins STEAP1 and B7-H3, and the immune cell surface proteins CD3 and IL-21R. In some embodiments, the first domain comprises an anti-STEAPl antibody, the second domain comprises IL-21, the third domain comprises an anti-B7-H3 antibody, and the fourth domain comprises an anti-CD3 antibody. In some embodiments, the first polypeptide comprises an amino acid sequence having at least 80% identity to SEQ ID NOs: 54, and wherein the second polypeptide comprises an amino acid sequence having at least 80% identity to SEQ ID NO: 55.
[0025] In some embodiments, the multi-specific binding protein binds to the cancer cell surface proteins STEAP1 and B7-H3, and the immune cell surface proteins CD3 and CD28. In some embodiments, the first domain comprises an anti-STEAPl antibody, the seconddomain comprises an anti-CD3 antibody, the third domain comprises an anti-B7-H3 antibody, and the fourth domain comprises a CD80 or CD86. In some embodiments, the first polypeptide comprises an amino acid sequence having at least 80% identity to SEQ ID NO: 56 or 58, and wherein the second polypeptide comprises an amino acid sequence having at least 80% identity to SEQ ID NO: 57 or 59.
[0026] In some embodiments, the multi-specific binding protein binds to the cancer cell surface protein STEAP1 and the immune cell surface protein PD-L1. In some embodiments, the first and third domains each comprises an anti-STEAPl antibody, the second and fourth domains each comprises PD-1. In some embodiments, the first polypeptide comprises an amino acid sequence having at least 80% identity to SEQ ID NOs: 60, and wherein the second polypeptide comprises an amino acid sequence having at least 80% identity to SEQ ID NO: 61.
[0027] In some embodiments, the multi-specific binding protein binds to the cancer cell surface protein B7-H3 and the immune cell surface protein PD-L1. In some embodiments, the first and third domains each comprises an anti-B7-H3 antibody, the second and fourth domains each comprises PD-1. In some embodiments, the first polypeptide comprises an amino acid sequence having at least 80% identity to SEQ ID NOs: 62, and wherein the second polypeptide comprises an amino acid sequence having at least 80% identity to SEQ ID NO: 63.
[0028] In some embodiments, the first and / or second polypeptides further comprise a signal sequence at the N-terminus. In some embodiments, the signal sequence comprises an amino acid sequence having at least 80% identity to SEQ ID NO: 64. In some embodiments, the first and / or second polypeptides further comprise a 6x His tag at the C-terminus.
[0029] The present disclosure further provides a nucleic acid encoding the first or second polypeptide of the multi-specific binding protein described herein, a vector comprising the nucleic acid described herein. In some embodiments, the nucleic acid is operably linked to a promoter.
[0030] The present disclosure also provides a host cell comprising the nucleic acid or the vector described herein, and a method for producing a multi-specific binding protein described herein in such host cell. In some embodiments, the method comprises culturing the host cell of described herein under conditions suitable for the expression of the multi-specific binding protein; and recovering the produced multi-specific binding protein from the host cell or from the culture.
[0031] In another aspect, the present disclosure provides a composition comprising one or more of the multi-specific binding proteins described herein. In some embodiments, the composition described herein further comprises a chemical compound and / or biological protein capable of providing an activation signal for T cells and / or blocking an inactivation signal for T cells. The present disclosure further provides a pharmaceutical composition comprising the composition described herein, and a pharmaceutically acceptable excipient.
[0032] In yet another aspect, the present disclosure provides a method for treating a subject in need thereof, comprising administering a therapeutically effective amount of the pharmaceutical composition described herein to the subject. In some embodiments, the subject has cancer. In some embodiments, the subject has epithelial or glandular cancer, prostate cancer, or Ewing sarcoma.
[0033] In yet another aspect, the present disclosure provides a kit comprising one or more of the multi-specific binding proteins, the nucleic acid, the vector, the host cell, the composition, or the pharmaceutical composition described herein.BRIEF DESCRIPTION OF THE DRAWINGS
[0034] FIG. 1 depicts a schematic drawing of TILsRx architecture. (A) Each TILsRx binding protein comprises an Fc dimer and one, two, or three TAA-binding domains (TAA-BDs) and one, two, or three immune modulatory domains (IMDs) for a total of four binding domains. Each TAA-BD or IMD is connected to the Fc region with a linker. The Fc dimer optionally contains knob-in-hole (KiH) mutation(s). (B) Each TAA-BD or IMD comprises an active domain (AD) and optionally an inhibitory domain (ID) to keep the AD inactive. The AD and ID are connected via a linker containing a protease cleavage site (PCS) comprising at least one cleavage motif for a protease.
[0035] FIG. 2 depicts schematic drawings of exemplary TILsRx constructs with zero or one PCS. (A) shows a TILsRx construct without a PCS. (B) shows a TILsRx construct with a PCS located within an IMD. (C) shows a TILsRx construct with a PCS presented between an IMD and an Fc region.
[0036] FIG. 3 depicts schematic drawings of exemplary TILsRx constructs with two or three PCSs. (A) shows a TILsRx construct with two PCSs, one located between an IMD (e.g., IL-21 molecule) and the first Fc region, and the other located between an IMD (e.g., IL-2 molecule) and the second Fc region. (B) shows a TILsRx construct with two PCSs, each located between an IMD (e.g., IL-21 or IL-2) and either the N- or C- terminus of a Fc region.(C) shows a TILsRx construct with three PCSs. The first two PCSs are located at the N- and C- terminus of the first Fc region, each connecting to an IMD (e.g., IL-21 or IL-2). The third PCS is located between an IMD (e.g., IL-21 molecule) and the second Fc region.
[0037] FIG. 4 depicts that IL-21 induces CD28 expression and cooperates with anti-CD3 in IFN-gamma (IFNy) production in CD8+ T cells. (A) The wells of 96 well plates were coated with anti-CD3 at 0, 0.5 or 1 or 2 ug / ml. CD8+ T cells obtained from the Stanford Blood Bank were plated at 50,000 cells per well. Cells were also treated with IL-21at 50, 25 or 12.5 ng / mL or left alone untreated. Cells were incubated for 7 days and proliferation was assessed using flow cytometry. Then the cells were washed with staining buffer and stained with APC conjugated anti-CD28 or isotype control antibody. Cells were analyzed by flow cytometry using FlowJo software (Free Trial Version). Note there is no “no treatment” control as the cells did not survive the culture period without any stimulation. This confirms the utility of IL-21 in enhancing CD28 expression on T cells. (B) The supernatants from the cell cultures described in A were assayed for IFNY production after 4 days. The addition of IL-21 markedly augmented IFNY production compared with anti-CD3 antibody alone (0 ng / mL condition). Shown are IFNy levels in ng / ml.
[0038] FIG. 5 depicts schematic drawings of the first generation TILsRx constructs. (A) shows a TILsRx construct comprising two IMDs (IL-21 and CD86) and two TAA-BDs (anti-EpCAM scFvs or anti-STEAPl scFvs). (B) shows a TILsRx construct comprising two IMDs (PD-1) and two TAA-BDs (anti-EpCAM scFvs or anti-STEAPl scFvs). (C) shows a TILsRx construct comprising two IMDs (IL-21 and anti-CD3 scFv) and two TAA-BDs (anti-EpCAM scFvs or anti-STEAPl scFvs).
[0039] FIG. 6 depicts purity assessment of the TILsRx construct comprising chain A3 and chain B4: IL-21 x CD86 x a-EpCAM x a-EpCAM. The construct diagram is shown in FIG.5A. (A) shows sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis (PAGE) evaluation of the purified construct under reducing (lane 1) and non-reducing (lane 2) conditions. Ml indicates TaKaRa protein marker (Cat. No. 3452). Western Blot analysis of the construct under reducing (lane 1) and non-reducing (lane 2) conditions with mouse anti-His tag monoclonal antibody (GenScript, Cat. No. A00186) (B), Goat Anti-Human IgG-HRP (GenScript, Cat. No. A00166) (C), and goat Anti -Human IL-21 antibody (Biolegend, Cat. No. AF15001) (D). M2 indicates GenScript protein Marker (Cat. No. M00521). Pl contains amultiple-tag protein (GenScript, Cat. No. M0101, and P2 contains Human IgGl, Kappa (Sigma, Cat. No. 15154), both as positive controls.
[0040] FIG. 7 depicts purity assessment of the TILsRx construct comprising chain A3 and chain B4: IL-21 x CD86 x a-EpCAM x a-EpCAM. The construct diagram is shown in FIG.5A
[0041] FIG. 8 depicts purity assessment of the TILsRx construct comprising chain A4 and chain B5: PD-1 x PD-1 x a-STEAPlx a-STEAPl. The construct diagram is shown in FIG.5B. (A) shows SDS-PAGE evaluation of the purified construct under reducing (lane 1) and non-reducing (lane 2) conditions. Ml indicates TaKaRa protein marker (Cat. No. 3452). Western Blot analysis of the construct under reducing (lane 1) and non-reducing (lane 2) conditions with mouse anti-His tag monoclonal antibody (GenScript, Cat. No. A00186) (B) and Goat Anti -Human IgG-HRP (GenScript, Cat. No. A00166) (C). M2 indicates GenScript protein Marker (Cat. No. M00521). Pl contains a multiple-tag protein (GenScript, Cat. No. M0101, and P2 contains Human IgGl, Kappa (Sigma, Cat. No. 15154), both as positive controls.
[0042] FIG. 9 depicts purity assessment of the TILsRx construct comprising chain A4 and chain B5: PD-1 x PD-1 x a-STEAPlx a-STEAPl. The construct diagram is shown in FIG.5B
[0043] FIG. 10 depicts purity assessment of the TILsRx construct comprising chain A3 and chain B6: IL-21 x a-CD3 x a-STEAPl x a-STEAPl. The construct diagram is shown in FIG.5C. (A) shows SDS-PAGE evaluation of the purified construct under reducing (lane 1) and non-reducing (lane 2) conditions. Ml indicates TaKaRa protein marker (Cat. No. 3452). Western Blot analysis of the construct under reducing (lane 1) and non-reducing (lane 2) conditions with mouse anti-His tag monoclonal antibody (GenScript, Cat. No. A00186) (B) and Goat Anti -Human IgG-HRP (GenScript, Cat. No. A00166) (C). M2 indicates GenScript protein Marker (Cat. No. M00521). Pl contains a multiple-tag protein (GenScript, Cat. No. M0101, and P2 contains Human IgGl, Kappa (Sigma, Cat. No. 15154), both as positive controls.
[0044] FIG. 11 depicts purity assessment of the TILsRx construct comprising chain A3 and chain B6: IL-21 x a-CD3 x a-STEAPl x a-STEAPl. The construct diagram is shown in FIG.5C
[0045] FIG. 12 depicts cytotoxicity effect of the TILsRx construct comprising chain A3 and chain B6: IL-21 x a-CD3 x a-STEAPl x a-STEAPl on LNCaP clone FGC prostate cancer cells with different E / T ratios and incubation times. Shown are mean %target cell lysis values with standard deviations from triplicate wells. The construct diagram is shown in FIG. 5C.The results indicate that the A3+B6 construct is capable to activate CD8+ T cells to lyse the STEAP1 -expressing LNCaP clone FGC cells. The best condition among those tested includes a 6-hour incubation and an effector / target (E / T) ratio of 50:1 effector: target cells. % Target cell lysis = 100*(OD of Sample - OD of tumor cells plus effector cells) / (OD Maximum release - OD Minimum release).
[0046] FIG. 13 depicts ADCC assay of the TILsRx construct comprising chain A3 and chain B6: IL-21 x a-CD3 x a-STEAPl x a-STEAPl with varying concentrations on LNCaP clone FGC prostate cancer cells. The construct diagram is shown in FIG. 5C. The results indicate that the A3+B6 construct induced prostate cancer cell killing with an ECso value of 15.91 ng / mL. The construct is therefore able to activate T cells and potentially target them to LNCaP clone FGC cells.
[0047] FIG. 14 depicts exemplary cleavable linkers with one or more protease cleavage sites (PCS). (A) shows linkers in the exemplary TILsRx constructs; (B) shows an exemplary cleavable linker, and (C) shows alternative cleavable linkers.
[0048] FIG. 15 depicts exemplary second-generation TILsRx constructs: CD80 x CD3 x STEAP1 and CD3 x CD21 x STEAP1. (A) shows a TDCC assay against Raji target cells with CD8+ T cells using an anti-CD3 x CD20 antibody; (B) shows a TDCC assay against LNCaP clone FGC target cells with CD8+ T cells using the two TILsRx constructs: CD80 x CD3 x STEAP1 comprising SEQ ID Nos: 22 and 23; and CD3 x CD21 x STEAP1 comprising SEQ ID Nos: 14 and 15. The HyHEL-10 isotype antibody was tested as a negative control.
[0049] FIG. 16 depicts affinity of CD80 variants for PD-L1 (first and second SPR experiments). (A) (first SPR experiment) shows the KD values measured for several CD80 ECD variants and the CD80 IgV variant A71D. No binding was observed for the CD80 ECD variants N55D and A71E and the CD80 IgV wild type (WT) as well as the CD80 IgV variants E10Y, N55D, A71E, and A71 Y. (B) (second SPR experiment) shows the KD values measured for several CD80 ECD variants. No binding was observed for T62I, V68W, A71C, A71F, A71 S, A71W, L72F, L72W, and L72Y. For both (A) and (B), CD80 constructs were expressed in Chinese Hamster Ovary (CHO)-derived cells as Fc fusion proteins. “Atezolizumab” denotesa positive control anti-PD-Ll antibody and “WT” the wild-type sequence. IgV and IgC indicate that the mutations are in the IgV (“Ig-like V-type” in UniProt P33681) or IgC (“Ig-like C2-type” in UniProt P33681), respectively, domains of the CD80 ECD. Samples were assayed as singlets.
[0050] FIG. 17 depicts affinity of CD80 ECD variants for PD-L1 (third SPR experiments). Shown are KD values measured for several CD80 ECD variants. Particularly high affinity increases (low KD) were obtained with the dual mutations D60E-E160R and V68M-E160R. CD80 constructs were expressed in CHO-derived cells as Fc fusion proteins. “Atezolizumab” denotes a positive control anti-PD-Ll antibody and “WT” the wild-type sequence. The R29Y-Y31R-Q33K mutation increased the affinity of CD80 for CTLA-4 in a published report [Hajihassan et al., 2025], Samples were assayed as singlets.
[0051] FIG. 18 depicts binding sensor-grams for PD-L1. Shown are SPR sensor-grams for PD-L1 for the CD80 wild-type (A), V68M (B), E160R (C), and V68M-E160R (D) mutant constructs of FIG. 17.
[0052] FIG. 19 depicts affinity of CD80 ECD variants for CD28 and CTLA-4. Shown are KD values measured for several CD80 ECD variants for CD28 (left axis) and CTLA-4 (right axis) binding. D60E selectively increased the affinity for CTLA-4 (lower KD) while maintaining wild-type CD28 affinity. CD80 constructs were expressed in CHO-derived cells as Fc fusion proteins. “Atezolizumab” denotes a positive control anti-PD-Ll antibody. The CD28 and CTLA-4 threshold lines indicate the KD values of the CD80 wild-type (WT) construct for CD28 and CTLA-4, respectively. Samples were assayed as singlets.
[0053] FIG. 20 depicts binding sensor-grams for CD28. Shown are SPR sensor-grams for CD28 for the CD80 wild-type (A), D60E (B), V68M (C), and E160R (D) constructs of FIG.19.
[0054] FIG. 21 depicts binding sensor-grams for CTLA-4. Shown are SPR sensor-grams for CTLA-4 for the CD80 wild-type (A), D60E (B), V68M (C), and E160R (D) constructs of FIG.19
[0055] FIG. 22 depicts TILsRx multi-specific binding proteins tested in a bioassay for their ability to block the interaction between PD-L1 and PD-1. Each TILsRx construct contains 2 targeting and 2 effector domains genetically fused to Fc fragments with knob-in-hole mutations. (A) shows TILsRx constructs targeted to STEAP1 via scFv domains at the C-terminiof each chain (marked with “C”) and the following effector domains at the N-termini of each chain (marked with “N”): anti-hen egg-white lysozyme (HEL) scFvs derived from the Hy HELIO antibody (Complex 1; negative control), CD80 wild-type (WT) extracellular domains (ECDs) (Complex 2), and CD80 ECDs with V68M / E160R double mutations (Complex 3). (B) shows TILsRx constructs targeted to STEAP1 via scFv domains at the N and C-termini of the “knob”-containing chain and the effector domains of (A) at the N and C-termini of the “hole”-containing chain. (C) shows TILsRx constructs targeted to B7-H3 via scFv domains at the C-termini of each chain and the effector domains of (A) at the N-termini of each chain.
[0056] FIG. 23 depicts the principle of a reporter bioassay employed as a proxy for assessing the potential of TILsRx multi-specific binding proteins with CD80 domain(s) to activate T cells. (A) CHO-K1 cells engineered to express both PD-L1 and an agonistic CD3 antibody in scFv format are cocultured with reporter cells expressing PD-1. Whereas CD3 stimulation induces luciferase activity in the reporter cells, the signal is suppressed by PD-LEPD-l engagement. To study the effects of a CD80-TILsRx construct on PD-1 signaling, the gene encoding the tumor-associated antigen (TAA) targeted by the TILsRx construct (e.g., B7-H3) is transfected as a plasmid into the engineered CHO-K1 cells. (B) A TILsRx construct with CD80 and anti-B7-H3 antibody (Ab) (e.g., as scFv) domains binds to both B7-H3 on the transfected CHO-K1 cells and to PD-L1 (via CD80) on the reporter cells, thereby antagonizing the PD-LEPD-l engagement and consequently reducing PD-1 signaling, resulting in increased luciferase activity.
[0057] FIG. 24 depicts the results of preliminary bioassay runs to determine suitable experimental conditions including TILsRx concentrations. For both (A) and (B), CHO-K1 cells engineered to express both PD-L1 and an agonistic CD3 antibody in scFv format were transfected with a human B7-H3 expression plasmid then co-cultured with PD-1 -expressing reporter cells (GS-J2B / PD-1). Cell mixtures were treated with a negative control antibody (HYHEL-10), a positive control antibody (Keytruda Biosimilar), a B7-H3 -targeted TILsRx construct with two CD80 wild-type ECDs (Complex 8), or a B7-H3 -targeted TILsRx construct with two CD80 ECDs, each with a V68MZE160R double mutation (Complex 9) (B only). Whereas both Complex 8 (A and B) and 9 (B) induced luciferase activity, the induction was stronger with Complex 9, suggesting that the CD80 ECD with the V68M / E160R double mutation is a stronger inhibitor of PD-1 signaling than the wild-type CD80 ECD.
[0058] FIG. 25 depicts detection of STEAP1 (A) or B7-H3 (B) on the cell surface of CHO-K1 cells engineered to express both PD-L1 and an agonistic CD3 antibody in scFv format after transient transfection with plasmids encoding STEAP1 (A) or B7-H3 (B). The following primary antibodies were used: 120. v24 (ProBio) and Vandortuzumab (MCE, CAT# HY-P990673) to detect STEAP1 (A), and PE anti -human CD276 (B7-H3) Antibody (BioLegend, CAT# 331606) and Anti-Human B7-H3 / CD276 Rabbit Recombinant Antibody (Proteintech, CAT# 98017-1-PBS) to detect B7-H3 (B). For both (A) and (B), “Target Induction (fold)” is the ratio between the median fluorescence signal of the Target positive (STEAP1+ or B7-H3+) and the Target negative (STEAP1- or B7-H3-) populations.
[0059] FIG. 26 depicts the results of a bioassay experiment. CH0-K1 cells were engineered to express both PD-L1 and an agonistic anti-CD3 antibody in scFv format. The engineered CH0-K1 cells in (B) were further transfected with a human B7-H3 expression plasmid. Both groups of engineered CH0-K1 cells: CHO-Kl / PD-Ll / anti-CD3 in (A) and CHO-K1 / PD-Ll / anti-CD3 / B7-H3 in (B) were co-cultured with human PD-1 -expressing reporter cells (GS-J2B / PD-1). Cell mixtures were treated with the indicated TILsRx constructs, CD80-Fc constructs, or controls (positive control anti-PD-1 antibody: Keytruda Biosimilar; negative control antibody: HYHEL-10).
[0060] FIG. 27 depicts the results of a bioassay experiment conducted in combination with the experiment depicted in FIG.26. CH0-K1 cells were engineered to express both PD-L1 and an agonistic CD3 antibody in scFv format. The engineered CH0-K1 cells in (B) were transfected with a human STEAP1 expression plasmid. Both groups of engineered CH0-K1 cells: CHO-Kl / PD-Ll / anti-CD3 in (A) and CHO-Kl / PD-Ll / anti-CD3 / STEAPl in (B) were co-cultured with human PD-1 -expressing reporter cells (GS-J2B / PD-1). Cell mixtures were treated with the indicated TILsRx constructs or controls (positive control anti-PD-1 antibody: Keytruda Biosimilar; negative control antibody: HYHEL-10).DETAILED DESCRIPTIONI. Introduction
[0061] The present disclosure provides compositions and methods for inducing and enhancing anti-cancer immune responses in a subject. Specifically, the present disclosure describes multi-specific binding proteins, also referred to herein as TIL-activating reagents (TILsRx), and their uses for cancer treatment. These multi-specific binding proteins comprise at least one tumor-associated antigen (TAA) binding domain (TAA-BD) and at least oneimmune modulatory domain (IMD), enabling the connection of immune cells to target cancer cells and thereby triggering an anti-cancer immune response in the subject.
[0062] As disclosed herein, the multi-specific binding proteins may comprise an Fc dimer linked to the TAA-BD(s) and the IMD(s). In some embodiments, the TAA-BD(s) and / or the IMD(s) comprise an active domain (AD) and an inhibitory domain (ID), wherein the ID blocks the AD, resulting in the inactivation of the TAA-BD(s) and / or the IMD(s). In some embodiments, the multi-specific binding proteins further comprise one or more cleavable linkers, such as “regional cleavable linkers” located between the Fc dimer and the TAA-BD(s) or the IMD(s), and “domain cleavable linkers” located between the ADs and the IDs. The incorporation of cleavable linkers allows for the controlled release of TAA-BD(s), IMD(s), and / or IDs under specific conditions, such as within the tumor environment where the expression of certain proteases is elevated.
[0063] The present disclosure further provides compositions, pharmaceutical compositions, and kits comprising the multi-specific binding proteins described herein. Additionally, the present disclosure provides methods for treating cancer in a subject in need thereof, utilizing the multi-specific binding proteins, as well as the related compositions and pharmaceutical formulations.II. Definitions
[0064] Unless defined otherwise, technical and scientific terms used herein have the same meaning as commonly understood by a person of ordinary skill in the art. See, e.g., Lackie, The Dictionary of Cell and Molecular Biology, 4th ed., Elsevier, 2007; Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press (Cold Spring Harbor, NY, 1989). Any methods, devices and materials similar or equivalent to those described herein can be used in the practice of this invention. The following definitions are provided to facilitate understanding of certain terms used frequently herein and are not meant to limit the scope of the present disclosure.
[0065] The terms “a,” “an,” or “the” as used herein not only include aspects with one member, but also include aspects with more than one member. For instance, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “a cell” includes a plurality of such cells and reference to “the agent” includes reference to one or more agents known to those skilled in the art, and so forth.
[0066] The terms “about” and “approximately” shall generally mean an acceptable degree of error for the quantity measured given the nature or precision of the measurements. Typical, exemplary degrees of error are within 20 percent (%), preferably within 10%, and more preferably within 5% of a given value or range of values. Alternatively, and particularly in biological systems, the terms “about” and “approximately” may mean values that are within an order of magnitude, preferably within 5-fold and more preferably within 2-fold of a given value. Numerical quantities given herein are approximate unless stated otherwise, meaning that the term “about” or “approximately” can be inferred when not expressly stated.
[0067] As used herein, the term “administering” includes oral administration, topical contact, administration as a suppository, intravenous, intraperitoneal, intramuscular, intralesional, intratumoral, intradermal, intralymphatic, intrathecal, intranasal, or subcutaneous administration to a subject. Administration is by any route, including parenteral and transmucosal (e.g., buccal, sublingual, palatal, gingival, nasal, vaginal, rectal, or transdermal). Parenteral administration includes, e.g., intravenous, intramuscular, intra-arteriole, intradermal, subcutaneous, intraperitoneal, intraventricular, and intracranial. Other modes of delivery include, but are not limited to, the use of liposomal formulations, intravenous infusion, transdermal patches, etc.
[0068] The terms “binds to”, “recognizes”, and “interacts with” are used interchangeably herein to include the binding / interaction of a polypeptide motif which shows the capacity of specific interaction with a specific antigen or a specific group of antigens. The terms “specifically binds to”, “specifically recognizes”, and “specifically interacts with” in the context of the present invention refers to the ability of a binding agent such as an antibody or a fragment or domain thereof to interact with and / or bind to a target antigen and without crossreacting with molecules of similar sequences or structures. In some cases, a binding agent specifically binds to a target antigen when it binds to the target antigen with a substantially lower dissociation constant (i.e., tighter binding) than a molecule of similar sequence or structure. For example, in some cases, a specific binding occurs when the binding agent binds to the target antigen with an about 2, 3, 4, 5, 6, 8, 10, 15, 20, 25, 30, 40, 50, 100, or 1000-fold or greater affinity than a related molecule.
[0069] Cross-reactivity may be tested, for example, by assessing binding of the binding agent under conventional conditions (see, e.g., Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, 1988; Harlow and Lane, Using Antibodies: ALaboratory Manual, Cold Spring Harbor Laboratory Press, 1999) to the target antigen as well as to a number of more or less (e.g., structurally and / or functionally) closely related molecules. These methods may include, without limitation, binding studies, blocking and competition studies with closely related molecules, FACS analysis, surface plasmon resonance (e.g., with BIAcore), analytical ultracentrifugation, isothermal titration calorimetry, fluorescence anisotropy, fluorescence spectroscopy, radiolabeled ligand binding assays, and combinations thereof.
[0070] “Nucleic acid” refers to deoxyribonucleotides or ribonucleotides and polymers thereof in either single- or double-stranded form and complements thereof. The term "polynucleotide" refers to a linear sequence of nucleotides. The term “nucleotide” typically refers to a single unit of a polynucleotide, i.e., a monomer. Nucleotides can be ribonucleotides, deoxyribonucleotides, or modified versions thereof. Examples of polynucleotides contemplated herein include single- and double-stranded DNA, single- and double-stranded RNA (including siRNA), and hybrid molecules having mixtures of single- and double-stranded DNA and RNA.
[0071] The terms “polypeptide,” “peptide,” and “protein” are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers and non-naturally occurring amino acid polymers. As used herein, the terms encompass amino acid chains of any length, including full-length proteins ( / .< ., alleles), wherein the amino acid residues are linked by covalent peptide bonds. As used herein, the amino acid sequence of a polypeptide is presented from the N-terminus to the C-terminus. In other words, when describing an amino acid sequence of a polypeptide, the first amino acid at the N-terminus is referred to as the “first amino acid.”
[0072] When used in the context of describing partners of a recombinant polypeptide, the term “heterologous” refers to the relationship of one polynucleotide fusion partner to the other polynucleotide fusion partner: the manner in which the fusion partners are present in the recombinant polynucleotide is not one that can be found in a polynucleotide naturally occurs or encoding a naturally occurring protein.
[0073] The term “amino acid” refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function similarly to the naturallyoccurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline, y-carboxy glutamate, and O-phosphoserine. Amino acid analogs refers to compounds that have the same basic chemical structure as a naturally occurring amino acid, e.g., an a carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs may have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. Amino acid mimetics refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions similarly to a naturally occurring amino acid.
[0074] Amino acids may be referred to herein by their commonly used full name (e.g., cysteine), their commonly known three letter symbols (e.g., Cys), or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission (e.g., C). Nucleotides, likewise, may be referred to by their commonly accepted single-letter codes.
[0075] “Conservatively modified variants” applies to both amino acid and nucleic acid sequences. With respect to particular nucleic acid sequences, conservatively modified variants refers to those nucleic acids which encode identical or essentially identical amino acid sequences, or where the nucleic acid does not encode an amino acid sequence, to essentially identical or associated, e.g., naturally contiguous, sequences. Because of the degeneracy of the genetic code, a large number of functionally identical nucleic acids encode most proteins. For instance, the codons GCA, GCC, GCG and GCU all encode the amino acid alanine. Thus, at every position where an alanine is specified by a codon, the codon can be altered to another of the corresponding codons described without altering the encoded polypeptide. Such nucleic acid variations are “silent variations,” which are one species of conservatively modified variations. Every nucleic acid sequence herein which encodes a polypeptide also describes silent variations of the nucleic acid. One of skill will recognize that in certain contexts each codon in a nucleic acid (except AUG, which is ordinarily the only codon for methionine, and UGG, which is ordinarily the only codon for tryptophan) can be modified to yield a functionally identical molecule. Accordingly, often silent variations of a nucleic acid which encodes a polypeptide is implicit in a described sequence with respect to the expression product, but not with respect to actual probe sequences.
[0076] As to amino acid sequences, one of skill will recognize that individual substitutions, deletions or additions to a nucleic acid, peptide, polypeptide, or protein sequence which alters, adds or deletes a single amino acid or a small percentage of amino acids in the encoded sequence is a “conservatively modified variant” where the alteration results in the substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art. Such conservatively modified variants are in addition to and do not exclude polymorphic variants, paralogs, orthologs, and alleles of the invention. The following amino acids are typically conservative substitutions for one another: 1) Alanine (A), Glycine (G); 2) Aspartic acid (D), Glutamic acid (E); 3) Asparagine (N), Glutamine (Q); 4) Arginine (R), Lysine (K); 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W); 7) Serine (S), Threonine (T); and 8) Cysteine (C), Methionine (M) (see, e.g., Creighton, Proteins: Structures and Molecular Properties, W. H. Freeman and Company, 1984).
[0077] A “mutation” is a change in a nucleic acid sequence. A mutation may or may not affect the amino acid sequence of a protein. Mutation (singular) can also refer to multiple amino acid changes in the same protein molecule or construct, whereby “construct” comprises one or more molecules. This applies in particular to “knob-in-hole” AA substitutions, where there can be more than one AA change with a mutation.
[0078] The terms “identical” or “percent identity,” in the context of two or more nucleic acids, or two or more polypeptides, refer to two or more sequences or subsequences that are the same or have a specified percentage of nucleotides, or amino acids, that are the same (i.e., about 60% identity, preferably 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or higher identity over a specified region, when compared and aligned for maximum correspondence over a comparison window or designated region) as measured using a BLAST or BLAST 2.0 sequence comparison algorithms with default parameters, or by manual alignment and visual inspection. See, e.g., the NCBI web site at ncbi.nlm.nih.gov / BLAST. Such sequences are then said to be "substantially identical." This definition also refers to, or may be applied to, the complement of a nucleotide test sequence. The definition also includes sequences that have deletions and / or additions, as well as those that have substitutions. As described below, the algorithms can account for gaps and the like. Typically, identity exists over a region comprising an antibody epitope, or a sequence that is at least about 25 amino acids or nucleotides in length, or over a region that is 50-100 amino acids or nucleotides in length, or over the entire length of the reference sequence.
[0079] The term “antigen” refers to a molecule bound by an “antibody”. Antigens may be proteins recognized by immunoglobulins, in which case the sites on the proteins bound by the immunoglobulins are referred to as “epitopes.” Antigens may also, or alternatively, be recognized by non-immunoglobulin ligand binding domain of a multi-specific binding protein. In such cases, “antigen” refers to binding partners of the non-immunoglobulin ligand binding domain of the multi-specific binding protein. In some cases, the antigen can be a ligand of a cell surface receptor, e.g., a ligand of NKG2D. In some cases, the multi-specific binding protein contains a cell surface receptor ligand, or receptor binding portion thereof, and the antigen is the ligand binding portion of the cell surface receptor.
[0080] The term “multi-specific binding protein” refers to a molecule that can specifically bind two or more different target antigens simultaneously. Multi-specific binding proteins generally have two or more structurally distinct binding regions (domains), each of which specifically binds to a single target antigen. Multi-specific binding proteins can be used to bind a target antigen on a cell and a different target antigen on a different cell or two different target antigens on the same cell. Multi -specific binding proteins can include polypeptide sequences (domains) of one or more antibodies or antibody fragments (e.g., one or more scFvs). An exemplary multi-specific binding protein has a first domain having a scFv that specifically binds a cell surface antigen and a second domain that specifically binds a different target antigen. Another exemplary multi-specific binding protein has a first domain derived from a cell surface receptor that specifically binds a ligand of the receptor and a second domain that specifically binds a different target antigen. Yet another exemplary multi-specific binding protein has a first domain that is derived from a ligand for a cell surface receptor that specifically binds the cell surface receptor and a second domain that specifically binds to a different target antigen.
[0081] Multi-specific binding proteins can include a polypeptide linker sequence that links the first domain or the second domain to the third domain or the fourth domain. Additionally, the multi-specific binding protein can contain linker sequences between subdomains of the domains. For example, if one of the domains is an scFv, the multi-specific binding protein will have a linker between the VH and VL domains of the scFv. Suitable linker sequences are known in the art, and the multi-specific binding proteins are not limited to any one specific linker. In general, suitable linker sequences consist of relatively flexible and hydrophilic amino acid residues. Additionally, interdomain linker sequences (e.g., scFv to scFv) are generally shorter than inter-subdomain linker sequences (e.g., intra scFv linkers, such as VH to VL or VL to VH1linkers). Suitable linker sequences, however, are not restricted to any one length or range of lengths. In some cases, a suitable linker sequence can contain a plurality of glycine and serine residues.
[0082] A multi-specific binding protein is “substantially pure” when it exists in solution as a substantially monodisperse population of molecules. For example, a multi-specific binding protein is substantially pure when it has a poly dispersity index (PDI), a measure of the degree of mono- or poly dispersity of a polymer in solution, as measured by photon correlation spectroscopy of less than about 0.2 (e.g., less than about 0.15, 0.1, or 0.08). As another example, a multi-specific binding protein is substantially pure when at least about a majority proportion of the multi-specific binding protein is not aggregated (e.g., at least about 50%, 60%, 75%, 80%, 90%, 95%, 99% or more). In some cases, aggregation or poly dispersity of a multi-specific binding protein is minimized through the introduction of disulfide bridges between domains or subdomains of the multi-specific binding proteins. In an exemplary embodiment, the disulfide bridges are within a taFv antibody and are between a VH subdomain of one scFv domain and a VL subdomain of another scFv domain.
[0083] An “antibody” can consist of one or more polypeptides substantially encoded by immunoglobulin genes or fragments of immunoglobulin genes. The recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon and mu constant region genes, as well as myriad immunoglobulin variable region genes. Light chains are classified as either kappa or lambda. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD and IgE, respectively. An "antibody" functions as a binding protein and is structurally defined as comprising an amino acid sequence from or derived from the framework region of an immunoglobulin encoding gene of an animal producing antibodies.
[0084] A typical immunoglobulin (antibody) structural unit is known to comprise a tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one "light" (about 25 kD) and one "heavy" (about 50-70 kD) chain. The N-terminus of each chain defines a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. The terms variable light chain (VL) and variable heavy chain (VH) or light chain variable region and heavy chain variable region and the like refer to these light and heavy chains and their variable regions respectively.
[0085] The term “antibody” as used herein includes antibody fragments that retain binding activity. For example, there are a number of well characterized antibody fragments. Thus, for example, pepsin digests an antibody C-terminal to the disulfide linkages in the hinge region to produce F(ab')2, a dimer of Fab which itself is a light chain joined to VH-CH1 by a disulfide bond. The F(ab')2 may be reduced under mild conditions to break the disulfide linkage in the hinge region thereby converting the F(ab')2 dimer into an Fab' monomer. The Fab' monomer is essentially an Fab with part of the hinge region (see, e.g., W. E. Paul, Fundamental Immunology, 3rd ed., Raven Press, N. Y., 1993 for a more detailed description of other antibody fragments). While various antibody fragments are defined in terms of the digestion of an intact antibody, one of skill will appreciate that fragments can be synthesized de novo either chemically or by utilizing recombinant DNA methodology. Thus, the term antibody, as used herein also includes antibody fragments either produced by the modification of whole antibodies or synthesized using recombinant DNA methodologies.
[0086] Antibodies include VH-VL dimers, including those generated as single-chain antibodies (antibodies that exist as a single polypeptide chain) such as single-chain Fv antibodies (sFv or scFv) in which a variable heavy and a variable light region are joined together (directly or through a peptide linker) to form a continuous polypeptide. The singlechain Fv antibody may be expressed from a nucleic acid in which the VH- and VL- encoding sequences are either joined directly or are joined by a peptide-encoding linker (e.g., Huston et al., Proc Natl Acad Sci USA, 85(16):5879-5883, 1988). While the VH and VL are connected to each as a single polypeptide chain, the VH and VL subdomains associate non-covalently. In some cases, the non-covalent association of the VH and VL subdomains is further stabilized through one or more disulfide bridges between cysteine residues in the VH and VL subdomains. The VH and VL domains of an scFv can be oriented from the amino terminus (N) to the carboxy terminus (C) of the scFv coding sequence. Alternatively, the VL and VH domains can be oriented N to C. Thus, for example, an scFv can have two different possible topologies.
[0087] Alternatively, the antibody can be another fragment. Other fragments can also be generated, e.g., using recombinant techniques, as soluble proteins or as fragments obtained from display methods. Antibodies can also include diantibodies and miniantibodies. Antibodies of the invention also include heavy chain dimers, such as antibodies from camelids. In a preferred embodiment, the antibody is a tandem tandem single-chain variable fragment antibody molecule (taFv) having a first scFv and a second scFv.
[0088] As used herein, “V-region” refers to an antibody variable region domain comprising the segments of Framework 1, CDR1, Framework 2, CDR2, and Framework 3, including CDR3 and Framework 4, which segments are added to the V-segment as a consequence of rearrangement of the heavy chain and light chain V-region genes during B-cell differentiation.
[0089] As used herein, “complementarity-determining region (CDR)” refers to the three hypervariable regions in each chain of an antibody that interrupt the four "framework" regions established by the light and heavy chain variable regions. The CDRs are primarily responsible for binding to an epitope of an antigen. The CDRs of each chain are typically referred to as CDR1, CDR2, and CDR3, numbered sequentially starting from the N-terminus, and are also typically identified by the chain in which the particular CDR is located. Thus, a VH CDR3 is located in the variable domain of the heavy chain of the antibody in which it is found, whereas a VL CDR1 is the CDR1 from the variable domain of the light chain of the antibody in which it is found.
[0090] The sequences of the framework regions of different light or heavy chains are relatively conserved within a species. The framework region of an antibody, that is the combined framework regions of the constituent light and heavy chains, serves to position and align the CDRs in three-dimensional space.
[0091] The amino acid sequences of the CDRs and framework regions can be determined using various well known definitions in the art, e.g., by Kabat, Chothia, or the IMGT®, the international ImMunoGeneTics information system® (available at imgt.org; founder and director: Marie-Paule Lefranc, Montpellier, France) (see, e.g., Johnson and Wu, Nucleic Acids Res, 28(1):214-218, 2000; Johnson and Wu, Nucleic Acids Res, 29(l):205-206, 2001; Chothia andLesk, J Mol Biol, 196(4): 901-917, 1987; Chothia et al., Nature, 342(6252):877-883, 1989; Chothia et al., J Mol Biol, 227(3):799-817, 1992; Al-Lazikani et al., J Mol Biol, 273(4):927-948, 1997; Lefranc et al., Dev Comp Immunol, 27(l):55-77, 2003; and Lefranc, Front Immunol, 5:22, 2014). Definitions of antigen combining sites are also described in the following: Ruiz et al., Nucleic Acids Res, 28(1):219-221, 2000; Lefranc, Nucleic Acids Res, 29(l):207-209, 2001; MacCallum et al., J Mol Biol, 262(5 .732-7 N5, 1996; Martin et al., Proc Natl Acad Sci USA, 86(23):9268-9272, 1989; Martin et < ., Methods Enzymol, 203:121-153, 1991; Pedersen et al., ImmunoMethods, 1(2): 126-136, 1992; and Rees et al., In Sternberg M.J.E. (ed.), Protein Structure Prediction, Oxford University Press, Oxford, 141-172, 1996).
[0092] An “isotype” is a class of antibodies defined by the heavy chain constant region. Immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon, and mu constant region genes. Light chains are classified as either kappa or lambda. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, which in turn define the isotype classes, IgG, IgM, IgA, IgD and IgE, respectively.
[0093] A “monoclonal antibody” refers to a clonal preparation of antibodies. A “polyclonal antibody” refers to a preparation of antibodies that are raised against a single antigen, but with different complementarity determining regions.
[0094] As used herein, “chimeric antibody” refers to an immunoglobulin molecule in which (a) the constant region, or a portion thereof, is altered, replaced or exchanged so that the antigen binding site (variable region) is linked to a constant region of a different or altered class, effector function and / or species, or an entirely different molecule which confers new properties to the chimeric antibody, e.g., an enzyme, toxin, hormone, growth factor, drug, etc.,' or (b) the variable region, or a portion thereof, is altered, replaced or exchanged with a variable region, or portion thereof, having a different or altered antigen specificity; or with corresponding sequences from another species or from another antibody class or subclass.
[0095] As used herein, “humanized antibody” refers to an immunoglobulin molecule in which CDRs from a donor antibody are grafted onto human framework sequences. Humanized antibodies may also comprise residues of donor origin in the framework sequences. The humanized antibody can also comprise at least a portion of a human immunoglobulin constant region. Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. Humanization can be performed using methods known in the art (e.g., Jones et al., Nature, 321(6069):522-525, 1986; Riechmann et al., Nature, 332(6162):323-327, 1988; Verhoeyen et al., Science, 239(4847): 1534-1536, 1988; Presta, Curr Opin Struct Biol, 2(4):593-596, 1992; U.S. Patent No. 4,816,567; U.S. Patent No. 5,225,539), including techniques such as “superhumanizing" antibodies (Tan et al., J Immunol, 169(2): 1119-1125, 2002) and "resurfacing” (e.g., Staelens et al., Mol Immunol, 43(8): 1243-1257, 2006; and Roguska et al., Proc Natl Acad Sci USA, 91(3):969-973, 1994).
[0096] As used herein, the phrase “agonistic antibody” refers to an antibody or antibody fragment (e.g., an scFv, taFv, e / c.) that activates or stimulates an antigen upon binding. For example, an agonistic anti-CD28 antibody is capable of binding to CD28 and activating a co-stimulatory signal mediated by CD28. As another example, an agonistic CD3 antibody is capable of binding to CD3 and activating a co-stimulatory signal mediated by CD3. In some cases, the agonistic antibody provides a stronger activating signal than a natural ligand (e.g., it is a superagonistic antibody). In other cases, the agonistic antibody is weaker than or substantially the same as a natural ligand.
[0097] An antibody can contain additional amino acids or molecules for purification or identification. For example, the antibody can contain an epitope or affinity tag. Exemplary epitope or affinity tags include, without limitation, peptide tags (e.g., FLAG-tag, HA-tag, His-tag, Myc-tag, S-tag, SBP-tag, Strep-tag, eXact-tag), and protein tags (e.g., GST-tag, MBP-tag, GFP-tag). In some cases, the antibody is biotinylated. Other suitable epitope or affinity tags are known in the art.
[0098] The antibody binds to an “epitope” on the antigen. The epitope is the specific antibody binding interaction site on the antigen. If the antigen is a peptide, the epitope can include a few amino acids or portions of a few amino acids, e.g., 5 or 6, or more, e.g., 20 or more amino acids, or portions of those amino acids. In some cases, the epitope includes nonprotein components, e.g., from a carbohydrate, nucleic acid, or lipid. In some cases, the epitope is a three-dimensional moiety. Thus, for example, where the target is a protein, the epitope can be comprised of consecutive amino acids, or amino acids from different parts of the protein that are brought into proximity by protein folding (e.g., a discontinuous epitope). The same is true for other types of target molecules that form three-dimensional structures.
[0099] Antibodies can be produced using any number of expression systems, including prokaryotic and eukaryotic expression systems. For example, the antibody can be produced in or by bacteria (e.g., E. coH, P. mirabilis), fungi (e.g., S. cerevisiae. P. Pastoria, T. reesei), plants or plant cells, insects or insect cells (e.g., SF-9, SF21, Hi-5), or mammalian cells. In some embodiments, the expression system is a mammalian cell expression system, such as a hybridoma, or a CHO or 293 cell expression system. Many such systems are widely available from commercial suppliers.
[0100] In some cases, the antibody or antibody fragment can be conjugated to another molecule, e.g., polyethylene glycol (PEGylation) or serum albumin, to provide an extended half-life in vivo or to decrease non-specific binding. Examples of PEGylation of antibody fragments are provided in Knight et al., Platelets, 15(7):409-418, 2004 (for abciximab); Pedley et al., Br J Cancer, 70(6): 1126-1130, 1994 (for an anti-CEA antibody); Chapman et al., NatureBiotechnol, 17(8):780-783, 1999; and Humphreys et al., Protein Eng Des, 20(5):227-234, 2007. The antibody or antibody fragment can also be labeled or conjugated to a therapeutic agent as described herein.
[0101] The term “cytokine” refers to small proteins released by cells that have a specific effect on the interactions and communications between cells. Cytokines are generally known as lymphokines (e.g., cytokines made by lymphocytes), monokines (e.g., cytokines made by monocytes), or chemokines (e.g., cytokines made by one leukocyte and acting on other leukocytes). Cytokines may act on the cells that secrete them (e.g., autocrine action), on nearby cells (e.g., paracrine action), or on distant cells (e.g., endocrine action). In the context of the present disclosure, cytokines may comprise a chemokine, an interferon, an interleukin, and / or a tumor necrosis factor (TNF). As an example, cytokines may comprise an early T cell activation antigen- 1 (ETA-1), a lymphocyte-activating factor (LAF), an interleukin- 1 family member (IL-la, IL-P, IL-IRa, IL-18, IL-33, IL-36Ra, IL-36a, IL-36P, IL-36Y, IL-37, IL-38), an interleukin-2 (IL-2), an interleukin-3 (IL-3), an interleukin-4 (IL-4), an interleukin-5 (IL-5), an interleukin-6 (IL-6), an interleukin-7 (IL-7), an interleukin-8 (IL-8), an interleukin-9 (IL-9), an interleukin- 10 (IL-10), an interleukin- 12 (IL-12), an interleukin- 13 (IL-13), an interleukin- 15 (IL- 15), an interleukin- 17 (IL- 17), an interleukin- 18 (IL- 18), an interleukin-23 (IL-21), an interleukin-23 (IL-23), an interleukin-25 (IL-25), an interleukin-33 (IL-33), a type I interferon family member (IFN-a, IFNP, IFNs, IFNK, IFNCO), a type II interferon family member (IFNy), a type III interferon family member (IFNX1 (IL-29), IFNX2 (IL-28 A), IFNA3 (IL-28B), IFNX4), a granulocyte-macrophage colony-stimulating factor (GM-CSF), a macrophage CSF (CSF-1), a macrophage migration inhibitory factor (MIF), a CD40L molecule (CD40L), a RANTES molecule (RANTES), a monocyte chemoattractant protein (MCP-1), a monocyte inflammatory protein (MIP-la, MIP-ip), a lymphotactin, and / or a fractalkine. As disclosed herein, the cytokine can be designed as an AD of the multi-specific binding protein and binds to the corresponding cytokine receptor on the target cells. In some embodiments, the cytokine may be an intact cytokine or a fragment, fusion, or derivative thereof.
[0102] The term “receptor ligand” refers to a polypeptide capable of binding at least one cellsurface receptor, such as T-cell receptor or B-cell receptor. In some embodiments, the cellsurface receptor comprises an extracellular ligand-binding domain and, optionally, other domains (e.g. transmembrane domain, intracellular domain and / or membrane anchor). As disclosed herein, the receptor ligand can be designed as an AD of the multi-specific bindingprotein and binds to the corresponding surface receptor of target cells. In some embodiments, the receptor ligand may be an intact receptor ligand or a fragment, fusion, or derivative thereof.
[0103] As used herein, an “immune cell” refers to a cell of the immune system. Immune cells can be categorized as lymphocytes, neutrophils, granulocytes, mast cells, monocytes / macrophages, and dendritic cells. As disclosed herein, in some embodiments, the multi-specific binding protein targets lymphocytes. In some embodiments, the lymphocytes can be T-cells (CD4 T cells and / or CD8 T cells), B-cells, and natural killer (NK) cells. In some embodiments, the lymphocytes are tumor-infiltrating lymphocytes (TILs). In some embodiments, an immune cell disclosed herein can be a cytotoxic lymphocyte. As used herein, a “cytotoxic lymphocyte” refers to a lymphocyte capable cytolysis. For example, but not limited to, a cytotoxic lymphocyte can be capable of killing cancer cells, cells that are infected (particularly with viruses), and cells that are damaged in one or more other ways. In some embodiments, a cytotoxic lymphocyte can be a NK cell or a CD8 T cell.
[0104] As used herein, a “cancer cell” or “cancerous cell” refers to an abnormal cell from a cancer that grows and divides in an uncontrolled manner. The term “cancer” is intended to include any member of a class of diseases characterized by the uncontrolled growth of aberrant cells. The term includes all known cancers and neoplastic conditions, whether characterized as malignant, benign, recurrent, soft tissue, or solid, and cancers of all stages and grades including advanced, pre- and post-metastatic cancers. Examples of different types of cancer include, but are not limited to, gynecological cancers (e.g., ovarian, cervical, uterine, vaginal, and vulvar cancers); lung cancers (e.g., non-small cell lung cancer, small cell lung cancer, mesothelioma, carcinoid tumors, lung adenocarcinoma); breast cancers (e.g., triple-negative breast cancer, ductal carcinoma in situ, invasive ductal carcinoma, tubular carcinoma, medullary carcinoma, mucinous carcinoma, papillary carcinoma, cribriform carcinoma, invasive lobular carcinoma, inflammatory breast cancer, lobular carcinoma in situ, Paget’s disease, Phyllodes tumors); digestive and gastrointestinal cancers such as gastric cancer (e.g, stomach cancer), colorectal cancer, gastrointestinal stromal tumors (GIST), gastrointestinal carcinoid tumors, colon cancer, rectal cancer, anal cancer, bile duct cancer, small intestine cancer, and esophageal cancer; thyroid cancer; gallbladder cancer; liver cancer; pancreatic cancer; appendix cancer; prostate cancer (e.g, prostate adenocarcinoma); renal cancer (e.g., renal cell carcinoma); cancer of the central nervous system (e.g., glioblastoma, neuroblastoma, medulloblastoma); skin cancer e.g., melanoma); bone and soft tissue sarcomas (e.g., Ewing’s sarcoma); lymphomas; choriocarcinomas; urinary cancers (e.g., urothelial bladder cancer);head and neck cancers; and bone marrow and blood cancers (e.g., acute leukemia, chronic leukemia (e.g., chronic lymphocytic leukemia), lymphoma, multiple myeloma). As used herein, a “tumor” comprises one or more cancerous cells.
[0105] As used herein, a first multi-specific binding protein, or an antigen-binding portion thereof, “competes” for binding to a target with a second multi-specific binding protein, or an antigen-binding portion thereof, when binding of the first multi-specific binding protein with the target is detectably decreased in the presence of the second multi-specific binding protein compared to the binding of the first multi-specific binding protein in the absence of the second multi-specific binding protein. The alternative, where the binding of the second multi-specific binding protein to the target is also detectably decreased in the presence of the first multispecific binding protein, can, but need not be the case. However, where each multi-specific binding protein detectably inhibits the binding of the other multi-specific binding protein to its cognate epitope or ligand, whether to the same, greater, or lesser extent, the multi-specific binding proteins are said to “cross-compete” with each other for binding of their respective epitope(s). Both competing and cross-competing multi-specific binding proteins are encompassed by the present invention. The term “competitor” multi-specific binding protein can be applied to the first or second multi-specific binding protein as can be determined by one of skill in the art. In some cases, the presence of the competitor multi-specific binding protein (e.g., the second multi-specific binding protein) reduces binding of, e.g., the first multi-specific binding protein to the target by at least 10%, e.g., 20%, 30%, 40%, 50%, 60%, 70%, 80%, or more, e.g., so that binding of the first multi-specific binding protein to target is undetectable in the presence of the second (competitor) multi-specific binding protein. In some cases, a competitor multi-specific binding protein can be used to replace a first interaction between an immune cell and a target cancer cell with a second interaction between the immune cell and the target cancer cell as further described herein.
[0106] A “control” sample or value refers to a sample that serves as a reference, usually a known reference, for comparison to a test sample. For example, a test sample can be taken from a test condition, e.g., in the presence of a test compound, and compared to samples from known conditions, e.g., in the absence of the test compound (negative control), or in the presence of a known compound (positive control). A control can also represent an average value gathered from a number of tests or results. One of skill in the art will recognize that controls can be designed for assessment of any number of parameters. For example, a control can be devised to compare therapeutic benefit based on pharmacological data (e.g., half-life)or therapeutic measures (e.g., comparison of benefit and / or side effects, such as mean time of survival of a cancer patient). Controls can be designed for in vitro applications. One of skill in the art will understand which controls are valuable in a given situation and be able to analyze data based on comparisons to control values. Controls are also valuable for determining the significance of data. For example, if values for a given parameter are widely variant in controls, variation in test samples may not be considered as significant.
[0107] A “label” or a “detectable moiety” is a composition detectable by spectroscopic, photochemical, biochemical, immunochemical, chemical, or other physical means. For example, useful labels include32P, fluorescent dyes, electron-dense reagents, enzymes (e.g., as commonly used in an ELISA), biotin, digoxigenin, or haptens and proteins or other entities which can be made detectable, e.g., by incorporating a radiolabel into a peptide or antibody specifically reactive with a target peptide. Any method known in the art for conjugating an antibody to the label may be employed, e.g., using methods described in Hermanson, Bioconjugate Techniques, Academic Press / Elsevier, 1996.
[0108] A “labeled” molecule (e.g., nucleic acid, protein, or antibody) is one that is bound, either covalently, through a linker or a chemical bond, or noncovalently, through ionic, van der Waals, electrostatic, or hydrogen bonds to a label such that the presence of the molecule may be detected by detecting the presence of the label bound to the molecule.
[0109] The terms “therapy,” “treatment,” and “amelioration” refer to any reduction in the severity of symptoms. In the case of treating cancer, treatment can refer to, e.g., reducing tumor size, number of cancer cells, growth rate, metastatic activity, reducing cell death of noncancer cells, reduced score or stabilized score as assessed by an accepted diagnostic or prognostic set of criteria (e.g., reduced or stabilized Gleason Score, Gleason Pattern, TNM stage, Whitmore- Jewett stage, histological grade, PSA level or status, DAmico classification, Partin outcome, CAPRA score, efc.), reduced nausea and other chemotherapy or radiotherapy side effects, etc. As used herein, the terms “treat” and “prevent” are not intended to be absolute terms. Treatment and prevention can refer to any delay in onset, amelioration of symptoms, improvement in patient survival, increase in survival time or rate, etc. Treatment and prevention can be complete (undetectable levels of neoplastic cells) or partial, such that fewer neoplastic cells are found in a patient than would have occurred without the present invention. The effect of treatment can be compared to an individual or pool of individuals not receiving the treatment, or to the same patient prior to treatment or at a different time during treatment.In some aspects, the severity of disease is reduced by at least 10%, as compared, e.g., to the individual before administration or to a control individual not undergoing treatment. In some aspects, the severity of disease is reduced by at least 25%, 50%, 75%, 80%, or 90%, or in some cases, no longer detectable using standard diagnostic techniques. In some aspects of the current invention, treatment means mixing one or more types of multi-specific binding protein with target and effector cells in vitro. For such treatments, the therapeutic effect may, e.g., refer to the fraction of target cells lysed due to the presence of the multi-specific binding protein(s).
[0110] The term “treating” refers to an approach for obtaining beneficial or desired results including, but not limited to, a therapeutic benefit and / or a prophylactic benefit. By therapeutic benefit is meant any therapeutically relevant improvement in or effect on one or more diseases, conditions, or symptoms under treatment. Therapeutic benefit can also mean to effect a cure of one or more diseases, conditions, or symptoms under treatment.[OHl] The term “effective amount”, “sufficient amount”, “effective dose”, or “therapeutically effective amount” etc., refers to that amount of the therapeutic agent sufficient to ameliorate a disorder, as described above. For example, for the given parameter (e.g., mean time of survival), a therapeutically effective amount will show an increase or decrease of the therapeutic effect of at least 5%, 10%, 15%, 20%, 25%, 40%, 50%, 60%, 75%, 80%, 90%, or at least 100%. Therapeutic efficacy can also be expressed as “-fold” increase or decrease. For example, a therapeutically effective amount can have at least a 1.1-fold, 1.2-fold, 1.5-fold, 2-fold, 5-fold, or more effect over a control. The therapeutically effective amount may vary depending upon one or more of: the subject and disease condition being treated, the weight and age of the subject, the severity of the disease condition, the manner of administration and the like, which can readily be determined by one of ordinary skill in the art. The specific amount may vary depending on one or more of: the particular agent chosen, the target cell type, the location of the target cell in the subject, the dosing regimen to be followed, whether it is administered in combination with other compounds, timing of administration, and the physical delivery system in which it is carried.
[0112] For the purposes herein, an effective amount is determined by such considerations as may be known in the art. The amount must be effective to achieve the desired therapeutic effect in a subject suffering from cancer. The desired therapeutic effect may include, for example, amelioration of undesired symptoms associated with cancer, prevention of the manifestation of such symptoms before they occur, slowing down the progression of symptomsassociated with cancer, slowing down or limiting any irreversible damage caused by cancer, lessening the severity of or curing a cancer, or improving the survival rate or providing more rapid recovery from a cancer.
[0113] The effective amount depends, inter alia, on the type and severity of the disease to be treated and the treatment regime. The effective amount is typically determined in appropriately designed clinical trials (dose range studies) and the person versed in the art will know how to properly conduct such trials in order to determine the effective amount. As generally known, an effective amount depends on a variety of factors including the distribution profile of a therapeutic agent (e.g, a whole-cell cancer vaccine) or composition within the body, the relationship between a variety of pharmacological parameters (e.g., half-life in the body) and undesired side effects, and other factors such as age and gender, etc.
[0114] The term “pharmaceutically acceptable carrier” refers to a substance that aids the administration of an active agent to a cell, an organism, or a subject. “Pharmaceutically acceptable carrier” refers to a carrier or excipient that can be included in the compositions of the disclosure and that causes no significant adverse toxicological effect on the subject. Nonlimiting examples of pharmaceutically acceptable carriers include water, sodium chloride, normal saline solutions, lactated Ringer’s, normal sucrose, normal glucose, binders, fillers, disintegrants, lubricants, coatings, sweeteners, flavors and colors, liposomes, dispersion media, microcapsules, cationic lipid carriers, isotonic and absorption delaying agents, and the like. The carrier may also be substances for providing the formulation with stability, sterility and isotonicity (e.g. antimicrobial preservatives, antioxidants, chelating agents and buffers), for preventing the action of microorganisms (e.g. antimicrobial and antifungal agents, such as parabens, chlorobutanol, sorbic acid and the like) or for providing the formulation with an edible flavor etc. In some instances, the carrier is an agent that facilitates the delivery of a multi-specific binding protein to a target cell or tissue. One of skill in the art will recognize that other pharmaceutical carriers are useful in the present disclosure.
[0115] “ Inhibits” or “inhibition” as used herein, e.g, inhibition of characteristics such as cellular growth, proliferation, metabolic activity, viability, survival or division refers to a decrease in the characteristic relative to a control. In some cases, a multi-specific binding protein may inhibit one of the foregoing characteristics. For example, a cancer cell treated with one or more multi-specific binding proteins described herein may exhibit a decrease in one of the foregoing characteristics of approximately 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%,12%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 97.5%, 99%, 99.5%, 99.9% or more as compared to an untreated cell. In some cases, a cancer cell treated with a one or more multi-specific binding proteins described herein may exhibit a growth, proliferation, metabolic activity, viability, survival or division that is less than about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 12%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 97.5%, 99%, 99.5%, 99.9% of a control (e.g., untreated) cell. In some cases, the inhibited cancer cell is treated with one or more multispecific binding proteins described herein in the presence of immune cells. In some cases, the inhibited cancer cell is also treated with one or more additional modulators of immune cell function (e.g., one or more cytokines). In some cases, the inhibited cancer cell is also treated with one or more additional chemotherapeutic agents.
[0116] The terms “dose” and “dosage” are used interchangeably herein. A dose refers to the amount of active ingredient given to an individual at each administration. For the present invention, the dose can refer to the concentration of the multi-specific binding protein or associated components, e.g., the amount of therapeutic agent or dosage of radiolabel. The dose will vary depending on a number of factors, including frequency of administration; size and tolerance of the individual; severity of the condition; risk of side effects; the route of administration; and the imaging modality of the detectable moiety (if present). One of skill in the art will recognize that the dose can be modified depending on the above factors or based on therapeutic progress. The term “dosage form” refers to the particular format of the pharmaceutical and depends on the route of administration. For example, a dosage form can be in a liquid, e.g., a saline solution for injection.
[0117] “Subject,” “patient,” “individual” and like terms are used interchangeably and refer to, except where indicated, mammals such as humans and non-human primates, as well as rabbits, rats, mice, goats, pigs, and other mammalian species. The term does not necessarily indicate that the subject has been diagnosed with a particular disease, but typically refers to an individual under medical supervision. A patient can be an individual that is seeking treatment, monitoring, adjustment or modification of an existing therapeutic regimen, etc. A “cancer patient” can refer to an individual that has been diagnosed with cancer, is currently following a therapeutic regimen, or is at risk of recurrence, e.g., after surgery to remove a tumor. In some embodiments, the cancer patient has been diagnosed with cancer and is a candidate for therapy. Cancer patients can include individuals that have not received treatment, are currently receiving treatment, have had surgery, and those that have discontinued treatment.
[0118] In the context of treating cancer, a subject in need of treatment can refer to an individual that has cancer or a pre-cancerous condition, has had cancer and is at risk of recurrence, is suspected of having cancer, or is undergoing standard treatment for cancer, such as radiotherapy or chemotherapy, etc. In a preferred embodiment, the subject in need of treatment has epithelial, glandular or prostate cancer or Ewing’s sarcoma.
[0119] The term “combination effect” in the context of this invention refers to the effect resulting from a treatment with at least two structurally different therapeutic agents, such as two structurally different multi-specific binding proteins. Combination effects can be additive, synergistic, or antagonistic. Combination effects can, for instance, refer to the therapeutic efficacy. An additive effect means that the sum of the effects resulting from the individual therapeutic agents equals the effect resulting from the therapeutic agents applied in combination. A synergistic effect means that the combination effect is greater than the sum of the effects resulting from the individual therapeutic agents. An antagonistic effect means that the effect of the combination treatment is smaller than the sum of the effects resulting from the individual therapeutic agents. In some cases, additive, synergistic, or antagonistic effects can be readily detected by manual inspection of individual and combination treatment effects. In some cases, data on individual and combination treatment outcomes can suggest the presence of synergism.
[0120] Additionally, or in the alternative, a widely accepted method to identify the type of effect includes determining the “combination index” (CI) as described by Chou and Talalay (Chou, Pharmacol Rev, 58(3):621-681, 2006; Chou, Cancer Res, 70(2): 440-446, 2010; and US 2009 / 0324744), incorporated herein by reference. Drugs (e.g., multi-specific binding proteins) with a CI < 1 are thought to act synergistically, with a CI = 1 additively, and with a CI > 1 antagonistically. CI values for two mutually exclusive (similar mechanisms / modes of action) drugs are described by the classic isobologram formula CI = (D)l / (Dx)l + (D)2 / (Dx)2 (Formula 1), wherein (Dx)l means the concentration of Drug 1 without Drug 2 that results in a particular effect, for instance, 50% cell killing, and (Dx)2 refers to the concentration of Drug 2 without Drug 1 that leads to the same effect. (D)l and (D)2 are the individual concentrations of Drug 1 and Drug 2 in Drug 1-Drug 2 combinations.
[0121] Classic isobolograms are graphical representations of the concentrations of two drugs which in combination induce a particular effect, e.g., 50% cell killing, under the assumption the effects of the two drugs are additive (CI = 1). If Drug 1 concentrations are shown on theX-axis, and Drug 2 concentrations on the Y-axis, such isobolograms may be generated by drawing a straight line from the position on the X-axis representing the concentration of Drug 1 by which the particular effect is achieved without Drug 2 to the position on the Y-axis representing the concentration of Drug 2 by which the same effect is achieved without Drug 1. Actual data points (with combinations of drugs at concentrations resulting in the particular effect) outside the triangle given by the X-axis, Y-axis, and the aforementioned “straight line” refer to drugs acting (at the tested concentrations) antagonistically (CI > 1), on the “straight line” additively (CI = 1), and inside the triangle synergistically (CI < 1).
[0122] To assess whether experimental data supports synergistic, additive, or antagonistic relationships between two therapeutic agents, CI values may be calculated via software such as CompuSyn (by ComboSyn, Inc., available at combosyn.com).III. Detailed Description of the Embodiments
[0123] The present disclosure relates to multi-specific binding proteins designed to connect immune cells with cancer cells, thereby triggering an anti-cancer immune response in a subject in need. In some embodiments, the multi-specific binding protein binds to cancer cell surface proteins STEAP1, B7-H3, and / or EpCAM, and immune cell surface proteins CD3, IL-21R, IL-2R, CD28, PD-L1, PD-L2, and / or PD-1. The present disclosure also provides exemplary uses of these multi-specific binding proteins.A. Multi-Specific Binding Proteins
[0124] In one aspect, the present disclosure provides a multi-specific binding protein comprising at least one tumor-associated antigen binding domain (TAA-BD) and at least one immune modulatory domain (IMD). These domains enable the protein to bind both immune and cancer cells, thereby triggering and enhancing anti-cancer immune responses. Multispecific binding proteins activate immune cells within the tumor microenvironment and are also referred to herein as tumor-infiltrating lymphocyte activating reagents (TILsRx).
[0125] As illustrated in FIG. 1A, each TILsRx comprises an Fc dimer and four binding domains. The four binding domains can be either TAA-binding domains (TAA-BDs) or immune modulatory domains (IMDs). However, each TILsRx includes at least one TAA-BD and at least one IMD. In some embodiments, the binding domain is connected to the Fc dimer via a linker. In some embodiments, the linker contains a protease cleavage site (PCS)comprising at least one cleavage motif for a protease. In some embodiments, the linker does not contain a PCS.
[0126] As disclosed herein, in some embodiments, the multi-specific binding protein comprises (a) a first polypeptide comprising a first Fc region that is linked to a first domain at the N-terminus and a second domain at the C-terminus; and (b) a second polypeptide comprising a second Fc region that is linked to a third domain at the N-terminus and a fourth domain at the C-terminus. In some embodiments, each of the first, second, third, and fourth domains independently comprises a tumor-associated antigen (TAA) binding domain (TAA-BD) or an immune modulatory domain (IMD). In some embodiments, the multi-specific binding protein comprises at least one TAA-BD and at least one IMD. In some embodiments, the first Fc region and the second Fc region form an Fc dimer.
[0127] FIG. IB illustrates a schematic drawing of a binding domain of the multi-specific binding protein, which can be either a TAA-BD or an IMD. In some embodiments, the binding domain comprises an active domain (AD) that binds to a surface protein of a target cell, such as an immune cell or a cancer cell. In some embodiments, each AD comprises an antibody, a cytokine, a receptor, a receptor ligand, or any derivative, fragment or fusion thereof. In some embodiments, the antibody comprises a monoclonal antibody, domain antibody, single chain, Fab fragment, a F(ab')2 fragment, a single-chain variable fragment (scFv), a scab, a dAb, a single domain heavy chain antibody, or a single domain light chain antibody. In certain embodiments, the antibody comprises a scFv.
[0128] Also as illustrated in FIG. IB, in some embodiments, the binding domain comprising an AD, can further comprise an inhibitory domain (ID) which blocks the corresponding AD’s binding activity to the target cell. In some embodiments, the AD and ID are connected via a linker. In some embodiments, the linker contains a PCS comprising at least one cleavage motif for a protease.
[0129] The TILsRx elements and their functions are described in Table 1, and Table 2 provides examples of TILsRx domains.Table 1. Elements of A Multi-Specific Binding Protein (TILsRx)Domain Full Name and FunctionTAA-BD Tumor-Associated Antigen (TAA)-Binding Domain• Binds TAAs, anchors construct to tumorsIMD Immune Modulatory Domain• Binds surface proteins or receptors of immune cells, modulates (activates, inhibits, or acts as immune checkpoint inhibitor) immune cells such as T cells and NK cells directly or indirectly• An immune modulatory domain (IMD) can be:• Immune stimulatory• Immune inhibitory• Act as an Immune Checkpoint Inhibitor = anti-inhibitory• Or any combination of the abovePCS Protease Cleavage Site• Stretch of amino acids containing cleavage motif(s) for protease(s) present at sites of cancer cellsAD Active Domain• Biologically active part of TAA-BD or IMD• E.g., domain without a shielding mask directly binding to TAA• E.g., cytokine without a shielding mask capable of directly binding to receptorID Inhibitory Domain• Mask (shielding) domain to keep AD inactiveTable 2. Exemplary TILsRx DomainsDomain ExamplesTAA-BD, AD Anti-STEAPl scFv, anti-B7-H3 scFv, anti-EpCAM scFvIMD, AD Anti-CD3, IL-21, IL-2, CD80 ECD, CD86 ECD, anti-PD-Ll scFv, anti-PD-L2 scFv,PD-1 ECD(ECD: extracellular domain)ID Pro-domains of IL- lb, TGF-beta (LAP), PAS, CTLA4 for CD80PCS Cleavage motifs for MMPs, MT-SP1, cathepsin B, plasmin1. Tumor-Associated Antigen Binding Domains (TAA-BDs)
[0130] As disclosed herein, a TAA-BD of a multi-specific binding protein, through its AD, binds to a tumor-associated antigen (TAA) on a cancer cell, thereby anchoring the multispecific binding protein to the cancer cell. In some embodiments, the TAA-BD may comprise an antibody, a cytokine, a receptor, a receptor ligand, or any derivative, fragment or fusion thereof. In some embodiments, the TAA-BD may comprise a scFv that specifically binds to a TAA.
[0131] As used herein, the term “tumor-associated antigen” or “TAA” refers to a molecule-typically a protein, carbohydrate, lipid or some combination thereof-that is expressed on thesurface of a cancer cell, either entirely or as a fragment (e.g., MHC / peptide). As used herein, the term “cancer cell” or “cancerous cell” refers to a cell that is undergoing or has undergone uncontrolled proliferation. TAAs are particularly useful for selectively targeting pharmacological agents to cancer cells to facilitate their destruction.
[0132] In some instances, a TAA is expressed exclusively by cancer cells, either in full or as a fragment (e.g., MHC / peptide), and is not synthesized or expressed by normal (e.g., non-cancerous) cells. Such TAAs are specific to cancer cells and are sometimes known in the art as tumor-specific antigens (“TSAs”). Typically, TSAs are found in cancer cells only and not in healthy cells. TSAs may arise from oncogenic driver mutations that generate novel peptide sequences, such as neoantigens. A non-limiting example of a TSA is alpha fetoprotein (AFP), which is expressed in germ cell tumors and hepatocellular carcinoma.
[0133] In other instances, a TAA can be expressed by both normal (e.g., non-cancerous) cells and cancer cells, but at elevated levels in cancer cells compared to normal cells. In some embodiments, a TAA is a cell surface molecule that is overexpressed in cancer cells relative to normal cells, with overexpression levels ranging from 1-fold, 2-fold, or 3-fold to even higher levels. For example, a prostate TAA can be identified as an antigen that has a high expression level in prostate cancer cells relative to the highest mean expression level among normal prostate tissue cells. In some cases, a TAA may be highly expressed in both malignant and normal (benign) cells but not in normal nonprostatic cells. Such TAAs are especially relevant after the tissue harboring the primary tumor(s) has been removed by, e.g. , radical prostatectomy for prostate cancer because thereafter, in principle, only cancerous prostate cells - if any -remain in the body. The level of prostate cancer expression relative to highest mean expression level in normal nonprostatic male tissues is the PCa / MaxN value. In some cases, an antigen is identified as a prostate TAA if it has a PCa / MaxN value of at least about 2 (e.g., at least about 2, 2.5, 3, 4, 5, 8, 10 or more). In some cases, prostate TAAs can be identified as those that have a high expression level in the cancer cell relative to the second highest mean expression level among normal nonprostatic male tissues of the same origin. This ratio is referred to as the PCa / 2ndMaxN value. In some cases, an antigen is identified as a TAA if it has a PCa / 2ndMaxN value of at least about 2 or 3 (e.g., at least about 2, 2.5, 3, 4, 5, 8, 10 or more). In still other cases, an antigen can be identified as a TAA from a database, a scientific journal article, or a histological experiment. TAAs may also be expressed inappropriately in cancer cells, such as through deletions, additions or mutations in comparison to the molecule’s expression in normal cells.
[0134] Non-limiting examples of TAAs disclosed herein include six transmembrane epithelial antigen of the prostate 1 (STEAP1), B7 Homolog 3 (B7-H3, CD276), epithelial cell adhesion molecule (EpCAM), ABCC4, ANO7, CEACAM1, FOLH1, OR51E1, OR51E2, PSCA, SLC30A4, SLC45A3, SPON2, STEAP2, TARP, TMEFF2, TMPR8, TMPRSS2, vascular endothelial growth factor (VEGF), programmed cell death ligand 1 (PD-L1, B7-H1, CD274), programmed cell death 1 ligand 2 (PD-L2, CD273), cytotoxic T-lymphocyte associated protein 4 (CTLA-4, CD152), and V-domain immunoglobulin suppressor of T-cell activation (VISTA, VSIR), HER2 (ERBB2), HER3, Trop2 (TACSTD2), B7-H4 (VTCN1), MUC1, EGFRvIII, BCMA, CD19, CD20, CD22, CD33, CD123, CD138, CD171, PSMA, Ig-kappa, LeY, ROR1, FAP, FR, Glypican-3, IL13Ralpha2, mesothelin, and an NKG2D ligand. In some embodiments, the NKG2D ligand is selected from the group consisting of MICA, MICB, RAET1E, RAET1G, RAET1L, ULBP1, ULBP2, and ULBP3. In some embodiments, the TAA is expressed by glandular epithelial (gland) cells, prostate cancer cells, or Ewing sarcoma cells.
[0135] In some embodiments, the TAA comprises STEAP1 or a derivative, fragment, or fusion thereof. STEAP1, or six-transmembrane epithelial antigen of prostate 1, is a membrane protein primarily expressed in the prostate tissue and localized in the plasma membrane of epithelial cells at cell-to-cell junctions. STEAP1 expression is low or absent in normal tissues, and is significantly increased in various types of human cancers, including prostate cancer, Ewing sarcoma, breast cancer, and lung cancer.
[0136] In some embodiments, the multi-specific binding protein binds to STEAP1 of a cancer cell. In some embodiments, the multi-specific binding protein comprises at least one TAA-BD that its AD comprises an anti-STEAPl antibody. In some embodiments, the anti-STEAP1 antibody comprises a VH amino acid sequence having at least 80% identity to SEQ ID NO: 6 and a VL amino acid sequence having at least 80% identity to SEQ ID NO: 7. In some embodiments, the VH of the anti-STEAPl antibody comprises an amino acid sequence having at least 80%, 85%, or 90% identity to SEQ ID NO: 6 or comprises a sequence having at least 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 6. In some embodiments, the VL of the anti-STEAPl antibody comprises an amino acid sequence having at least 80%, 85%, or 90% identity to SEQ ID NO: 7 or comprises a sequence having at least 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 7. In some embodiments, the anti-STEAPl antibody comprises a VH amino acid sequence of SEQ ID NO: 6 and a VL amino acid sequence of SEQ ID NO: 7.
[0137] In some embodiments, the TAA comprises B7-H3 or a derivative, fragment, or fusion thereof. B7-H3, also known as CD276, is a member of the B7 family of immune checkpoint proteins and highly expressed in cancer cells and activated tumor-infiltrating immune cells. B7-H3 enables cancer cells to evade the surveillance of cytotoxic T-cells and natural killer cells. Its high expression, with limited heterogeneity, is observed in differentiated tumor cells, cancer-initiating cells (CICs), tumor-associated vasculature (TAV), and stroma, but not in normal tissues. These characteristics indicate that B7-H3 is a potent target for antibody-based immunotherapy.
[0138] In some embodiments, the multi-specific binding protein binds to B7-H3 of a cancer cell. In some embodiments, the multi-specific binding protein comprises at least one TAA-BD that its AD comprises an anti-B7-H3 antibody. In some embodiments, the anti-B7-H3 antibody comprises a VH amino acid sequence having at least 80% identity to SEQ ID NO: 4 and a VL amino acid sequence having at least 80% identity to SEQ ID NO: 5. In some embodiments, the VH of the anti-B7-H3 antibody comprises an amino acid sequence having at least 80%, 85%, or 90% identity to SEQ ID NO: 4 or comprises a sequence having at least 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 4. In some embodiments, the VL of the anti-B7-H3 antibody comprises an amino acid sequence having at least 80%, 85%, or 90% identity to SEQ ID NO: 5 or comprises a sequence having at least 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 5. In some embodiments, the anti-B7-H3 antibody comprises a VH amino acid sequence of SEQ ID NO: 4 and a VL amino acid sequence of SEQ ID NO: 5.
[0139] In some embodiments, the TAA comprises EpCAM or a derivative, fragment, or fusion thereof. EpCAM, or epithelial cell adhesion molecule (also known as CD326), is a transmembrane glycoprotein expressed on the surface of most epithelial cells and epithelial-derived neoplasms. EpCAM mediates Ca2+-independent homotypic cell-cell adhesion in epithelial tissues. EpCAM is also involved in cell signaling, migration, proliferation, and differentiation. Since EpCAM is expressed exclusively in epithelial tissues and epithelial-derived neoplasms, it serves as both a diagnostic marker for various cancers and a promising immunotherapeutic target for cancer treatment.
[0140] In some embodiments, the multi-specific binding protein binds to EpCAM of a cancer cell. In some embodiments, the multi-specific binding protein comprises at least one TAA-BD that its AD comprises an anti-EpCAM antibody. In some embodiments, the anti-EpCAM antibody comprises a VH amino acid sequence having at least 80% identity to SEQ ID NO: 109or 111, and a VL amino acid sequence having at least 80% identity to SEQ ID NO: 110 or 112. In some embodiments, the VH of the anti-EpCAM antibody comprises an amino acid sequence having at least 80%, 85%, or 90% identity to SEQ ID NO: 109 or 111, or comprises a sequence having at least 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 109 or 111. In some embodiments, the VL of the anti-EpCAM antibody comprises an amino acid sequence having at least 80%, 85%, or 90% identity to SEQ ID NO: 110 or 112, or comprises a sequence having at least 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 110 or 112. In some embodiments, the anti-EpCAM antibody comprises a VH amino acid sequence of SEQ ID NO: 109 and a VL amino acid sequence of SEQ ID NO: 110. In some embodiments, the anti-EpCAM antibody comprises a VH amino acid sequence of SEQ ID NO: 111 and a VL amino acid sequence of SEQ ID NO: 112.2. Immune Modulatory Domains (IMDs)
[0141] As disclosed herein, an IMD of a multi-specific binding protein binds, through its AD, to a surface protein on an immune cell, such as a T cell, B cell, or NK cell, thereby anchoring the multi-specific binding protein to the immune cell and modulating the immune cell. In some embodiments, the IMD may comprise an antibody, a cytokine, a receptor, a receptor ligand, or any derivative, fragment or fusion thereof. In some embodiments, the IMD may comprise a scFv that specifically binds to an immune cell surface protein.
[0142] As described herein, an immune modulatory domain (IMD) may function as an immune stimulatory factor, an immune inhibitory factor, an immune checkpoint inhibitor (CPI), or any combination thereof. In some embodiments, an IMD directly activates immune cells as an immune stimulatory factor. Examples of such IMDs include, but are not limited to, interleukin-2 (IL-2), interleukin-4 (IL-4), interleukin-5 (IL-5), interleukin-6 (IL-6), interleukin-12 (IL- 12), interleukin- 17 (IL- 17), interleukin-22 (IL-22), C-X-C chemokine receptor type 3 (CXCR3), interferon-gamma (INFy), tumor necrosis factor-alpha (TNFa), granulocytemacrophage colony-stimulating factor (GM-CSF), or any combination thereof. In other embodiments, an IMD prevents immune cell deactivation by inhibiting immune checkpoint factors, such as programmed death-ligand 1 (PD-L1), programmed cell death 1 ligand 2 (PD-L2), programmed death protein 1 (PD-1), cytotoxic T-lymphocyte-associated protein 4 (CTLA4), T-cell immunoglobulin and mucin-domain containing-3 (TIM3), lymphocyte activation gene 3 (LAG3), V-domain Ig suppressor of T-cell activation (VISTA), B- and T-lymphocyte attenuator (BTLA), or any combination thereof. Examples of IMDs acting as CPIsinclude, but are not limited to, PD-1 extracellular domain (ECD) (shielding / preventing PD-L1 on cancer cells from binding to T cell PD-1) and antibodies against immune checkpoint factors such as anti-PD-Ll antibodies or anti -PD-1 antibodies. In yet other embodiments, an IMD acts as an immune inhibitory factor, suppressing immune cell activity. Examples of IMDs acting as immune inhibitory factors include, but are not limited to, PD-L1 ECD (signaling via T cell PD-1) and PD-1 agonist antibodies. As disclosed herein, a multi-specific binding protein may comprise one or more types of IMDs. For example, a multi-specific binding protein may comprise one or more immune stimulatory factors and one or more immune checkpoint inhibitors.
[0143] In some embodiments, the immune cell surface protein is selected from the group consisting of CD2, CD3, CD27, CD28, CD69, ICOS, IL2RB, PTPRC (CD45), CD48, SELL, CD137 (4-1BB, TNFRSF9), CD134 (0X40, TNFRSF4), IL7R, IL15R, IL21R, CTLA4, PD-Ll, PD-L2, PD-1 (PDCD-1, CD279), TIGIT, and HAVCR2 (TIM3). As disclosed herein, CD3 comprises four distinct chains: CD3y (CD gamma chain), CD36 (CD3 delta chain), CD3s (CD3 epsilon chain), and CD3(^ (CD3 zeta chain, CD247). An IMD of a multi-specific binding protein may be designed to bind to one or more CD3 chains to activate cytotoxic T cells (CD8+ T cells) and / or T helper cells (CD4+ T cells).
[0144] In some embodiments, the multi-specific binding protein described herein is designed to bind to CD3, CD28, IL2R, IL21R, PD-L1, PD-L2, or PD-1 of an immune cell. For example, in some embodiments, a multi-specific binding protein targeting CD3 may include at least one IMD comprising an anti-CD3 antibody. Similarly, in some embodiments, a multi-specific binding protein targeting CD28 comprises one or more IMDs comprising an anti-CD28 antibody, CD80, CD86, or a derivative, fragment, fusion or combination thereof. In some embodiments, the one or more IMDs binding to CD28 comprises a CD80 extracellular domain (ECD) and / or a CD86 ECD. In some embodiments, the CD86 ECD is a variant comprising one or more substitutions according to the wild-type CD86 ECD (e.g., SEQ ID NO. 2). In some embodiments, a multi-specific binding protein may target the IL2 receptor (IL2R) on the surface of an immune cell and include at least one IMD comprising IL2. In some embodiments, a multi-specific binding protein targeting IL21 receptor (IL21R) on the surface of an immune cell may include one or more IMDs comprising IL21. In some embodiments, a multi-specific binding protein may target PD-L1 and comprise at least one binding domain comprising an anti-PD-Ll antibody, PD-1, or a derivative, fragment or fusion thereof. In some embodiments, the one or more IMDs binding to PD-L1 comprise a PD-1 ECD. Similarly, in someembodiments, a multi-specific binding protein targeting PD-1 may include at least one binding domain comprising an anti-PD-1 antibody, PD-L1, PD-L2, or a derivative, fragment or fusion thereof. In some embodiments, the one or more IMDs binding to PD-1 comprise a PD-L1 ECD and / or a PD-L2 ECD.a) Anti-CD3 antibodies
[0145] In some embodiments, the multi-specific binding protein binds to CD3 of an immune cell. In some embodiments, the multi-specific binding protein comprises at least one IMD that its AD comprises an anti-CD3 antibody. In some embodiments, the anti-CD3 antibody comprises a VH amino acid sequence having at least 80% identity to SEQ ID NO: 8 and a VL amino acid sequence having at least 80% identity to SEQ ID NO: 9. In some embodiments, the VH of the anti-CD3 antibody comprises an amino acid sequence having at least 80%, 85%, or 90% identity to SEQ ID NO: 8 or comprises a sequence having at least 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 8. In some embodiments, the VL of the anti-CD3 antibody comprises an amino acid sequence having at least 80%, 85%, or 90% identity to SEQ ID NO: 9 or comprises a sequence having at least 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 9. In some embodiments, the anti-CD3 antibody comprises a VH amino acid sequence of SEQ ID NO: 8 and a VL amino acid sequence of SEQ ID NO: 9.b) PD-L1
[0146] In some embodiments, the multi-specific binding protein binds to PD-1 of an immune cell. In some embodiments, the multi-specific binding protein comprises at least one IMD that its AD comprises a PD-L1 ECD or a fragment thereof. In some embodiments, the PD-L1 ECD comprises an amino acid sequence having at least 80% identity to SEQ ID NO: 117. In some embodiments, the PD-L1 ECD comprises an amino acid sequence having at least 80%, 85%, or 90% identity to SEQ ID NO: 117 or comprises an amino acid sequence having at least 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 117. In some embodiments, the PD-L1 ECD comprises an amino acid sequence of SEQ ID NO: 117.Q IL-21
[0147] In some embodiments, the multi-specific binding protein binds to IL-21R of an immune cell. In some embodiments, the multi-specific binding protein comprises at least one IMD that its AD comprises IL-21 or a fragment thereof. In some embodiments, the IL-21 comprises an amino acid sequence having at least 80% identity to SEQ ID NO: 1. In someembodiments, the IL-21 comprises an amino acid sequence having at least 80%, 85%, or 90% identity to SEQ ID NO: 1 or comprises an amino acid sequence having at least 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 1. In some embodiments, the IL-21 comprises an amino acid sequence of SEQ ID NO: 1.d) CD80 ECD
[0148] CD80 (also known as B7-1) is an important costimulatory molecule expressed on antigen-presenting cells (APCs). Through its extracellular domain (ECD), CD80 interacts in cis with PD-L1 on APCs or tumor cells and in trans with CD28 and CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) on T cells. In some embodiments, the multi-specific binding protein comprises at least one IMD that its AD comprises a CD80 ECD or a fragment thereof. In some embodiments, the CD80 ECD comprises an amino acid sequence having at least 80% identity to SEQ ID NO: 2. In some embodiments, the CD80 ECD comprises an amino acid sequence having at least 80%, 85%, or 90% identity to SEQ ID NO: 2 or comprises an amino acid sequence having at least 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 2. In some embodiments, the CD80 ECD comprises an amino acid sequence of SEQ ID NO: 2.
[0149] In some embodiments, the CD80 ECD of the multi-specific binding protein is a CD80 ECD variant comprising one or more substitutions according to the wild type (WT) CD80 ECD (e.g., SEQ ID NO. 2). These CD80 ECD variants exhibit alternative binding affinities for PD-Ll, CD28, and / or CTLA-4. In some embodiments, a multi-specific binding protein comprising a CD80 ECD variant exhibits increased binding affinity for PD-L1 compared with a multispecific binding protein comprising the WT CD80 ECD. In some embodiments, a multispecific binding protein comprising a CD80 ECD variant exhibits reduced binding affinity for CD28 compared with a multi-specific binding protein comprising the WT CD80 ECD. In some embodiments, a multi-specific binding protein comprising a CD80 ECD variant exhibits increased binding affinity for CTLA-4 compared with a multi-specific binding protein comprising the WT CD80 ECD. In some embodiments, a multi-specific binding protein comprising a CD80 ECD variant displays increased binding affinity for PD-L1 while simultaneously exhibiting reduced binding affinity for CD28 and / or increased binding affinity for CTLA-4. Such combinatorial modifications may enable context-dependent modulation of T-cell responses, including in PD-L1 -expressing environments, while reducing excessive CD28-mediated co-stimulation. This balance may be particularly desirable in clinical settingssuch as cancer immunotherapy, where precise regulation of immune checkpoint and costimulatory pathways is critical.(1) CD80 ECD Variants with Increased PD-L1 Binding Affinity
[0150] In some embodiments, the present disclosure provides multi-specific binding proteins comprising one or more CD80 ECD variants with increased binding affinity for PD-L1. As disclosed herein, the increased affinity may result from one or more amino acid substitutions within the IgV and / or IgC domains of the WT CD80 ECD.
[0151] The multi-specific binding proteins comprising such CD80 ECD variants potentiate the blockade of PD-L1, thereby enhancing immune checkpoint inhibition and promoting antitumor immunity. Increased binding to PD-L1 may effectively neutralize its immunosuppressive activity, leading to greater T cell activation and improved therapeutic efficacy in cancer and other diseases where PD-L1 expression is upregulated. In some embodiments, the binding affinity of the CD80 ECD variant for PD-L1 is increased by at least 1.5-fold, at least 2-fold, at least 3-fold, at least 5-fold, at least 10-fold, or at least 20-fold compared to the wild-type (WT) CD80 ECD. In particular embodiments, the binding affinity of the CD80 ECD variant for PD-L1 is increased by at least 2-fold compared to the WT CD80 ECD. The degree of affinity increase may vary depending on the specific substitutions introduced and the method of measurement. Affinity increases may be determined, for example, by surface plasmon resonance (SPR), biolayer interferometry (BLI), enzyme-linked immunosorbent assay (ELISA), or other suitable binding assays.
[0152] In some embodiments, the binding affinity of the CD80 ECD variant for PD-L1 falls within a range of about 2-fold to about 10-fold, about 2-fold to about 20-fold, about 2-fold to about 50-fold, or about 2-fold to about 100-fold greater than that of the WT CD80 ECD. In some embodiments, the affinity increase is within a range of about 1.5-fold to about 50-fold, about 10-fold to about 100-fold, or about 20-fold to about 200-fold.
[0153] In some embodiments, the CD80 ECD variant with increased binding affinity for PD-L1 comprises at least one, two, three, or more amino acid substitutions as described herein. In some embodiments, the substitutions occur at positions 8, 9, 10, 11, 13, 35, 47, 54, 55, 56, 57, 58, 60, 62, 63, 68, 70, 71, 107, 158, 159, 160, and 161, wherein the substitutions and the positions are determined with reference to SEQ ID NO: 2. In particular embodiments, the CD80 ECD variant with increased binding affinity for PD-L1 comprises one, two, three, four,five, six, seven, eight, nine, ten, or more substitutions listed in Table 16 of the present disclosure.
[0154] It is of note that, to date, there does not appear to be reported that specific residues within the CD80 IgC domain directly interact with PD-L1 and thereby contribute to enhanced affinity of the CD80 ECD for PD-L1. The current understanding is that the IgC domain of CD80 primarily modulates the binding of the IgV domain to its canonical receptors, for example, by shielding the hydrophobic binding face in the N-terminal IgV domain from solvent. In this context, the identification and characterization of novel CD80 ECD variants harboring mutations within the IgC domain, such as substitutions at positions 107, 158, 159, 160, and 161, that result in enhanced PD-L1 binding represent a significant and unexpected advance. These newly discovered substitutions are believed to confer unique functional properties, advancing understanding of the structural determinants underlying CD80 ECD interactions and providing new strategies to modulate immune responses.
[0155] In these embodiments, the CD80 ECD variant of the multi-specific binding protein described herein comprises one, two, three, four, or five substitutions at amino acid positions 8, 56, 158, 159, and 161, wherein the substitutions and positions are determined with reference to SEQ ID NO: 2. In some embodiments, the substitution at position 8 is selected from A, C, F, I, K, L, M, R, T, W, or Y. In particular embodiments, the substitution at position 8 is I or W. In some embodiments, the substitution at position 56 is K. In some embodiments, the substitution at position 158 is selected from A, C, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W, or Y. In some embodiments, the substitution at position 159 is selected from A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W, or Y. In particular embodiments, the substitution at position 159 is A, C, F, G, H, I, K, L, M, N, Q, S, T, V, W, or Y. In some embodiments, the substitution at position 161 is selected from A, C, D, E, F, G, H, I, K, L, M, N, P, Q, S, V, or Y.
[0156] In some embodiments, the CD80 ECD variant of the multi-specific binding protein described herein comprising the one or more substitutions at amino acid positions 8, 56, 158, 159, and 161, further comprises one, two, three, four, five, or more substitutions at positions 9, 10, 11, 13, 35, 47, 54, 55, 57, 58, 60, 62, 63, 68, 70, 71, 107, and 160. In some embodiments, the substitution at position 9 is R. In some embodiments, the substitution at position 10 is selected from A, C, D, F, G, H, I, K, L, M, N, Q, R, S, T, V, W, or Y. In particular embodiments, the substitution at position 10 is A, C, D, F, H, I, K, L, M, N, Q, R, S, T, V, W, or Y. In some embodiments, the substitution at position 11 is selected from A, C, F, H, I, K, L, M, Q, R, S,T, W, or Y. In particular embodiments, the substitution at position 11 is C, F, H, I, L, M, T, W, or Y. In some embodiments, the substitution at position 13 is selected from A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, V, W, or Y. In particular embodiments, the substitution at position 13 is A, C, D, E, F, H, I, L, M, Q, S, V, W, or Y. In some embodiments, the substitution at position 35 is selected from A, C, D, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y. In some embodiments, the substitution at position 47 is selected from A, C, E, F, G, H, I, L, N, Q, R, S, T, V, W, or Y. In particular embodiments, the substitution at position 47 is A, C, F, H, I, L, Q, T, V, W, or Y. In some embodiments, the substitution at position 54 is selected from A, C, D, E, F, G, H, I, L, M, N, P, Q, R, S, T, V, W, or Y. In particular embodiments, the substitution at position 54 is A, C, D, E, F, G, H, I, L, M, N, Q, R, S, T, V, W, or Y. In some embodiments, the substitution at position 55 is selected from A, C, E, F, G, H, I, K, L, M, P, Q, R, S, T, V, W, or Y. In some embodiments, the substitution at position 57 is selected from A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, or W. In particular embodiments, the substitution at position 57 is A, C, F, H, I, L, M, S, V, or W. In some embodiments, the substitution at position 58 is selected from C, F, L, M, Q, R, T, V, W, or Y. In particular embodiments, the substitution at position 58 is C, F, L, M, V, W, or Y. In some embodiments, the substitution at position 60 is selected from A, C, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W, or Y. In particular embodiments, the substitution at position 60 is E. In some embodiments, the substitution at position 62 is selected from A, C, D, E, F, G, H, K, L, M, N, P, Q, R, S, V, W, or Y. In some embodiments, the substitution at position 63 is selected from A, C, D, E, F, G, H, I, K, L, M, P, Q, R, S, T, V, or W. In particular embodiments, the substitution at position 63 is A, C, D, E, F, G, H, I, L, M, Q, S, T, V, W, or Y. In some embodiments, the substitution at position 68 is selected from A, C, D, F, I, L, M, N, Q, S, T, or Y. In particular embodiments, the substitution at position 68 is C, F, I, L, M, T, or Y. In some embodiments, the substitution at position 70 is C, F, M, or Y. In some embodiments, the substitution at position 71 is selected from D, G, I, L, M, N, Q, T, or V. In particular embodiments, the substitution at position 71 is D, I, L, M, or V. In some embodiments, the substitution at position 107 is selected from A, C, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y. In particular embodiments, the substitution at position 107 is A, C, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W, or Y. In some embodiments, the substitution at position 160 is selected from A, C, F, G, H, I, K, L, M, N, Q, R, S, T, V, W, or Y.
[0157] In particular embodiments, the CD80 ECD variant described herein comprises one substitution at position 8 and at least one more substitution at positions 60, 68, and 160. In some instances, the CD80 ECD variant comprises two substitutions at positions 8 and 68 (e.g.,V8W and V68M). In other instances, the CD80 ECD variant comprises two substitutions at positions 8 and 160 (e.g., V8W and E160R).
[0158] In some embodiments, the present disclosure provides a multi-specific binding protein comprising a CD80 ECD variant, which is characterized by at least two amino acid substitutions at positions 60, 68, and 160, numbered and substituted according to SEQ ID NO: 2.
[0159] In certain embodiments, the substitutions at these positions may be independently selected from a specified group of amino acids. In some embodiments, the substitution at position 60 is A, C, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W, or Y. In particular embodiments, the substitution at position 60 is E. In some embodiments, the substitutions at position 68 may include A, C, D, F, I, L, M, N, Q, S, T, or Y. In particular embodiments, the substitution at position 68 is C, F, I, L, M, T, or Y. In some embodiments, the substitutions at position 160 may include A, C, F, G, H, I, K, L, M, N, Q, R, S, T, V, W, or Y.
[0160] As disclosed herein, the present disclosure encompasses all combinations of at least two substitutions among these positions, such as at positions 60 and 68, at positions 60 and 160, or at positions 68 and 160. For example, the at least two substitutions can be D60E and V68M, D60E and E160R, or V68M and E160R. In specific embodiments, the CD80 ECD variant may comprise three substitutions at positions 60, 68, and 160 (e.g., D60E, V68M, and E160R).
[0161] In further embodiments, the CD80 ECD variant of the multi-specific binding protein may include additional substitutions at one, two, three, four, five, or more of the following positions: 8, 9, 10, 11, 13, 35, 47, 54, 55, 56, 57, 58, 62, 63, 70, 71, 107, 158, 159, and 161. Each position may be substituted with one or more specified amino acids.
[0162] In some embodiments, the substitution at position 8 may be A, C, F, I, K, L, M, R, T, W, or Y. In particular embodiments, the substitution at position 8 is I or W. In some embodiments, the CD80 ECD variant comprises a substitution at position 9, wherein the substituted residue is R. In some embodiments, the CD80 ECD variant comprises a substitution at position 10, wherein the substituted residue is selected from A, C, D, F, G, H, I, K, L, M, N, Q, R, S, T, V, W, or Y. In particular embodiments, the substitution at position 10 is A, C, D, F, H, I, K, L, M, N, Q, R, S, T, V, W, or Y. In some embodiments, the CD80 ECD variant comprises a substitution at position 11, wherein the substituted residue is selected from A, C, F, H, I, K, L, M, Q, R, S, T, W, or Y. In particular embodiments, the substitution at position 11is C, F, H, I, L, M, T, W, or Y. In some embodiments, the CD80 ECD variant comprises a substitution at position 13, wherein the substituted residue is selected from A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, V, W, or Y. In particular embodiments, the substitution at position 13 is A, C, D, E, F, H, I, L, M, Q, S, V, W, or Y. In some embodiments, the CD80 ECD variant comprises a substitution at position 35, wherein the substituted residue is selected from A, C, D, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y. In some embodiments, the CD80 ECD variant comprises a substitution at position 47, wherein the substituted residue is selected from A, C, E, F, G, H, I, L, N, Q, R, S, T, V, W, or Y. In particular embodiments, the substitution at position 47 is A, C, F, H, I, L, Q, T, V, W, or Y. In some embodiments, the CD80 ECD variant comprises a substitution at position 54, wherein the substituted residue is selected from A, C, D, E, F, G, H, I, L, M, N, P, Q, R, S, T, V, W, or Y. In particular embodiments, the substitution at position 54 is A, C, D, E, F, G, H, I, L, M, N, Q, R, S, T, V, W, or Y. In some embodiments, the CD80 ECD variant comprises a substitution at position 55, wherein the substituted residue is selected from A, C, E, F, G, H, I, K, L, M, P, Q, R, S, T, V, W, or Y. In some embodiments, the CD80 ECD variant comprises a substitution at position 56, wherein the substituted residue is K. In some embodiments, the CD80 ECD variant comprises a substitution at position 57, wherein the substituted residue is selected from A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, V, or W. In particular embodiments, the substitution at position 57 is A, C, F, H, I, L, M, S, V, or W. In some embodiments, the CD80 ECD variant comprises a substitution at position 58, wherein the substituted residue is selected from C, F, L, M, Q, R, T, V, W, or Y. In particular embodiments, the substitution at position 58 is C, F, L, M, V, W, or Y. In some embodiments, the CD80 ECD variant comprises a substitution at position 62, wherein the substituted residue is selected from A, C, D, E, F, G, H, K, L, M, N, P, Q, R, S, V, W, or Y. In some embodiments, the CD80 ECD variant comprises a substitution at position 63, wherein the substituted residue is selected from A, C, D, E, F, G, H, I, K, L, M, P, Q, R, S, T, V, or W. In particular embodiments, the substitution at position 63 is A, C, D, E, F, G, H, I, L, M, Q, S, T, V, W, or Y. In some embodiments, the CD80 ECD variant comprises a substitution at position 70, wherein the substituted residue is C, F, M, or Y. In some embodiments, the CD80 ECD variant comprises a substitution at position 71, wherein the substituted residue is D, G, I, L, M, N, Q, T, or V. In particular embodiments, the substitution at position 71 is D, I, L, M, or V. In some embodiments, the CD80 ECD variant comprises a substitution at position 107, wherein the substituted residue is selected from A, C, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y. In particular embodiments, the substitution at position 107 is A, C, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W, or Y. In some embodiments, the CD80 ECD variant comprises a substitutionat position 158, wherein the substituted residue is selected from A, C, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W, or Y. In some embodiments, the CD80 ECD variant comprises a substitution at position 159, wherein the substituted residue is selected from A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W, or Y. In particular embodiments, the substitution at position 159 is A, C, F, G, H, I, K, L, M, N, Q, S, T, V, W, or Y. In some embodiments, the CD80 ECD variant comprises a substitution at position 161, wherein the substituted residue is selected from A, C, D, E, F, G, H, I, K, L, M, N, P, Q, S, V, or Y.(2) CD80 ECD Variants That Modulate CD28 and / or CTLA4 Binding Affinities
[0163] In some embodiments, the multi-specific binding protein comprising one or more CD80 ECD variants exhibits reduced binding affinity for CD28 relative to, or binding affinity for CD28 no greater than, that of the WT CD80 ECD. The reduced affinity of the CD80 ECD variant for CD28 can be beneficial in therapeutic applications where it is desirable to decrease or modulate CD28-mediated signaling while retaining or enhancing other functional properties of the CD80 molecule. As disclosed herein, the reduced affinity for CD28 may result from one or more amino acid substitutions within the IgV domain of the CD80 ECD.
[0164] In some embodiments, the binding affinity of the CD80 ECD variant for CD28 is reduced by a certain percentage relative to the WT CD80 ECD. The reduction in binding affinity may be measured as a percentage decrease in the equilibrium dissociation constant (KD), the association or dissociation rate constants (konor koir), or by other quantitative assays such as surface plasmon resonance (SPR), bio-layer interferometry (BLI), or enzyme-linked immunosorbent assay (ELISA) using recombinant CD28.
[0165] In some instances, the binding affinity of the CD80 ECD variant for CD28 is reduced by at least 10%, 20%, 30%, 40%, or 50% relative to WT CD80 ECD. In other instances, the reduction in affinity may be by at least 60%, 70%, 80%, or 90% relative to WT CD80 ECD. In particular embodiments, the CD80 ECD variant has a binding affinity for CD28 that is reduced by at least 50%. In some embodiments, the binding affinity is reduced by a range, for example, within a range of about 10% to about 90%, from about 20% to about 80%, from about 30% to about 70%, or from about 40% to about 60% relative to the WT CD80 ECD.
[0166] In some embodiments, the binding affinity of the CD80 ECD variant for CD28 is reduced to a specific fold, for example, reduced to 0.9-fold, 0.8-fold, 0.7-fold, 0.6-fold, 0.5-fold, 0.4-fold, 0.3-fold, 0.2-fold, or 0.1-fold compared to the binding affinity of the WT CD80 ECD.
[0167] In some embodiments, the present disclosure provides a multi-specific binding protein comprising one or more CD80 ECD variants with increased binding affinity for CTLA4, compared to that of the WT CD80 ECD. As disclosed herein, the increased affinity for CTLA4 may result from one or more amino acid substitutions within the IgV domain of the CD80 ECD.
[0168] In some embodiments, the binding affinity of the CD80 ECD variant for CTLA4 is increased by at least 1.5-fold, at least 2-fold, at least 5-fold, at least 10-fold, at least 20-fold compared to the WT CD80 ECD. In particular embodiments, the binding affinity of the CD80 ECD variant for CTLA4 is increased by at least 2-fold compared to the WT CD80 ECD. The degree of affinity increase may vary depending on the specific substitutions introduced and the method of measurement. Affinity increases may be determined, for example, by surface plasmon resonance (SPR), biolayer interferometry (BLI), enzyme-linked immunosorbent assay (ELISA), or other suitable binding assays.
[0169] In some embodiments, the binding affinity of the CD80 ECD variant for CTLA4 falls within a range of about 2-fold to about 10-fold, about 2-fold to about 20-fold, about 2-fold to about 50-fold, or about 2-fold to about 100-fold greater than that of the WT CD80 ECD. In some embodiments, the affinity increase is within a range of about 1.5-fold to about 50-fold, about 10-fold to about 100-fold, or about 20-fold to about 200-fold.
[0170] In some embodiments, the present disclosure provides a multi-specific binding protein comprising one or more CD80 ECD variants which exhibit reduced binding affinity for CD28 while maintaining or enhancing binding affinity for CTLA-4. Such variants are advantageous for selectively modulating T cell responses, for example, by diminishing costimulatory signaling through CD28 while preserving or potentiating the inhibitory regulation mediated by CTLA-4. In some embodiments, the CD80 ECD variant maintains or enhances binding affinity for CTLA-4, thus preserving or augmenting immune inhibitory functions while reducing stimulatory signals via CD28. These modifications support the therapeutic potential of CD80 ECD variants in conditions where dampening T cell activation is desirable, such as autoimmune disease or transplantation.
[0171] As increases of the CD80-CTLA4 affinity are considered beneficial, CD80 ECD variants can be ranked based on their differential effects between CD28- and CTLA-4 binding,with those having larger differences potentially reducing the CD28 affinity more substantially than the CTLA-4 affinity or even having an increased CTLA-4 affinity.
[0172] In some embodiments, the CD80 ECD variant with reduced binding affinity for CD28 and / or increased binding affinity for CTLA-4 comprises at least one, two, three, or more amino acid substitutions as described herein. In some embodiments, the substitutions occur at positions 29, 31, 33, 36, 38, 50, 81, 83, 85, 88, 90, 91, 92, 93, 94, and 97, wherein the substitutions and the positions are determined with reference to SEQ ID NO: 2. In particular embodiments, the CD80 ECD variant with reduced binding affinity for CD28 and / or increased binding affinity for CTLA-4 comprises one, two, three, four, five, six, seven, eight, nine, ten, or more substitutions listed in Table 17. In particular embodiments, the one or more substitutions of CD80 ECD that reduce binding affinity for CD28 and / or increase binding affinity for CTLA-4 occur at positions 50, 54, and / or 88.
[0173] In another aspect, the present disclosure provides a multi-specific binding protein comprising a CD80 ECD variant with one, two, three, four, five, or more substitutions at amino acid positions 29, 31, 33, 36, 38, 50, 81, 83, 85, 88, 90, 91, 92, 93, 94, and 97, wherein the substitutions and the positions are determined with reference to SEQ ID NO: 2. In some embodiments, such CD80 ECD variant exhibits reduced binding affinity for CD28. In some embodiments, such CD80 ECD variant exhibits increased binding affinity for CTLA-4. In some embodiments, such CD80 ECD variant exhibits reduced binding affinity for CD28 and increased binding affinity for CTLA-4.
[0174] In some embodiments, the substitution at position 29 is V, H, E, F, Q, T, S, G, N, A, C, D, P, K, I, or M. In some embodiments, the substitution at position 31 is W, F, E, I, V, H, T, M, C, P, A, D, G, S, N, Q, K, or R. In some embodiments, the substitution at position 33 is D, R, N, E, P, S, A, K, or G. In some embodiments, the substitution at position 36 is P. In some embodiments, the substitution at position 38 is W, R, K, H, T, Q, I, E, C, D, A, P, S, G, or N. In some embodiments, the substitution at position 50 is P, K, Q, D, N, S, E, R, A, G, H, C, I, T, V, M, or F. In some embodiments, the substitution at position 81 is P. In some embodiments, the substitution at position 83 is K, R, C, T, E, G, H, A, S, P, N, Q, or D. In some embodiments, the substitution at position 85 is R, H, K, D, V, C, T, G, E, N, A, S, P, I, or Q. In some embodiments, the substitution at position 88 is P, K, N, S, or D. In some embodiments, the substitution at position 90 is P. In some embodiments, the substitution at position 91 is R, K, N, P, or Q. In some embodiments, the substitution at position 92 is R, S,G, A, E, N, D, P, or Q. In some embodiments, the substitution at position 93 is N, P, or D. In some embodiments, the substitution at position 94 is P, H, or D. In some embodiments, the substitution at position 97 is M, F, I, H, C, V, E, T, N, D, P, A, G, S, R, Q, or K.
[0175] In some embodiments, the one or more substitutions at positions 29, 31, 33, 36, 38, 50, 81, 83, 85, 88, 90, 91, 92, 93, 94, and 97 are selected from the group consisting of R29V, R29H, R29E, R29F, R29Q, R29T, R29S, R29G, R29N, R29A, R29C, R29D, R29P, R29K, R29I, R29M, Y31W, Y31F, Y31E, Y31I, Y31V, Y31H, Y31T, Y31M, Y31C, Y31P, Y31A, Y31D, Y31G, Y31S, Y31N, Y31Q, Y31K, Y31R, Q33D, Q33R, Q33N, Q33E, Q33P, Q33S, Q33A, Q33K, Q33G, K36P, M38W, M38R, M38K, M38H, M38T, M38Q, M38I, M38E, M38C, M38D, M38A, M38P, M38S, M38G, M38N, W50P, W50K, W50Q, W50D, W50N, W50S, W50E, W50R, W50A, W50G, W50H, W50C, W50I, W50T, W50V, W50M, W50F, E81P, V83K, V83R, V83C, V83T, V83E, V83G, V83H, V83A, V83S, V83P, V83N, V83Q, V83D, L85R, L85H, L85K, L85D, L85V, L85C, L85T, L85G, L85E, L85N, L85A, L85S, L85P, L85I, L85Q, E88P, E88K, E88N, E88S, E88D, D90P, A91R, A91K, A91N, A91P, A91Q, F92R, F92S, F92G, F92A, F92E, F92N, F92D, F92P, F92Q, K93N, K93P, K93D, R94P, R94H, R94D, R94S, L97M, L97F, L97I, L97H, L97C, L97V, L97E, L97T, L97N, L97D, L97P, L97A, L97G, L97S, L97R, L97Q, and L97K.(3) CD80 ECD Variants with Increased PD-L1 Affinity and Reduced CD28 Affinity
[0176] The present disclosure further provides a multi-specific binding protein comprising one or more CD80 ECD variants, wherein the protein exhibits increased binding affinity for PD-L1 and reduced binding affinity for CD28. Such dual modifications allow for differential modulation of T cell responses, favoring immune activation in the presence of PD-L1 but limiting overstimulation via CD28. This balance is particularly desirable in clinical settings, such as cancer immunotherapy, where precise regulation of immune checkpoints is critical.
[0177] As disclosed herein, the CD80 ECD variants are selected to increase the PD-L1 binding affinity by at least 1.5-fold, 2-fold, 5-fold, 10-fold, or more, compared to WT CD80 ECD. These affinity enhancements may span a range, for example, from 1.2-fold to 20-fold, depending on the specific combination of mutations introduced. Concurrently, the CD80 ECD variants may exhibit a reduction in CD28 binding affinity by at least 50%, 70%, or 90%, with exemplary ranges from 10% to 95% reduction relative to WT CD 80 ECD.
[0178] These CD80 ECD variants can be achieved by combining mutations previously identified to enhance PD-L1 interaction, as disclosed in the section “CD80 ECD Variants with Increased Binding Affinity For PD-L1” with those that attenuate CD28 binding, as disclosed in the section “CD80 ECD Variants That Modulate CD28 and / or CTLA4 Binding Affinities”.
[0179] In one aspect, the present disclosure provides a multi-specific binding protein comprising a CD80 ECD variant, wherein the CD80 ECD variant comprises one or more amino acid substitutions at positions selected from the group consisting of 8, 9, 10, 11, 13, 35, 47, 54, 55, 56, 57, 58, 60, 62, 63, 68, 70, 71, 107, 158, 159, 160, and 161, and one or more substitutions at amino acid positions selected from the group consisting of 29, 31, 33, 36, 38, 50, 81, 83, 85, 88, 90, 91, 92, 93, 94, and 97, wherein the substitutions and the positions are determined with reference to SEQ ID NO: 2. In some embodiments, the CD80 ECD variant with increased PD-L1 affinity and reduced CD28 affinity comprises one, two, three, four, five, or more substitutions selected from Table 16 and one, two, three, four, five, or more substitutions selected from Table 17.
[0180] In some embodiments, the CD80 ECD variant with increased PD-L1 affinity and reduced CD28 affinity comprises (i) one or more substitutions at amino acid positions 8, 56, 158, 159, and 161, and (ii) one or more substitutions at amino acid positions 29, 31, 33, 36, 38, 50, 81, 83, 85, 88, 90, 91, 92, 93, 94, and 97, wherein the substitutions and the positions are determined with reference to SEQ ID NO: 2.
[0181] In some embodiments, the substitution at position 8 is selected from A, C, F, I, K, L, M, R, T, W, or Y. In particular embodiments, the substitution at position 8 is I or W. In some embodiments, the substitution at position 56 is K. In some embodiments, the substitution at position 158 is selected from A, C, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W, or Y. In some embodiments, the substitution at position 159 is selected from A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W, or Y. In particular embodiments, the substitution at position 159 is A, C, F, G, H, I, K, L, M, N, Q, S, T, V, W, or Y. In some embodiments, the substitution at position 161 is selected from A, C, D, E, F, G, H, I, K, L, M, N, P, Q, S, V, or Y. In some embodiments, the substitution at position 29 is V, H, E, F, Q, T, S, G, N, A, C, D, P, K, I, or M. In some embodiments, the substitution at position 31 is W, F, E, I, V, H, T, M, C, P, A, D, G, S, N, Q, K, or R. In some embodiments, the substitution at position 33 is D, R, N, E, P, S, A, K, or G. In some embodiments, the substitution at position 36 is P. In some embodiments, the substitution at position 38 is W, R, K, H, T, Q, I, E, C, D, A, P, S, G, or N. In someembodiments, the substitution at position 50 is P, K, Q, D, N, S, E, R, A, G, H, C, I, T, V, M, or F. In some embodiments, the substitution at position 81 is P. In some embodiments, the substitution at position 83 is K, R, C, T, E, G, H, A, S, P, N, Q, or D. In some embodiments, the substitution at position 85 is R, H, K, D, V, C, T, G, E, N, A, S, P, I, or Q. In some embodiments, the substitution at position 88 is P, K, N, S, or D. In some embodiments, the substitution at position 90 is P. In some embodiments, the substitution at position 91 is R, K, N, P, or Q. In some embodiments, the substitution at position 92 is R, S, G, A, E, N, D, P, or Q. In some embodiments, the substitution at position 93 is N, P, or D. In some embodiments, the substitution at position 94 is P, H, or D. In some embodiments, the substitution at position 97 is M, F, I, H, C, V, E, T, N, D, P, A, G, S, R, Q, or K.
[0182] In some embodiments, the CD80 ECD variant with increased PD-L1 affinity and reduced CD28 affinity further comprises (iii) one or more substitutions at positions 9, 10, 11, 13, 35, 47, 54, 55, 57, 58, 60, 62, 63, 68, 70, 71, 107, and 160.
[0183] In some embodiments, the substitution at position 9 is R. In some embodiments, the substitution at position 10 is selected from A, C, D, F, G, H, I, K, L, M, N, Q, R, S, T, V, W, or Y. In particular embodiments, the substitution at position 10 is A, C, D, F, H, I, K, L, M, N, Q, R, S, T, V, W, or Y. In some embodiments, the substitution at position 11 is selected from A, C, F, H, I, K, L, M, Q, R, S, T, W, or Y. In particular embodiments, the substitution at position 11 is C, F, H, I, L, M, T, W, or Y. In some embodiments, the substitution at position 13 is selected from A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, V, W, or Y. In particular embodiments, the substitution at position 13 is A, C, D, E, F, H, I, L, M, Q, S, V, W, or Y. In some embodiments, the substitution at position 35 is selected from A, C, D, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y. In some embodiments, the substitution at position 47 is selected from A, C, E, F, G, H, I, L, N, Q, R, S, T, V, W, or Y. In particular embodiments, the substitution at position 47 is A, C, F, H, I, L, Q, T, V, W, or Y. In some embodiments, the substitution at position 54 is selected from A, C, D, E, F, G, H, I, L, M, N, P, Q, R, S, T, V, W, or Y. In particular embodiments, the substitution at position 54 is A, C, D, E, F, G, H, I, L, M, N, Q, R, S, T, V, W, or Y. In some embodiments, the substitution at position 55 is selected from A, C, E, F, G, H, I, K, L, M, P, Q, R, S, T, V, W, or Y. In some embodiments, the substitution at position 57 is selected from A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, or W. In particular embodiments, the substitution at position 57 is A, C, F, H, I, L, M, S, V, or W. In some embodiments, the substitution at position 58 is selected from C, F, L, M, Q, R, T, V, W, or Y. In particular embodiments, the substitution at position 58 is C, F, L, M, V, W, or Y.In some embodiments, the substitution at position 60 is selected from A, C, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W, or Y. In particular embodiments, the substitution at position 60 is E. In some embodiments, the substitution at position 62 is selected from A, C, D, E, F, G, H, K, L, M, N, P, Q, R, S, V, W, or Y. In some embodiments, the substitution at position 63 is selected from A, C, D, E, F, G, H, I, K, L, M, P, Q, R, S, T, V, or W. In particular embodiments, the substitution at position 63 is A, C, D, E, F, G, H, I, L, M, Q, S, T, V, W, or Y. In some embodiments, the substitution at position 68 is selected from A, C, D, F, I, L, M, N, Q, S, T, or Y. In particular embodiments, the substitution at position 68 is C, F, I, L, M, T, or Y. In some embodiments, the substitution at position 70 is C, F, M, or Y. In some embodiments, the substitution at position 71 is selected from D, G, I, L, M, N, Q, T, or V. In particular embodiments, the substitution at position 71 is D, I, L, M, or V. In some embodiments, the substitution at position 107 is selected from A, C, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y. In particular embodiments, the substitution at position 107 is A, C, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W, or Y. In some embodiments, the substitution at position 160 is selected from A, C, F, G, H, I, K, L, M, N, Q, R, S, T, V, W, or Y.
[0184] In particular embodiments, the CD80 ECD variant with increased PD-L1 affinity and reduced CD28 affinity comprises (i) one substitution at position 8 (e.g., V8W), (ii) at least one more substitution at positions 60, 68, and 160 (e.g., D60E, V68M, E160R), and (iii) one or more substitutions at amino acid positions 29, 31, 33, 36, 38, 50, 81, 83, 85, 88, 90, 91, 92, 93, 94, and 97, wherein the substitutions and the positions are determined with reference to SEQ ID NO: 2.
[0185] In some embodiments, the CD80 ECD variant with increased PD-L1 affinity and reduced CD28 affinity comprises (i) at least two amino acid substitutions at positions 60, 68, and 160, and (ii) one or more substitutions at amino acid positions 29, 31, 33, 36, 38, 50, 81, 83, 85, 88, 90, 91, 92, 93, 94, and 97, wherein the substitutions and the positions are determined with reference to SEQ ID NO: 2.
[0186] In some embodiments, the substitution at position 60 is A, C, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W, or Y. In particular embodiments, the substitution at position 60 is E. In some embodiments, the substitutions at position 68 may include A, C, D, F, I, L, M, N, Q, S, T, or Y. In particular embodiments, the substitution at position 68 is C, F, I, L, M, T, or Y. In some embodiments, the substitutions at position 160 may include A, C, F, G, H, I, K, L, M, N, Q, R, S, T, V, W, or Y. In some embodiments, the substitution at position 29 is V, H, E, F, Q,T, S, G, N, A, C, D, P, K, I, or M. In some embodiments, the substitution at position 31 is W, F, E, I, V, H, T, M, C, P, A, D, G, S, N, Q, K, or R. In some embodiments, the substitution at position 33 is D, R, N, E, P, S, A, K, or G. In some embodiments, the substitution at position 36 is P. In some embodiments, the substitution at position 38 is W, R, K, H, T, Q, I, E, C, D, A, P, S, G, or N. In some embodiments, the substitution at position 50 is P, K, Q, D, N, S, E, R, A, G, H, C, I, T, V, M, or F. In some embodiments, the substitution at position 81 is P. In some embodiments, the substitution at position 83 is K, R, C, T, E, G, H, A, S, P, N, Q, or D. In some embodiments, the substitution at position 85 is R, H, K, D, V, C, T, G, E, N, A, S, P, I, or Q. In some embodiments, the substitution at position 88 is P, K, N, S, or D. In some embodiments, the substitution at position 90 is P. In some embodiments, the substitution at position 91 is R, K, N, P, or Q. In some embodiments, the substitution at position 92 is R, S, G, A, E, N, D, P, or Q. In some embodiments, the substitution at position 93 is N, P, or D. In some embodiments, the substitution at position 94 is P, H, or D. In some embodiments, the substitution at position 97 is M, F, I, H, C, V, E, T, N, D, P, A, G, S, R, Q, or K.
[0187] In some embodiments, the CD80 ECD variant with increased PD-L1 affinity and reduced CD28 affinity further comprises (iii) one or more substitutions at positions 8, 9, 10, II, 13, 35, 47, 54, 55, 56, 57, 58, 62, 63, 70, 71, 107, 158, 159, and 161.
[0188] In some embodiments, the substitution at position 8 may be A, C, F, I, K, L, M, R, T, W, or Y. In particular embodiments, the substitution at position 8 is I or W. In some embodiments, the CD80 ECD variant comprises a substitution at position 9, wherein the substituted residue is R. In some embodiments, the CD80 ECD variant comprises a substitution at position 10, wherein the substituted residue is selected from A, C, D, F, G, H, I, K, L, M, N, Q, R, S, T, V, W, or Y. In particular embodiments, the substitution at position 10 is A, C, D, F, H, I, K, L, M, N, Q, R, S, T, V, W, or Y. In some embodiments, the CD80 ECD variant comprises a substitution at position 11, wherein the substituted residue is selected from A, C, F, H, I, K, L, M, Q, R, S, T, W, or Y. In particular embodiments, the substitution at position 11 is C, F, H, I, L, M, T, W, or Y. In some embodiments, the CD80 ECD variant comprises a substitution at position 13, wherein the substituted residue is selected from A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, V, W, or Y. In particular embodiments, the substitution at position 13 is A, C, D, E, F, H, I, L, M, Q, S, V, W, or Y. In some embodiments, the CD80 ECD variant comprises a substitution at position 35, wherein the substituted residue is selected from A, C, D, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y. In some embodiments, the CD80 ECD variant comprises a substitution at position 47, wherein the substituted residue is selected fromA, C, E, F, G, H, I, L, N, Q, R, S, T, V, W, or Y. In particular embodiments, the substitution at position 47 is A, C, F, H, I, L, Q, T, V, W, or Y. In some embodiments, the CD80 ECD variant comprises a substitution at position 54, wherein the substituted residue is selected from A, C, D, E, F, G, H, I, L, M, N, P, Q, R, S, T, V, W, or Y. In particular embodiments, the substitution at position 54 is A, C, D, E, F, G, H, I, L, M, N, Q, R, S, T, V, W, or Y. In some embodiments, the CD80 ECD variant comprises a substitution at position 55, wherein the substituted residue is selected from A, C, E, F, G, H, I, K, L, M, P, Q, R, S, T, V, W, or Y. In some embodiments, the CD80 ECD variant comprises a substitution at position 56, wherein the substituted residue is K. In some embodiments, the CD80 ECD variant comprises a substitution at position 57, wherein the substituted residue is selected from A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, V, or W. In particular embodiments, the substitution at position 57 is A, C, F, H, I, L, M, S, V, or W. In some embodiments, the CD80 ECD variant comprises a substitution at position 58, wherein the substituted residue is selected from C, F, L, M, Q, R, T, V, W, or Y. In particular embodiments, the substitution at position 58 is C, F, L, M, V, W, or Y. In some embodiments, the CD80 ECD variant comprises a substitution at position 62, wherein the substituted residue is selected from A, C, D, E, F, G, H, K, L, M, N, P, Q, R, S, V, W, or Y. In some embodiments, the CD80 ECD variant comprises a substitution at position 63, wherein the substituted residue is selected from A, C, D, E, F, G, H, I, K, L, M, P, Q, R, S, T, V, or W. In particular embodiments, the substitution at position 63 is A, C, D, E, F, G, H, I, L, M, Q, S, T, V, W, or Y. In some embodiments, the CD80 ECD variant comprises a substitution at position 70, wherein the substituted residue is C, F, M, or Y. In some embodiments, the CD80 ECD variant comprises a substitution at position 71, wherein the substituted residue is D, G, I, L, M, N, Q, T, or V. In particular embodiments, the substitution at position 71 is D, I, L, M, or V. In some embodiments, the CD80 ECD variant comprises a substitution at position 107, wherein the substituted residue is selected from A, C, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y. In particular embodiments, the substitution at position 107 is A, C, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W, or Y. In some embodiments, the CD80 ECD variant comprises a substitution at position 158, wherein the substituted residue is selected from A, C, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W, or Y. In some embodiments, the CD80 ECD variant comprises a substitution at position 159, wherein the substituted residue is selected from A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W, or Y. In particular embodiments, the substitution at position 159 is A, C, F, G, H, I, K, L, M, N, Q, S, T, V, W, or Y. In some embodiments, the CD80 ECD variant comprises a substitution at position 161, wherein the substituted residue is selected from A, C, D, E, F, G, H, I, K, L, M, N, P, Q, S, V, or Y.CD86ECD
[0189] In some embodiments, the multi-specific binding protein binds to CD28 of an immune cell. In some embodiments, the multi-specific binding protein comprises at least one IMD that its AD comprises a CD86 ECD or a fragment thereof. In some embodiments, the CD86 ECD comprises an amino acid sequence having at least 80% identity to SEQ ID NO: 3. In some embodiments, the CD86 ECD comprises an amino acid sequence having at least 80%, 85%, or 90% identity to SEQ ID NO: 3 or comprises an amino acid sequence having at least 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 3. In some embodiments, the CD86 ECD comprises an amino acid sequence of SEQ ID NO: 3.f) PD-1 ECD
[0190] In some embodiments, the multi-specific binding protein binds to PD-L1 or PD-L2 of an immune cell. In some embodiments, the multi-specific binding protein comprises at least one IMD that its AD comprises a PD-1 ECD or a fragment thereof. In some embodiments, the PD-1 ECD comprises an amino acid sequence having at least 80% identity to SEQ ID NO: 116. In some embodiments, the PD-1 ECD comprises an amino acid sequence having at least 80%, 85%, or 90% identity to SEQ ID NO: 116 or comprises an amino acid sequence having at least 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 116. In some embodiments, the PD-1 ECD comprises an amino acid sequence of SEQ ID NO: 116.3. Fc Regions
[0191] In some embodiments, the first and / or second Fc regions are from immunoglobulin (Ig). In some embodiments, the Ig is IgG, IgM, IgA, IgD, or IgE. In some embodiments, each of the first and second Fc regions comprises a hinge region. In some embodiments, the Fc dimer is formed via one or more disulfide bonds in the hinge regions of the first and second Fc regions. In some embodiments, one or more mutations are introduced in the hinge region to minimize aggregation and mispairing (Table 3).
[0192] As disclosed herein, each Fc region of a TILsRx construct optionally contains knobin-hole (KiH) mutation(s) such as S354C (knob), T366W (knob), Y349C (hole), T366S (hole), and L368A (hole), according to the EU numbering scheme (Mayer et al., Int J Mol Sci. 2015 Nov 17;16(ll):27497-507), mutations simplifying purification such as a HY->RF mutation, mutations minimizing aggregation and mispairing such as a C->S mutation in the hinge region,and / or mutations stabilizing scFvs such as a VH44->C and VL100->C mutation pair, according to the EU numbering scheme (Table 3).
[0193] In some embodiments, the multi-specific binding protein comprises two polypeptides. In some embodiments, the first and / or second Fc regions comprise one or more mutations to promote heterodimerization between the two polypeptides. In some embodiments, the first Fc region comprises one or more knob mutations (e.g., S354C or T366W). In some embodiments, the first Fc region comprises an amino acid sequence having at least 80% identity to SEQ ID NO: 10. In some embodiments, the first Fc region comprises an amino acid sequence having at least 80%, 85%, or 90% identity to SEQ ID NO: 10 or comprises an amino acid sequence having at least 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 10. In some embodiments, the first Fc region comprises an amino acid sequence of SEQ ID NO: 10. In some embodiments, the second Fc region comprises one or more hole mutations (e.g., Y349C, T366S, and / or L368A). In some embodiments, the second Fc region comprises an amino acid sequence having at least 80% identity to SEQ ID NO: 11. In some embodiments, the second Fc region comprises an amino acid sequence having at least 80%, 85%, or 90% identity to SEQ ID NO: 11 or comprises an amino acid sequence having at least 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 11. In some embodiments, the second Fc region comprises an amino acid sequence of SEQ ID NO: 11.
[0194] In some embodiments, the first and second Fc regions further comprise mutations that simplify purification, minimize aggregation and mispairing, and / or stabilize the heterodimer structure. In some embodiments, the Fc regions disclosed herein may further comprise modifications that reduce effector function, i.e., having a reduced ability to induce certain biological functions upon binding to an Fc receptor expressed on an effector cell that mediates the effector function. Examples of antibody effector functions include, but are not limited to, Clq binding and complement dependent cytotoxicity (CDC), Fc receptor binding, antibody -dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cell-mediated phagocytosis (ADCP), down-regulation of cell surface receptors (e.g., B cell receptor), and B-cell activation. Effector functions may vary with the antibody class. For example, native human IgGl and IgG3 antibodies can elicit ADCC and CDC activities upon binding to an appropriate Fc receptor present on an immune system cell; and native human IgGl, IgG2, IgG3, and IgG4 can elicit ADCP functions upon binding to the appropriate Fc receptor present on an immune cell.
[0195] As disclosed herein, the Fc regions of a TILsRx construct can be from human IgGl, IgG2, IgG3, or IgG4. In some embodiments, the Fc regions of a TILsRx construct is from human IgGl. In some embodiments, the Fc regions of the TILsRx construct comprises modifications that reduce or eliminate effector function. Illustrative Fc polypeptide mutations that reduce effector function include, but are not limited to, substitutions in a CH2 domain, e.g., at positions 234 and 235, according to the EU numbering scheme. For example, in some embodiments, the Fc region comprises alanine residues at positions 234 and 235, according to the EU numbering scheme. In such embodiments, the Fc region of the fusion protein disclosed herein comprises L234A and L235A (LALA) substitutions according to the EU numbering scheme.
[0196] In some embodiments, the Fc region comprising the LALA substitutions exhibits a high binding affinity to neonatal Fc receptor (FcRn), thereby supporting extended serum halflife of the fusion protein. In some embodiments, the LALA-containing Fc region does not bind or has a reduced binding affinity to Fc gamma receptors (FcyRs) compared to a Fc region without the L234A and L235A substitutions. In some embodiments, the LALA mutations inhibit binding to Fey receptors, including but not limited to FcyRIIa, FcyRIIIa, and FcyRIIIb, thereby avoiding or reducing antibody-dependent cellular toxicity (ADCC). In some embodiments, the LALA mutations retain low but measurable binding to the inhibitory receptor FcyRIIb (CD32b).Table 3. Point Mutations of TILxRxMutations(bold andunderlined)Description (mutation locations refer to the canonical sequence of withUniProt P01857)neighboringaminoacids)C103S Mutation in hinge region of Fc (knob) region (SEQ ID NO: 10) and SDK Fc (hole) region (SEQ ID NO: 11)• To minimize aggregation and mispairingH318R and Y319F mutations in Fc region of “hole” chain (SEQ ID NO: 11) RFTO • To simplify purification• Higher affinity of “RF heterodimer” than homodimer for Protein A Anti-CD3 Ab, VH 44C mutationCLE • Stabilization of scFv• To build disulfide bond with VL100 CAnti-CD3 Ab, VL100C mutationCGT• Stabilization of scFv• To build disulfide bond with VH44 CCRD S237C KiH mutation (S354C mutation in *)• Mutation in knob chain (SEQ ID. NO: 10)WCL T249W KiH mutation (T366W mutation in *)• Mutation in knob chain (SEQ ID. NO: 10)CTL Y232C KiH mutation (Y349C mutation in *)• Mutation in hole chain (SEQ ID. NO: 11)SCAVK T249S and L251A KiH mutations (T366S and L368A mutations in *)• Mutations in hole chain (SEQ ID. NO: 11)VSK Y290V KiH mutation (Y407V mutation in *)• Mutation in hole chain (SEQ ID. NO: 11)*References: Mayer et al. (https: / / pubmed.ncbi.nlm.nih.gov / 26593903 / ) and Merchant et al. (https: / / pubmed.ncbi.nlm.nih.gov / 9661204 / )4. Inhibitory Domains (IDs)
[0197] Biological molecules, such as therapeutic antibodies and cytokines, have significantly advanced cancer treatment, yet their toxicity remains a major concern. For example, interleukin-2 (IL-2) is a potent T-cell stimulator, but its non-targeted delivery can result in severe toxicity.
[0198] To mitigate off-target toxicity associated with multi-specific fusion proteins containing active domains (ADs) of therapeutic molecules, one strategy involves shielding or masking these ADs with inhibitory domains (IDs). These IDs prevent the ADs from binding to their targets outside the tumor microenvironment. As depicted in FIG. IB, certain embodiments of the multi-specific binding protein incorporate one or more IDs that bind to the ADs, thereby inhibiting the ADs from interacting with cell surface proteins. By leveraging the differential protease activity found in the tumor microenvironment compared to normal, non-malignant tissue -for instance, matrix metalloproteinases (MMPs) are frequently present in tumors at elevated levels- the IDs are linked to the ADs via a linker containing protease recognition and cleavage motifs. Once the protein reaches the tumor microenvironment, local proteases cleave the IDs from the ADs, enabling the ADs to bind to their intended targets within the vicinity. For instance, a multi-specific fusion protein containing IL-2 as an AD may include an IL-2 receptor or a fragment thereof as its ID. The ID is designed to be cleaved by MMP proteases within tumor tissues, thereby activating the IL-2 AD locally while minimizing systemic toxicity.
[0199] As described herein, inhibitory domains (IDs) may comprise peptides, motifs, proteins, antigens, antibodies, DNA, RNA, or other molecules capable of binding to an activedomain (AD) and preventing its interaction with target proteins. In some instances, the ID is specifically paired with a particular AD, such as an IL-2 receptor peptide shielding IL-2. In other instances, the ID may serve as a universal inhibitor, capable of interacting with various ADs, such as coiled coil motifs, autologous hinge motifs, and XTEN universal masks. In some embodiments, the ID may be designed to block one type of AD, such as using an anti-idiotype as an ID coupled to an antibody AD.
[0200] An ID may inhibit one AD, or it may bind to and inhibit multiple ADs at once, such as a bivalent peptide DNA. Some exemplary IDs include the pro-domains of natural proteins, such as transforming growth factor-P (TGF-P), myostatin, complement C3, complement C5, IL-lb, and IL-18. These proteins are typically expressed in an inactive form, with the prodomain shielding their active, mature domain. Other non-limiting examples of IDs include peptides, anti-idiotype antibodies, coiled coil motifs, autologous hinge motifs, endogenous protein (e.g. LAP), bivalent peptide DNA, dual variable domain, antigen fragment, XTEN universal masks, bispecific T cell engager (e.g., XPAT, COBRA, Preci si onGATE, ProTriTAC), as those described in Bleuez et al., Drug Discov Today. 2022 Jun;27(6): 1743-54, the entire disclosure of which is herein incorporated by reference.
[0201] In some embodiments, the ID comprises an IL-lb pro-peptide, or a derivative, fragment or fusion thereof. The IL-lb pro-peptide is a 116 amino acid pro-domain of IL-lb precursor which becomes active once the IL-lb pro-peptide is cleaved off by pyogenes SpeB proteases. The IL-lb pro-peptide may be particularly suitable as a shielding domain of a multispecific fusion protein for the following reasons: 1) It is expected to be nonimmunogenic in humans since it is of human origin; 2) With 116 amino acids it has a similar length as the Pl 00 PAS domain described by Maejima et al. (2017) but is substantially shorter than the 249-amino acid pro-domain of TGF-beta (LAP domain) (Chen et al., 2017; UniProt P01137). A shorter size may facilitate manufacturing; 3) It is predicted to have a disordered structure, suggesting flexibility in reaching the residues of the active domain (AD) mediating contacts with the intended target (e.g., CDRs of agonistic CD3 scFv binding CD3 antigen). In some embodiments, the IL-lb pro-peptide comprises an amino acid sequence having at least 80% identity to SEQ ID NO: 12. In some embodiments, the ID comprises an amino acid sequence having at least 80%, 85%, or 90% identity to SEQ ID NO: 12 or comprises an amino acid sequence having at least 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 12. In some embodiments, the ID comprises an amino acid sequence of SEQ ID NO: 12.
[0202] In some embodiments, the ID comprises a PAS peptide, or a derivative, fragment or fusion thereof. The PAS peptide refers to an amino acid sequences consisting of proline (P), alanine (A), and serine (S) residues. In some embodiments, the ID comprises 40 amino acid long PAS peptide (P40). In some embodiments, the ID comprises 100 amino acid long PAS peptide (Pl 00). Without being bound by theory, the shielding effect of the PAS peptide is attributed to steric hindrance due to a large fluid dynamic radius and disordered structure (Maejima et al., 2017). In some embodiments, the PAS peptide comprises an amino acid sequence having at least 80% identity to SEQ ID NO: 13. In some embodiments, the ID comprises an amino acid sequence having at least 80%, 85%, or 90% identity to SEQ ID NO: 13 or comprises an amino acid sequence having at least 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 13. In some embodiments, the ID comprises an amino acid sequence of SEQ ID NO: 13.5. Linkers
[0203] In certain embodiments, it may be desirable to insert one or more linkers, e.g., flexible linkers, between Fc regions and binding domains, and / or between ADs and IDs, to provide desired flexibility so that TAA-BDs and IMDs functionally bind to target proteins and IDs functionally bind to ADs. As shown in FIG. 14A, multiple linkers can be designed within a multi-specific binding protein, including “regional linkers” that connect Fc regions to binding domains and “domain linkers” that connect ADs to IDs.
[0204] The linkers (both regional linkers and domain linkers) may comprise stretches of amino acids that are or that are not naturally occurring. Exemplary flexible linkers include glycine polymers (G), glycine-serine polymers, glycine-alanine polymers, alanine-serine polymers, and other flexible linkers known in the art. Glycine and glycine-serine polymers are relatively unstructured, and therefore may be able to serve as a neutral tether between components. Glycine accesses significantly more phi-psi space than even alanine, and is much less restricted than residues with longer side chains (see Scheraga, Rev. Computational Chem.11173-142 (1992)). Exemplary flexible linkers include, but are not limited to, (GS)n, (GGS)n, (GGGS)n, and (GGGGS)n, where n is an integer of at least one (e.g., an integer from 1 to 10). In some embodiments, the linker (e.g., a regional linker or a domain linker) comprises an amino acid sequence having at least 80% identity to any one of SEQ ID NOs: 65-71. In some embodiments, the linker comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 65-71. An ordinarily skilled artisan will recognize that design of a proproteincan include linkers that are all or partially flexible, such that the linker can include a flexible linker as well as one or more portions that confer less flexible structure to provide for a desired proprotein structure.
[0205] As disclosed herein, the linker (e.g., a regional linker or a domain linker) may further comprise one or more protease cleavage sites (PCSs), referred to herein as a cleavable linker. In some embodiments, a regional cleavable linker comprises one or more PCSs, wherein cleavage at the PCSs of the regional linker by a protease releases the binding domain (TAA-BD or IMD) from the first or second Fc region. In some embodiments, a domain cleavable linker comprises one or more PCSs, wherein cleavage at the PCSs of the domain linker by a protease releases the ID from the AD, thereby allowing the AD to bind to the cell surface protein.
[0206] In some embodiments, the PCS is a substrate for a protease selected from the group consisting of matrix metalloprotease 1 (MMP-1), MMP-2, MMP-3, MMP-8, MMP-9, MMP-13, MMP-14, plasmin, prostate-specific antigen (PSA), prostate-specific membrane antigen (PSMA), cathepsin D, cathepsin K, cathepsin S, a disintegrin and metalloprotease 10 (ADAM10), ADAM12, ADAM I 7 (TACE), ADAM with Thrombospondin motifs (ADAMTS), caspase-1, caspase-2, caspase-3, caspase-4, caspase-5, caspase-6, caspase-7, caspase-8, caspase-9, caspase-10, caspase-11, caspase-12, caspase-13, caspase-14, tissue plasminogen activator (tPA), and urokinase plasminogen activator (uPA). In some embodiments, the PCS comprises an amino acid sequence having at least 80% identity to any one of SEQ ID NOs: 73-87. In some embodiments, the PCS comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 73-87 (Table 4).Table 4. Exemplary protease cleavage sitesAAGLLAPPGGLSGRSDAG (SEQ ID. NO: 73)AGLLAPPGGLSGRSDAG (SEQ ID. NO: 74)GGSGRSANAKC (SEQ ID. NO: 75)GPLGVR MMP2 PCS (SEQ ID. NO: 76)ISSGLLSGRSDAG (SEQ ID. NO: 77)ISSGLLSGRSDNH MMP2, MMP13, and MM14 PCS (SEQ ID. NO: 78) KKSPGRVVGGSVAH (native sequence from plasminogen) (SEQ ID. NO: 79) LGGSGRSANAILE (SEQ ID. NO: 80)LGGSGRSANAILSGRSDNH PCS (SEQ ID. NO: 81)LSGRSDAG (SEQ ID. NO: 82)LSGRSDAGSPLGLAG (SEQ ID. NO: 83)LSGRSDNH uPA / MT-SPl PCS (SEQ ID. NO: 84)SGQLLGFLTA (SEQ ID. NO: 85)SGRSA uPA PCS (SEQ ID. NO: 86)SPLGLSGRSDAG (SEQ ID. NO: 87)
[0207] A cleavable linker may comprise one or multiple PCSs. As illustrated in FIG. 14B, a cleavable linker comprises three PCSs that can be recognized and cleaved by uPA, MT-SP1, and MMP2. FIG. 14C shows some more exemplary cleavable linker comprising one, two, or three PCSs. In some embodiments, a cleavable linker (either a regional linker or domain linker) comprises an amino acid sequence having at least 80% identity to any one of SEQ ID NOs: 88-108. In some embodiments, the cleavable linker (either the regional linker or domain linker) comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 88-108 (Table 5)Table 5. Exemplary cleavable linkers GGGGSGGGGSLSGRSDNHGGGGSGPLGVRGGGGS (SEQ ID. NO: 88) GGGGSGGGGSLSGRSDNHGGSGGSGPLGVRGGGGS (SEQ ID. NO: 89) GGGGSGGGGSGPLGVRGGGGSLSGRSDNHGGGGS (SEQ ID. NO: 90) GGGGSGGGGSGPLGVRGGSGGSLSGRSDNHGGGGS (SEQ ID. NO: 91) GGGGSGPLGVRGGS (SEQ ID. NO: 92) GGGGSGRSAGGSLSGRSDNHGGSGGSGPLGVRGGGGS (SEQ ID. NO: 93) GGGGSLSGRSDNHGGGGS SGQLLGFLTAGGGGSGPLGVRGGGGS (SEQ ID. NO: 94)GGGGSLSGRSDNHGGS SGQLLGFLTAGGSGPLGVRGGGGS (SEQ ID. NO: 95) GGGGSLSGRSDNHGS SGQLLGFLTAGSGPLGVRGGGGS (SEQ ID. NO: 96) GGLGGSGRSANAILEGGSLSGRSDNHGGSGPLGVRGGGGS (SEQ ID. NO: 97) GGSGGSLGGSGRSANAILSGRSDNHGGGGSGPLGVRGGGGS (SEQ ID. NO: 98) GGSGGSLGGSGRSANAILSGRSDNHGGGGSGPLGVRGGS (SEQ ID. NO: 99)GGSGGSLGGSGRSANAILSGRSDNHGGGGSGPLGVRGGSGGSSG (SEQ ID. NO: 100)GGSGGSLSGRSDNHGGGGS (SEQ ID. NO: 101) GGSGGSLSGRSDNHGGGGSGPLGVRGGS (SEQ ID. NO: 102) GGSGGSLSGRSDNHGGS (SEQ ID. NO: 103)GGSGGSLSGRSDNHGGSGGSSG (SEQ ID. NO: 104) GSSGGSGGSGGSGLSGRSDNH-GSSGGSGGSGGSG (SEQ ID. NO: 105) GSSGGSGGSGGSGSGQLLGFLTA-GSSGGSGGSGGSG (SEQ ID. NO: 106) GGGGSGPLGVRGGSGGS SG (SEQ ID. NO: 107)GGGGSGPLGVRGGGGS (SEQ ID. NO: 108)6. Multi-Specific Binding Protein Constructs
[0208] In one aspect, the present disclosure provides a multi-specific binding protein comprising two or more polypeptides. The polypeptides may be covalently or non-covalently linked to form a multimeric structure, such as a dimer, trimer, tetramer, or higher-order multimer. The multi-specific binding protein may further comprise additional domains that facilitate multimerization, enhance stability, or provide therapeutic functionality, including but not limited to Fc regions, oligomerization motifs, membrane anchoring sequences, or targeting domains.
[0209] A “multi-specific binding protein”, or “multivalent binding protein” as used herein interchangeably, refers to a recombinant protein or protein complex that possesses two or more binding sites capable of simultaneously engaging with one or more target molecules. The multispecific binding protein can be constructed in homo-multimeric (including homo-dimeric) arrangements. For example, each polypeptide subunit is identical and comprises identical TAA-BD(s) and / or identical IMD(s). The multi-specific binding protein can be engineered in hetero-multimeric arrangements. For example, two different polypeptide chains are assembled, one polypeptide containing one or more TAA-BDs and the other polypeptide containing one or more IMDs; or one polypeptide containing one TAA-BD and one IMD and the other polypeptide containing a different TAA-BD and a different IMD. Another example of a heterodimer construct is the two polypeptides contain identical TAA-BD(s) and / or IMD(s), while one polypeptide contains one or more “knob” Fc mutations and the other polypeptide contains one or more “hole” Fc mutations. As disclosed herein, the TAA-BD(s) and IMD(s)of a multi-specific binding protein can link to one or more other functional domains, such as an Fc region, a signal peptide for protein secretion or intracellular localization, a membraneanchoring motif such as a transmembrane domain or a GPI transamidase recognition site / C-terminal signal peptide for GPI anchor attachment, and / or a multimerization motif.
[0210] In some embodiments, the multi-specific binding protein comprising two polypeptides. In some embodiments, the first polypeptide, in either N- to C- terminal direction or C- to N-terminal direction, comprises a first TAA-BD, a first Fc region, and a first IMD. In some instances, the second polypeptide, in either N- to C- terminal direction or C- to N-terminal direction, comprises a second TAA-BD, a second Fc region, and a second IMD. In other instances, the second polypeptide, in either N- to C- terminal direction or C- to N-terminal direction, comprises the second IMD, the second Fc region, and a third IMD. In yet other instances, the second polypeptide, in either N- to C- terminal direction or C- to N-terminal direction, comprises the second TAA-BD, the second Fc region, and a third TAA-BD. As disclosed herein, the first, second, and third TAA-BDs may be the same TAA-BD, or the multispecific binding protein carries different TAA-BDs that target different cancer cell proteins. Similarly, the first, second, and third HMDs may be the same IMD, or the multi-specific binding protein carries different HMDs that target different immune cell proteins. In some embodiments, the first Fc region comprises a knob mutation and the second Fc region comprises a hole mutation thereby facilitating heterodimerization of the two polypeptides.
[0211] In some embodiments, the multi-specific binding protein binds to the cancer cell surface protein STEAP1, B7-H3, and / or EpCAM; and the immune cell surface proteins CD3, IL-21R, IL-2R, CD28, PD-L1, PD-L2, and / or PD-1. In some embodiments, the first polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to any one of SEQ ID NOs: 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, and 62. In some embodiments, the second polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to any one of SEQ ID NOs: 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, and 63.
[0212] In some embodiments, the multi-specific binding protein binds to the cancer cell surface protein STEAP1 and the immune cell surface proteins CD3 and IL-21R. In some embodiments, the first domain comprises an anti-STEAPl antibody, the second domain comprises IL-21, the third domain comprises an anti-CD3 antibody, and the fourth domaincomprises an anti-STEAPl antibody, IL-21, or an anti-CD3 antibody. IL-21 is linked to the first or second Fc region through a cleavable regional linker comprising one or more PCSs, and wherein cleavage at the one or more PCSs by a protease releases the IL-21 from the first or second Fc region. In some embodiments, the first polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 14 or 18. In some embodiments, the second polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 15 or 19. In some embodiments, the first polypeptide comprises an amino acid sequence of SEQ ID NO: 14 or 18 and the second polypeptide comprises an amino acid sequence of SEQ ID NO: 15 or 19.
[0213] In some embodiments, the multi-specific binding protein binds to the cancer cell surface protein B7-H3 and the immune cell surface proteins CD3 and IL-21R. In some embodiments, the first domain comprises an anti-B7-H3 antibody, the second domain comprises IL-21, the third domain comprises an anti-CD3 antibody, and the fourth domain comprises an anti-B7-H3 antibody, IL-21, or an anti-CD3 antibody. IL-21 is linked to the first or second Fc region through a cleavable regional linker comprising one or more PCSs, and wherein cleavage at the one or more PCSs by a protease releases the IL-21 from the first or second Fc region. In some embodiments, the first polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 16 or 20. In some embodiments, the second polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 17 or 21. In some embodiments, the first polypeptide comprises an amino acid sequence of SEQ ID NO: 16 or 20 and the second polypeptide comprises an amino acid sequence of SEQ ID NO: 17 or 21.
[0214] In some embodiments, the multi-specific binding protein binds to the cancer cell surface protein STEAP1 and the immune cell surface proteins CD3 and CD28. In some embodiments, the first domain comprises an anti-STEAPl antibody, the second domain comprises an anti-CD3 antibody, the third domain comprises CD80 or CD86, and the fourth domain comprises an anti-STEAPl antibody, CD80, CD86, or an anti-CD3 antibody. In some embodiments, the anti-CD3 antibody binds to an inhibitory domain (ID), thereby inhibiting the anti-CD3 antibody from binding to CD3 present on an immune cell. In some embodiments, the ID is linked to the anti-CD3 antibody through a cleavable domain linker comprising one or more PCSs, and wherein cleavage at the one or more PCSs by a protease releases the ID fromthe anti-CD3 antibody, thereby allowing the anti-CD3 antibody to bind to the CD3 present on the immune cell. In some embodiments, the ID comprises an IL-lb pro-peptide fragment comprising an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 12. In some embodiments, the ID comprises a PAS peptide fragment comprising an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 13. In some embodiments, the first polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to any one of SEQ ID NOs: 22, 26, 30 and 34. In some embodiments, the second polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to any one of SEQ ID NO: 23, 27, 31, and 35. In some embodiments, the first polypeptide comprises an amino acid sequence of any one of SEQ ID NOs: 22, 26, 30 and 34, and the second polypeptide comprises an amino acid sequence of any one of SEQ ID NO: 23, 27, 31, and 35.
[0215] In some embodiments, the multi-specific binding protein binds to the cancer cell surface protein B7-H3 and the immune cell surface proteins CD3 and CD28. In some embodiments, the first domain comprises an anti-B7-H3 antibody, the second domain comprises an anti-CD3 antibody, the third domain comprises CD80 or CD86, and the fourth domain comprises an anti-B7-H3 antibody, CD80, CD86, or an anti-CD3 antibody. In some embodiments, the anti-CD3 antibody binds to an inhibitory domain (ID), thereby inhibiting the anti-CD3 antibody from binding to CD3 present on an immune cell. In some embodiments, the ID is linked to the anti-CD3 antibody through a cleavable domain linker comprising one or more PCSs, and wherein cleavage at the one or more PCSs by a protease releases the ID from the anti-CD3 antibody, thereby allowing the anti-CD3 antibody to bind to the CD3 present on the immune cell. In some embodiments, the ID comprises an IL-lb pro-peptide fragment comprising an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 12. In some embodiments, the ID comprises a PAS peptide fragment comprising an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 13. In some embodiments, the first polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to any one of SEQ ID NOs: 24, 28, 32 and 36. In some embodiments, the second polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to any one of SEQ ID NO: 25, 29, 33, and 37. In some embodiments, the first polypeptide comprises an amino acid sequence of any one of 24, 28, 32and 36, and the second polypeptide comprises an amino acid sequence of any one of SEQ ID NO: 25, 29, 33, and 37.
[0216] In some embodiments, the multi-specific binding protein binds to the cancer cell surface protein STEAP1 and the immune cell surface proteins CD28 and IL-21R. In some embodiments, the first domain comprises an anti-STEAPl antibody, the second domain comprises IL-21, the third domain comprises CD80 or CD86, and the fourth domain comprises an anti-STEAPl antibody, IL-21, CD80, or CD86. In some embodiments, the first polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 38 or 42. In some embodiments, the second polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 39 or 43. In some embodiments, the first polypeptide comprises an amino acid sequence of SEQ ID NO: 38 or 42, and the second polypeptide comprises an amino acid sequence of any one of SEQ ID NO: 39 or 43.
[0217] In some embodiments, the multi-specific binding protein binds to the cancer cell surface protein B7-H3 and the immune cell surface proteins CD28 and IL-21R. In some embodiments, the first domain comprises an anti-B7-H3 antibody, the second domain comprises IL-21, the third domain comprises CD80 or CD86, and the fourth domain comprises an anti-B7-H3 antibody, IL-21, CD80, or CD86. In some embodiments, the first polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 40 or 44. In some embodiments, the second polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 41 or 45. In some embodiments, the first polypeptide comprises an amino acid sequence of SEQ ID NO: 40 or 44, and the second polypeptide comprises an amino acid sequence of any one of SEQ ID NO: 41 or 45.
[0218] In some embodiments, the multi-specific binding protein binds to the cancer cell surface protein STEAP1 and the immune cell surface proteins CD28. In some embodiments, the first and third domains each comprises an anti-STEAPl antibody, and the second and fourth domains each comprises CD80 or CD86. In some embodiments, the first polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 46 or 50. In some embodiments, the second polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 47 or 51. In some embodiments, the first polypeptide comprisesan amino acid sequence of SEQ ID NO: 46 or 50, and the second polypeptide comprises an amino acid sequence of any one of SEQ ID NO: 47 or 51.
[0219] In some embodiments, the multi-specific binding protein binds to the cancer cell surface protein B7-H3 and the immune cell surface proteins CD28. In some embodiments, the first and third domains each comprises an anti-B7-H3 antibody, and the second and fourth domains each comprises CD80 or CD86. In some embodiments, the first polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 48 or 52. In some embodiments, the second polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 49 or 53. In some embodiments, the first polypeptide comprises an amino acid sequence of SEQ ID NO: 48 or 52, and the second polypeptide comprises an amino acid sequence of any one of SEQ ID NO: 49 or 53.
[0220] In some embodiments, the multi-specific binding protein binds to the multi-specific binding protein binds to the cancer cell surface proteins STEAP1 and B7-H3, and the immune cell surface proteins CD3 and IL-21R. In some embodiments, the first domain comprises an anti-STEAPl antibody, the second domain comprises IL-21, the third domain comprises an anti-B7-H3 antibody, and the fourth domain comprises an anti-CD3 antibody. In some embodiments, the first polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 54. In some embodiments, the second polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 55. In some embodiments, the first polypeptide comprises an amino acid sequence of SEQ ID NO: 54, and the second polypeptide comprises an amino acid sequence of any one of SEQ ID NO: 55.
[0221] In some embodiments, the multi-specific binding protein binds to the multi-specific binding protein binds to the cancer cell surface proteins STEAP1 and B7-H3, and the immune cell surface proteins CD3 and CD28. In some embodiments, the first domain comprises an anti-STEAPl antibody, the second domain comprises IL-21, the third domain comprises an anti-B7-H3 antibody, and the fourth domain comprises a CD80 or CD86. In some embodiments, the first polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 56 or 58. In some embodiments, the second polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 57 or 59. In someembodiments, the first polypeptide comprises an amino acid sequence of SEQ ID NO: 56 or 58, and the second polypeptide comprises an amino acid sequence of any one of SEQ ID NO: 57 or 59.
[0222] In some embodiments, the multi-specific binding protein binds to the cancer cell surface protein STEAP1 and the immune cell surface protein PD-L1. In some embodiments, the first and third domains each comprises an anti-STEAPl antibody, and the second and fourth domains each comprises PD-1. In some embodiments, the first polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 60. In some embodiments, the second polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 61. In some embodiments, the first polypeptide comprises an amino acid sequence of SEQ ID NO: 60, and the second polypeptide comprises an amino acid sequence of any one of SEQ ID NO: 61.
[0223] In some embodiments, the multi-specific binding protein binds to the cancer cell surface protein B7-H3 and the immune cell surface protein PD-L1. In some embodiments, the first and third domains each comprises an anti-B7-H3 antibody, and the second and fourth domains each comprises PD-1. In some embodiments, the first polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 62. In some embodiments, the second polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 63. In some embodiments, the first polypeptide comprises an amino acid sequence of SEQ ID NO: 62, and the second polypeptide comprises an amino acid sequence of any one of SEQ ID NO: 63.
[0224] In some embodiments, the multi-specific binding protein binds to the cancer cell surface protein B7-H3 and the immune cell surface protein PD-L1 or T cell receptors CD28 and / or CTLA-4. In some embodiments, the first and third domains each comprises an anti-B7-H3 antibody, and the second and fourth domains each comprises CD80 ECD. The CD80 ECD can be either the WT CD80 ECD or a CD80 ECD variant. In some embodiments, the first polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 160 or 162. In some embodiments, the second polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 161 or 163. In some embodiments, the firstpolypeptide comprises an amino acid sequence of SEQ ID NO: 160 or 162, and the second polypeptide comprises an amino acid sequence of any one of SEQ ID NO: 161 or 163.
[0225] In some embodiments, the multi-specific binding protein binds to the cancer cell surface protein STEAP1 and the immune cell surface protein PD-L1 or T cell receptors CD28 and / or CTLA-4. In some embodiments, the first and third domains each comprises an anti-STEAP1 antibody, and the second and fourth domains each comprises CD80 ECD. The CD80 ECD can be either the WT CD80 ECD or a CD80 ECD vairant. In some embodiments, the first polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 166 or 168. In some embodiments, the second polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 167 or 169. In some embodiments, the first polypeptide comprises an amino acid sequence of SEQ ID NO: 166 or 168, and the second polypeptide comprises an amino acid sequence of any one of SEQ ID NO: 167 or 169. In some embodiments, the first and second domains each comprises an anti-STEAPl antibody, and the third and fourth domains each comprises CD80 ECD. The CD80 ECD can be either the WT CD80 ECD or a CD80 ECD vairant. In some embodiments, the first polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 172 or 174. In some embodiments, the second polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 173 or 175. In some embodiments, the first polypeptide comprises an amino acid sequence of SEQ ID NO: 172 or 174, and the second polypeptide comprises an amino acid sequence of any one of SEQ ID NO: 173 or 175.
[0226] In some embodiments, the present disclosure provides a multi-specific binding protein comprising two polypeptides. In some embodiments, the first polypeptide, in either N-to C- terminal direction or C- to N-terminal direction, comprises a first TAA-BD, a first Fc region, and a first CD80 ECD. In some instances, the second polypeptide, in either N- to C-terminal direction or C- to N-terminal direction, comprises a second TAA-BD, a second Fc region, and a second CD80 ECD. In other instances, the second polypeptide, in either N- to C-terminal direction or C- to N-terminal direction, comprises the second CD80 ECD, the second Fc region, and a third CD80 ECD. In yet other instances, the second polypeptide, in either N-to C- terminal direction or C- to N-terminal direction, comprises the second TAA-BD, the second Fc region, and a third TAA-BD. As disclosed herein, the first, second, and third TAA-BDs may be the same TAA-BD, or the multi-specific binding protein carries different TAA-BDs that target different cancer cell proteins. The CD80 ECD can be either the WT CD80 ECD or a CD80 ECD variant. The first, second, and third CD80 ECD s may be the same CD80 ECD (WT or variant), or the multi-specific binding protein carries different CD80 ECDs (WT and variants, or different variants) with different modulated binding affinities to PD-L1, CD28, and / or CTLA-4. In some embodiments, the first Fc region comprises a knob mutation and the second Fc region comprises a hole mutation thereby facilitating heterodimerization of the two polypeptides.
[0227] In some embodiments, the multi-specific binding protein comprises (i) one or more CD80 ECDs (WT or variants) that bind to the immune cell surface proteins, such as CD28, PD-L1, and / or CTLA-4, and (ii) one or more TAA-BDs that bind to cancer cell surface proteins, such as STEAP1, B7-H3, and / or EpCAM. In some embodiments, the multi-specific binding protein comprises two polypeptides, wherein the first polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to any one of SEQ ID NOs: 158, 160, 162, 164, 166, 168, 170, 172, or 174. In some embodiments, the second polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to any one of SEQ ID NOs: 159, 161, 163, 165, 167, 169, 171, 173, or 175.
[0228] In some embodiments, the multi-specific binding protein binds to the cancer cell surface protein STEAP1 and the immune cell surface proteins CD28, PD-L1, and / or CTLA-4. In some embodiments, the multi-specific binding protein comprises two polypeptides. In some embodiments, the first polypeptide comprises a first CD80 ECD, a first Fc region, and a first anti-STEAPl antibody fragment, and the second polypeptide comprises a second CD80 ECD, a second Fc region, and a second anti-STEAPl antibody fragment. As described herein, the first and second Fc regions comprise one or more mutations to promote heterodimerization between the two polypeptides.
[0229] The first and second CD80 ECDs may be the same (the WT CD80 ECD or the same CD80 ECD variant comprising the same substitution(s)) or different (e.g., a WT CD80 ECD and a variant; or two different variants comprising different substitutions). In some embodiments, the first and second CD80 ECD (WT or variants) are the same. In particular embodiments, the first and second CD80 ECD variants comprise the substitutions V68M and E160R. The first and second anti-STEAPl antibody fragments may be the same or different antibody fragments. In some embodiments, the first polypeptide comprises an amino acidsequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 166 or 168. In some embodiments, the second polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 167 or 169. In some embodiments, the first polypeptide comprises an amino acid sequence of SEQ ID NO: 166 or 168 and the second polypeptide comprises an amino acid sequence of SEQ ID NO: 167 or 169.
[0230] In some embodiments, the first polypeptide comprises a first CD80 ECD, a first Fc region, and a second CD80 ECD, and the second polypeptide comprises a first anti-STEAPl antibody fragment, a second Fc region, and a second anti-STEAPl antibody fragment. The first and second Fc regions comprise one or more mutations to promote heterodimerization between the two polypeptides.
[0231] The first and second CD80 ECDs may be the same (the WT CD80 ECD or the same CD80 ECD variant comprising the same substitution(s)) or different (e.g., a WT CD80 ECD and a variant; or two different variants comprising different substitutions). In some embodiments, the first and second CD80 ECD (WT or variants) are the same. In particular embodiments, the first and second CD80 ECD variants comprise the substitutions V68M and E160R. The first and second anti-STEAPl antibody fragments may be the same or different antibody fragments. In some embodiments, the first polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 173 or 175. In some embodiments, the second polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 172 or 174. In some embodiments, the first polypeptide comprises an amino acid sequence of SEQ ID NO: 173 or 175 and the second polypeptide comprises an amino acid sequence of SEQ ID NO: 172 or 174.
[0232] In some embodiments, the multi-specific binding protein binds to the cancer cell surface protein B7H3 and the immune cell surface proteins CD28, PD-L1, and / or CTLA-4. In some embodiments, the multi-specific binding protein comprises two polypeptides. In some embodiments, the first polypeptide comprises a first CD80 ECD, a first Fc region, and a first anti-B7H3 antibody fragment, and the second polypeptide comprises a second CD80 ECD, a second Fc region, and a second anti-B7H3 antibody fragment. As discussed above, the first and second Fc regions comprise one or more mutations (e.g., KiH mutations) to promote heterodimerization between the two polypeptides. The first and second Fc regions may furthercomprise one or more mutations that simplify purification, minimize aggregation and mispairing, and / or stabilize the heterodimer structure.
[0233] The first and second CD80 ECDs may be the same (the WT CD80 ECD or the same CD80 ECD variant comprising the same substitution(s)) or different (e.g., a WT CD80 ECD and a variant; or two different variants comprising different substitutions). In some embodiments, the first and second CD80 ECD (WT or variants) are the same. In particular embodiments, the first and second CD80 ECD variants comprise the substitutions V68M and E160R. The first and second anti-B7H3 antibody fragments may be the same or different antibody fragments. In some embodiments, the first polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 160 or 162. In some embodiments, the second polypeptide comprises an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 161 or 163. In some embodiments, the first polypeptide comprises an amino acid sequence of SEQ ID NO: 160 or 162 and the second polypeptide comprises an amino acid sequence of SEQ ID NO: 161 or 163.
[0234] In some embodiments, the first polypeptide comprises a first CD80 ECD, a first Fc region, and a second CD80 ECD, and the second polypeptide comprises a first anti-B7H3 antibody fragment, a second Fc region, and a second anti-B7H3 antibody fragment; wherein the first and second Fc regions comprise one or more KiH mutations to promote heterodimerization between the two polypeptides. The first and second CD80 ECDs may be the same (the WT CD80 ECD or the same CD80 ECD variant comprising the same substitution(s)) or different (e.g., a WT CD80 ECD and a variant; or two different variants comprising different substitutions). In some embodiments, the first and second CD80 ECD (WT or variants) are the same. In particular embodiments, the first and second CD80 ECD variants comprise the substitutions V68M and E160R. The first and second anti-B7H3 antibody fragments may be the same or different antibody fragments.
[0235] In some embodiments, the multi-specific binding protein comprising one or more CD80 ECD variants exhibits increased binding affinity for PD-L1. In these embodiments, the one or more CD80 ECD variants each comprises at least one, two, three, or more amino acid substitutions as described herein. In some embodiments, the substitutions occur at positions 8, 9, 10, 11, 13, 35, 47, 54, 55, 56, 57, 58, 60, 62, 63, 68, 70, 71, 107, 158, 159, 160, and 161, wherein the substitutions and the positions are determined with reference to SEQ ID NO: 2. Inparticular embodiments, the multi-specific binding protein comprising the one or more CD80 ECD variants with increased binding affinity for PD-L1 comprises one, two, three, four, five, six, seven, eight, nine, ten, or more substitutions listed in Table 16.
[0236] In some embodiments, the multi-specific binding protein comprising one or more CD80 ECD variants exhibits reduced binding affinity for CD28. In these embodiments, the one or more CD80 ECD variants each comprises at least one, two, three, or more amino acid substitutions as described herein. In some embodiments, the substitutions occur at positions 29, 31, 33, 36, 38, 50, 81, 83, 85, 88, 90, 91, 92, 93, 94, and 97, wherein the substitutions and the positions are determined with reference to SEQ ID NO: 2. In particular embodiments, the multi-specific binding protein comprising the one or more CD80 ECD variants with reduced binding affinity for CD28 comprises one, two, three, four, five, six, seven, eight, nine, ten, or more substitutions listed in Table 17.
[0237] In some embodiments, the multi-specific binding protein comprises (i) one or more CD80 ECD variants with increased binding affinity for PD-L1, and (ii) one or more CD80 ECD variants with reduced binding affinity for CD28. For example, the multi-specific binding protein comprises two polypeptides, one polypeptide comprises one or more CD80 ECD variants comprising at least one, two, three, or more amino acid substitutions at positions 8, 9, 10, 11, 13, 35, 47, 54, 55, 56, 57, 58, 60, 62, 63, 68, 70, 71, 107, 158, 159, 160, and 161, wherein the substitutions and the positions are determined with reference to SEQ ID NO: 2, and the other polypeptide comprises one or more CD80 ECD variants comprising at least one, two, three, or more amino acid substitutions at positions 29, 31, 33, 36, 38, 50, 81, 83, 85, 88, 90, 91, 92, 93, 94, and 97, wherein the substitutions and the positions are determined with reference to SEQ ID NO: 2. In particular embodiments, the multi-specific binding protein comprises a first polypeptide comprising one or more CD80 ECD variants that include one or more substitutions listed in Table 16, and a second polypeptide comprising one or more CD80 ECD variants that include one or more substitutions listed in Table 17.
[0238] In some embodiments, the multi-specific binding protein comprises one or more CD80 ECD variants that bind to the immune cell surface protein PD-L1 or T cell receptors CD28 and / or CTLA-4. In some embodiments, the multi-specific binding protein comprises a CD80 ECD variant comprising one or more amino acid substitutions linked to an IgG region via a linker. In some embodiments, the multi-specific binding protein comprises an amino acid sequence having at least 80%, 85%, or 90% identity to any one of SEQ ID NOs: 131-154, orcomprises a sequence having at least 95%, 96%, 97%, 98%, or 99% identity to any one of SEQ ID NOs: 131-154. In particular embodiments, the multi-specific binding protein comprises an amino acid sequence of any one of SEQ ID NOs: 131-154.
[0239] As disclosed herein, the first and / or second polypeptides may comprise a signal sequence at the N-terminus to enhance protein secretion, thereby facilitating protein production and purification processes. In some embodiments, the signal sequence comprises an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 64. Additionally, in some embodiments, the first and / or second polypeptides further comprise a 6x His tag (SEQ ID NO: 72) at the C-terminus to facilitate protein purification.B. Compositions
[0240] In one aspect, the present disclosure provides a composition comprising a multispecific binding protein as described herein, the multi-specific binding protein comprising (a) a first polypeptide comprising a first Fc region that is linked to a first domain at the N-terminus and a second domain at the C-terminus; and (b) a second polypeptide comprising a second Fc region that is linked to a third domain at the N-terminus and a fourth domain at the C-terminus; wherein each of the first, second, third, and fourth domains independently comprises a tumor-associated antigen (TAA) binding domain (TAA-BD) or an immune modulatory domain (IMD); wherein the multi-specific binding protein comprises at least one TAA-BD and at least one IMD; and wherein the first Fc region and the second Fc region form an Fc dimer.
[0241] In some embodiments, the composition comprising the multi-specific binding protein binds to a cancer cell surface protein is selected from the group consisting of STEAP1, B7-H3, EpCAM, ABCC4, ANO7, CEACAM1, FOLH1, OR51E1, OR51E2, PSCA, SLC30A4, SLC45A3, SPON2, STEAP2, TARP, TMEFF2, TMPR8, TMPRSS2, VEGF, CD274 (PD-L1), CD273 (PD-L2), CTLA4, and V domain immunoglobulin suppressor of T-cell activation (VISTA, VSIR), HER2 (ERBB2), HER3, Trop2 (TACSTD2), B7-H4 (VTCN1), MUC1, EGFRvIII, BCMA, CD 19, CD20, CD22, CD33, CD 123, CD 138, CD171, PSMA, Ig-kappa, LeY, ROR1, FAP, FR, Glypican-3, IL13Ralpha2, mesothelin, and an NKG2D ligand, and an immune cell surface protein is selected from the group consisting of CD3y (CD3 gamma chain), CD36 (CD3 delta chain), CD3s (CD3 epsilon chain), CD3(^ (CD3 zeta chain, CD247), CD2, CD27, CD28, CD69, ICOS, IL-2RB, PTPRC (CD45), CD48, SELL, CD137 (4-1BB, TNFRSF9), CD 134 (0X40, TNFRSF4), IL-7R, IL-15R, IL-21R, CTLA4, PD-L1, PD-L2, PD-1 (PDCD-1, CD279), TIGIT, andHAVCR2 (TIM3).
[0242] In some embodiments, the composition comprising the multi-specific binding protein binds to cancer cell surface proteins STEAP1, B7-H3, and / or EpCAM, and an immune cell surface proteins CD3, IL-21R, IL-2R, CD28, PD-L1, PD-L2, and / or PD-1.
[0243] In some embodiments, the composition further comprises a chemical compound and / or biological protein capable of providing an activation signal for T cells and / or blocking an inactivation signal for T cells.1. Pharmaceutical Compositions
[0244] In another aspect, the present disclosure provides a pharmaceutical composition, which comprises one or more multi-specific binding proteins described herein, or an ADC thereof, or corresponding CAR-T cells, and a pharmaceutically acceptable carrier. Generally, these substances may be formulated in a non-toxic, inert, and pharmaceutically acceptable aqueous carrier medium, of which the pH may generally be about 5-8, for example, about 6-8, and a pH value may vary with the nature of the formulated substances and the disorders to be treated. The formulated pharmaceutical composition may be administered by conventional routes, comprising (but not limited to): intratumoral, intraperitoneal, intravenous, or topical administration.
[0245] The multi-specific binding protein of the present application may also be expressed in a cell by means of a nucleotide sequence for cell therapy. For example, the multi-specific binding protein is used for the chimeric antigen receptor T cell immunotherapy (CAR-T), etc.
[0246] The pharmaceutical composition of the present application may be directly used to bind a target cancer cell protein, and thus may be used to prevent and treat cancers. In addition, other therapeutic agents may also be used at the same time.
[0247] The pharmaceutical composition of the present application may comprise the multispecific binding protein of the present application at a safe and effective amount (such as 0.001-99 wt %, 0.01-90 wt %, or 0.1-80 wt %) and a pharmaceutically acceptable adjuvant (which may comprise a carrier or an excipient). Such carriers may comprise (but are not limited to): saline water, buffer, glucose, water, glycerol, ethanol, and combinations thereof. A pharmaceutical preparation should match the mode of administration. The pharmaceutical composition of the present application may be prepared into an injection form, for example, by means of a conventional method using normal saline or an aqueous solution containing glucose and other adjuvants. The pharmaceutical composition such as an injection and a solution shouldbe manufactured under an aseptic condition. The dosage of an active ingredient is a therapeutically effective amount, for example, about 1 mg / kg body weight to about 5 mg / kg body weight per day. In addition, the antibody of the present application may also be used together with other therapeutic agents.
[0248] The multi-specific binding protein, composition, or pharmaceutical composition described herein may be formulated, dosed, and administered in line with good medical practices. The considerations in this case comprise the specific disorder being treated, the specific mammal being treated, the clinical condition of a single patient, the cause of the disorder, the site of agent delivery, the method of administration, the schedule of administration, and other factors known to a medical practitioner. A therapeutic agent (for example, a multi-specific binding protein) does not need to be but is optionally formulated and / or administered together with one or more agents that are currently used for preventing or treating the disorder in question. The effective amount of such other agents depends on the amount of the therapeutic agent (for example, the multi-specific binding protein) existing in the preparation, the type of disorder or treatment, and other factors discussed above. Generally, these agents may be used at any dose that is empirically / clinically determined to be appropriate and via any route that is empirically / clinically determined to be appropriate.
[0249] The multi-specific binding protein, composition, or pharmaceutical composition described herein may be employed in combination therapies. The particular combination of therapies (e.g., therapeutics or procedures) to employ in a combination regimen will take into account compatibility of the desired therapeutics and / or procedures and the desired therapeutic effect to be achieved. The pharmaceutical compositions of the present disclosure can be employed in combination therapies (e.g., combination antibody therapies), that is, the pharmaceutical compositions can be administered concurrently with, prior to, or subsequent to, one or more other therapeutic active ingredients. In some embodiments, other active ingredient(s) can be an anti-cancer agent, monoclonal antibody, polyclonal antibody, RNA polymerase inhibitors, protease inhibitors, helicase inhibitors, immunomodulators, antisense compounds, short interfering RNAs, short hairpin RNAs, micro RNAs, RNA aptamers, ribozymes, and combinations thereof. The combination therapies employed may achieve a desired effect for the same purpose, or they may achieve different effects (e.g., control of any adverse effects). Compared with a single therapy, the dose of the multi-specific binding protein administered in a combination therapy may be reduced. The progress of such a therapy may be easily monitored by conventional techniques.2. Kits
[0250] In another aspect, the present disclosure provides a kit for treating a subject with a cancer. In some embodiments, the kit comprises one or more of the multi-specific binding proteins, the nucleic acid, the vector, the host cell, the composition, or the pharmaceutical composition described herein. The kits are useful for treating any cancer, some non-limiting examples of which include breast cancer, ovarian cancer, cervical cancer, prostate cancer, pancreatic cancer, colorectal cancer, gastric cancer, lung cancer, skin cancer, liver cancer, brain cancer, eye cancer, soft tissue cancer, renal cancer, bladder cancer, head and neck cancer, mesothelioma, acute leukemia, chronic leukemia, medulloblastoma, multiple myeloma, sarcoma, and any other cancer described herein, including a combination thereof.
[0251] Materials and reagents to carry out the various methods of the present disclosure can be provided in kits to facilitate execution of the methods. As used herein, the term “kit” includes a combination of articles that facilitates a process, assay, analysis, or manipulation. In particular, kits of the present disclosure find utility in a wide range of applications including, for example, diagnostics, prognostics, therapy, and the like.
[0252] Kits can contain chemical reagents as well as other components. In addition, the kits of the present disclosure can include, without limitation, instructions to the kit user, apparatus and reagents for sample collection and / or purification, apparatus and reagents for product collection and / or purification, apparatus and reagents for administering modified cancer cell(s) or other composition(s) of the present disclosure, apparatus and reagents for determining the level(s) of biomarker(s) and / or the activity and / or number of immune cells, sample tubes, holders, trays, racks, dishes, plates, solutions, buffers or other chemical reagents, suitable samples to be used for standardization, normalization, and / or control samples. Kits of the present disclosure can also be packaged for convenient storage and safe shipping, for example, in a box having a lid. For instance, the kits may be stored and shipped at room temperature, on wet ice or with cold packs, or frozen in the vapor phase of liquid nitrogen or in dry ice.
[0253] In some embodiments, the kits also contain negative and positive control samples, immune cell activity and / or number, and / or the presence or level of biomarkers. In some embodiments, the negative control samples are non-cancer cells, tissue, or biofluid obtained from the subject who is to be treated or is already undergoing treatment. In other embodiments, the negative control samples are obtained from individuals or groups of individuals who do not have cancer. In other embodiments, the positive control samples are obtained from the subject,or other individuals or groups of individuals, who have cancer. In some embodiments, the kits contain samples for the preparation of a titrated curve of one or more biomarkers in a sample, to assist in the evaluation of quantified levels of the activity and / or number of one or more immune cells and / or biomarkers in a biological sample.3. Nucleic Acids and Vectors
[0254] In another aspect, the present disclosure provides a nucleic acid encoding the first or second polypeptide of the multi-specific binding protein as described herein. In some embodiments, the nucleic acid comprises a nucleic acid sequence encoding a signal sequence at the N-terminus to enhance secretion of the first or second polypeptide, thereby facilitating production and purification processes of the multi-specific binding protein. In some embodiments, the nucleic acid comprises a nucleic acid sequence encoding a His-tag sequence at the N-terminus to facilitate production and purification processes of the multi-specific binding protein.
[0255] The present disclosure further provides a vector comprising the nucleic acid disclosed herein. In some embodiments, the vector comprises one or more polynucleotide sequences that encode the first or second polypeptide of the multi-specific binding protein as described herein. In some embodiments, the vector comprises one or more polynucleotide sequences that encode a cognate pair of the first and second polypeptides described herein. Vectors can be used in the transformation of a host cell with a nucleic acid sequence. In some embodiments, a vector can include one or more polynucleotides encoding a multi-specific binding protein described herein.
[0256] The term “vector” is used to refer to a carrier nucleic acid molecule into which a nucleic acid sequence can be inserted for introduction into a cell where it can be replicated. A nucleic acid sequence can be “exogenous” or “heterologous” which means that it is foreign to the cell into which the vector is being introduced or that the sequence is homologous to a sequence in the cell but in a position within the host cell nucleic acid in which the sequence is ordinarily not found. Vectors include plasmids, cosmids, and viruses (e.g., bacteriophage). One of skill in the art may construct a vector through standard recombinant techniques, which are described in Maniatis et al., 1988 and Ausubel et al., 1994, both of which references are incorporated herein by reference.
[0257] The term “expression vector” refers to a vector containing a nucleic acid sequence coding for at least part of a gene product capable of being transcribed. In some cases, RNA molecules are then translated into a protein, polypeptide, or peptide. Expression vectors can contain a variety of “control sequences,” which refer to nucleic acid sequences for the transcription and possibly translation of an operably linked coding sequence in a particular host organism. In addition, to control sequences that govern transcription and translation, vectors and expression vectors may contain nucleic acid sequences that serve other functions as well.
[0258] In some embodiments, a vector can include a promoter. In some embodiments, a vector can include an enhancer. A “promoter” is a control sequence that is a region of a nucleic acid sequence at which initiation and rate of transcription are controlled. It may contain genetic elements at which regulatory proteins and molecules may bind such as RNA polymerase and other transcription factors. The phrases “operatively positioned,” “operatively linked,” “under control,” and “under transcriptional control” mean that a promoter is in a correct functional location and / or orientation in relation to a nucleic acid sequence to control transcriptional initiation and / or expression of that sequence. A promoter may or may not be used in conjunction with an “enhancer,” which refers to a cis-acting regulatory sequence involved in the transcriptional activation of a nucleic acid sequence.
[0259] A promoter may be one naturally associated with a gene or sequence, as may be obtained by isolating the 5' non-coding sequences located upstream of the coding segment and / or exon. Such a promoter can be referred to as “endogenous.” Similarly, an enhancer may be one naturally associated with a nucleic acid sequence, located either downstream or upstream of that sequence. Alternatively, certain advantages will be gained by positioning the coding nucleic acid segment under the control of a recombinant or heterologous promoter, which refers to a promoter that is not normally associated with a nucleic acid sequence in its natural environment. A recombinant or heterologous enhancer refers also to an enhancer not normally associated with a nucleic acid sequence in its natural environment. Such promoters or enhancers may include promoters or enhancers of other genes, and promoters or enhancers isolated from any other prokaryotic cell, promoters or enhancers not “naturally occurring,” z.e., containing different elements of different transcriptional regulatory regions, and / or mutations that alter expression. In addition to producing nucleic acid sequences of promoters and enhancers synthetically, sequences may be produced using recombinant cloning and / or nucleic acid amplification technology, including PCR, in connection with the compositions disclosedherein (see U.S. Pat. No. 4,683,202, U.S. Pat. No. 5,928,906, each incorporated herein by reference).
[0260] In some embodiments, a promoter and / or enhancer that effectively directs the expression of the DNA segment in the cell type chosen for expression. One example of such promoter that may be used is the E. coli arabinose or T7 promoter. Those of skill in the art of molecular biology generally are familiar with the use of promoters, enhancers, and cell type combinations for protein expression, for example, see Sambrook et al. (1989), incorporated herein by reference. The promoters employed may be constitutive, tissue-specific, inducible, and / or useful under the appropriate conditions to direct high-level expression of the introduced DNA segment, such as is advantageous in the large-scale production of recombinant proteins and / or peptides. The promoter may be heterologous or endogenous.4. Host cells and Expression Systems
[0261] The present disclosure further provides a host cell comprising the multi-specific binding protein, the nucleic acid, or the vector described herein. In some embodiments, a host cell can include a eukaryotic cell (e.g., insect, yeast, or mammalian) or a prokaryotic cell (e.g., bacteria). In the context of expressing a heterologous nucleic acid sequence, “host cell” can refer to a prokaryotic cell, and it includes any transformable organism that is capable of replicating a vector and / or expressing a heterologous gene encoded by a vector. A host cell can and has been, used as a recipient for vectors. A host cell may be “transfected” or “transformed,” which refers to a process by which exogenous nucleic acid is transferred or introduced into the host cell. A transformed cell includes the primary subject cell and its progeny.
[0262] Many host cells from various cell types and organisms are available and would be known to one of skill in the art. Similarly, a viral vector may be used in conjunction with a prokaryotic host cell, particularly one that is permissive for replication or expression of the vector. Some vectors may employ control sequences that allow it to be replicated and / or expressed in both prokaryotic and eukaryotic cells. One of skill in the art would further understand the conditions under which to incubate all of the above-described host cells to maintain them and to permit replication of a vector. Also understood and known are techniques and conditions that would allow large-scale production of vectors, as well as production of the nucleic acids encoded by vectors and their cognate polypeptides, proteins, or peptides.
[0263] In some embodiments, a host cell is mammalian. Examples include CHO cells, CHO-K1 cells, or CHO-S cells. Other mammalian host cells include NSO cells and CHO cells that are dhfr-, e.g., CHO-dhfr-, DUKX-B11 CHO cells, and DG44 CHO cells.
[0264] Disclosed herein also includes a method of producing a multi-specific binding protein. In some embodiments, the method comprises culturing the host cell described herein under conditions suitable for the expression of the multi-specific binding protein; and recovering the produced multi-specific binding protein from the host cell or from the culture. The polypeptides may be secreted and isolated from a mixture of cells and medium containing the polypeptides. Alternatively, the polypeptide may be retained in the cytoplasm or in a membrane fraction and the cells harvested, lysed, and the polypeptide isolated using a desired method.C. Methods of Treatment
[0265] In another aspect, the present disclosure provides a method for treating cancer in a subject. In some embodiments, the method comprises administering a therapeutically effective amount of the pharmaceutical composition described herein to the subject. In some embodiments, the subject has a tumor, cancer, an immune disease, or an infectious disease.
[0266] In some embodiments, the subject has cancer. In some embodiments, the method can inhibit cancer proliferation and / or tumor growth in the subject. In some embodiments, the cancer is selected from the group consisting of a lung cancer, a colorectal cancer, a breast cancer, a prostate cancer, a gastric cancer, a liver cancer, a cervical cancer, a brain cancer, a ovarian cancer, a pancreatic cancer, a skin cancer, an eye cancer, a soft tissue cancer, a renal cancer, a bladder cancer, a head and neck cancer, a neuroblastoma, a melanoma, a mesothelioma, an acute leukemia, an chronic leukemia, a medulloblastoma, a multiple myeloma, and a sarcoma. In some embodiments, the subject has epithelial or glandular cancer. In some embodiments, the subject has prostate cancer. In some embodiments, the subject has Ewing sarcoma.
[0267] In some embodiments, treating the subject comprises inhibiting cancer cell growth, inhibiting cancer cell proliferation, inhibiting cancer cell migration, inhibiting cancer cell invasion, ameliorating or eliminating the symptoms of cancer, reducing the size (e.g., volume) of a cancer tumor, reducing the number of cancer tumors, reducing the number of cancer cells, inducing cancer cell necrosis, pyroptosis, oncosis, apoptosis, autophagy, or other cell death, orenhancing the therapeutic effects of a composition or pharmaceutical composition. In some embodiments, treating the subject results in an increased survival time. In some instances, overall survival is increased. In other instances, disease-free survival is increased. In some instances, progression-free survival is increased. In particular embodiments, treating the subject results in a reduction in tumor volume and / or increased survival time.
[0268] In particular embodiments, treating the subject enhances the therapeutic effects of an anti-cancer therapy such as a chemotherapeutic agent, an immunotherapeutic agent, radiotherapy, hormone therapy, a differentiating agent, and / or a small-molecule drug.IV. Examples
[0269] The present disclosure will be described in greater detail by way of specific examples. The following examples are offered for illustrative purposes only, and are not intended to limit the invention in any manner. Those of skill in the art will readily recognize a variety of noncritical parameters which can be changed or modified to yield essentially the same results.Example 1: TILsRx Constructs
[0270] This example illustrates design and generation of TILsRx constructs.
[0271] “ TILsRx” refers to tumor-infiltrating lymphocyte (TIL) activating reagents that can enhance anti-tumor activity through integrating both T cell engagers, which promote T cell-mediated tumor killing, and tumor-targeted immune modulators, which selectively block inhibitory signals on tumor infiltrating lymphocytes (TILs) (immune checkpoint inhibitors) and / or provide an activation / co-activation signal to TILs.
[0272] As illustrated in FIG.2, TILsRx constructs can be designed to incorporate either with or without a cleavable linker. FIG. 2A shows a TILsRx construct without a protease cleavage site (PCS), designed to target tumor cells expressing STEAP1 (e.g., prostate cancer tumors). This construct activates TILs by providing signal 1, TCR signaling via an agonistic anti-CD3 scFv, and signal 2, co-stimulatory signal via CD80.
[0273] In FIG.2B, the TILsRx construct incorporates a PCS positioned between an agonistic anti-CD3 scFv and an IL- lb masking domain. The IL- lb masking domain is intended to enhance safety (e.g., reduced toxicity) by shielding the anti-CD3 scFv, thereby keeping it inactive outside the tumor microenvironment. Upon cleavage by tumor-associated proteases at the PCS, the construct is activated, functioning similarly to the TILsRx construct shown inFIG. 2A. This design ensures that full T cell activation occurs specifically within the tumor site, minimizing systemic toxicity.
[0274] FIG. 2C illustrates a TILsRx construct featuring a PCS between an IL-21 molecule and an Fc region. Upon cleavage by tumor protease(s) at the PCS, the IL-21 molecule is released and can diffuse to nearby IL-21 receptors on TILs. This interaction facilitates cooperative activation of TILs alongside the agonistic anti-CD3 scFv. The TILsRx construct shown in FIG.2C is anticipated to be more effective in activating TILs than similar constructs lacking a PCS as the free IL-21 of this construct is more likely to encounter an IL-21 receptor than IL-21 tethered to the Fc region of alternative constructs.
[0275] TILsRx constructs can be also designed to incorporate with two, three, or more cleavable linkers. FIG.3A illustrates a TILsRx construct featuring two protease cleavage sites (PCSs): one located between an IL-21 molecule and the first Fc region, and the other located between an IL-2 molecule and the second Fc region. To facilitate tumor targeting, two anti-STEAP1 scFv domains are attached to the opposite ends of the Fc regions, ensuring efficient homing to tumors expressing STEAP1.
[0276] FIG. 3B shows a TILsRx construct with a single anti-STEAPl scFv domain for tumor homing, but with two cytokines, IL-21 and IL-2, linked to the N- and C- terminus of one Fc region via PCS-containing linkers. Additionally, this construct incorporates an agonistic anti-CD3 scFv to provide TCR signaling. Strong TIL activation is anticipated by the effective cooperation between the anti-CD3 scFv and the released cytokines after protease cleavage at the two PCSs.
[0277] FIG. 3C shows a TILsRx construct featuring three protease cleavage sites (PCSs). As a variation of the construct shown in FIG. 3B, the anti-CD3 scFv is replaced by a second IL-21 molecule. This IL-21 molecule is also attached via a PCS-containing linker, allowing for protease-mediated cleavage and release. The dual release of cytokines (IL-21 and IL-2) is expected to further amplify TIL activation and improve therapeutic efficacy.
[0278] The incorporation of IL-21 into various TILsRx constructs is based on our experimental assays, which confirms that IL-21 can induce CD28 expression and cooperate with anti-CD3 antibodies in interferon-gamma (IFNy) production in CD8+ T cells, and the work by Alves et al. (J Immunol. 2005 Jul 15;175(2):755-62), suggesting that IL-21 can antagonize the downregulation of CD28 by IL-15.
[0279] To evaluate the role of IL-21 in promoting CD28 expression, 96-well plates were coated with an anti-CD3 antibody at concentrations of 0.5, 1, or 2 pg / ml. CD8+ T cells, obtained from the Stanford Blood Bank, were seeded at 50,000 cells per well. The cells were treated with IL-21 at concentrations of 50, 25 or 12.5 ng / mL, or left alone untreated. The untreated cells did not survive the culture period without any stimulation. After incubation for 7 days, cell proliferation was assessed using flow cytometry. Then the cells were washed with staining buffer and stained with isotype control or APC-conjugated anti-CD28 antibody. Cells were analyzed by flow cytometry using FlowJo software (Free Trial Version). As shown in FIG. 4A, IL-21 cooperated with the anti-CD3 antibody to enhance CD28 expression on CD8+ T cells.
[0280] Additionally, the supernatants from the cell cultures were analyzed for IFNy production after 4 days of incubation. As shown in FIG. 4B, the presence of IL-21 markedly augmented IFNY production compared to cultures treated with anti-CD3 antibody alone.
[0281] Table 6 shows TILsRx constructs designed at the sequence level. The first- and second-generation designs refer to different designs in the Fc regions. Both the first- and second-generation constructs contain the knob-in-hole (KiH) mutations such as S354C (knob), T366W (knob), Y349C (hole), T366S (hole), and L368A (hole) (Mayer et al., Int J Mol Sci.2015 Nov 17; 16(11):27497-507). However, only second-generation constructs contain a HY->RF mutation to simplify purification and a C->S mutation in the hinge region to minimize aggregation and mispairing. Various mutations designed in TILsRx constructs are summarized in Table 3.Table 6: TILsRx constructsTILsRx Construct Design Mechanism CommentsCD3 xIL21 x STEAP1 First and second Signal 1 and Boost Cooperation of anti-CD3 and x STEAPl generation IL21 in T cell activation CD3 x IL21 x B7-H3 x Second generation Signal 1 and Boost (Figure X)B7-H3CD3 x COND-IL21 x Second generation Signal 1, and Boost afterSTEAP1 x STEAP1 conditional release of IL21CD3 x COND-IL21 x Second generation Signal 1, and Boost afterB7-H3 x B7-H3 conditional release of IL21CD80 x CD3 x Second generation Signal 1 and 2 (coTumor targeting with high- STEAP1 x STEAP1 stimulation) affinity scFvs and scaffold CD80 x CD3 x B7-H3 Second generation Signal 1 and 2 (comutations to prevent x B7-H3 stimulation) aggregation and minimize CD80 x ILlb-CD3 x Second generation Signal 1 after cleaving off IL 1 superagonistic stimulation of STEAP1 x STEAP1 inhibitory domain, and Signal extratumoral T cells2CD80 x ILlb-CD3 x Second generation Signal 1 after cleaving off IL 1B7-H3 x B7-H3 inhibitory domain, and Signal2CD80 x PAS-CD3 x Second generation Signal 1 after cleaving offSTEAP1 x STEAP1 PAS inhibitory domain, andSignal 2CD80 x PAS-CD3 x Second generation Signal 1 after cleaving offB7-H3 x B7-H3 PAS inhibitory domain, andSignal 2CD86 x CD3 x Second generation Signal 1 and 2 (coSTEAP1 x STEAP1 stimulation)CD86 x CD3 x B7-H3 Second generation Signal 1 and 2 (cox B7-H3 stimulation)CD80 x IL21 x Second generation Signal 2 (co-stimulation) andSTEAP1 x STEAP1 BoostCD80 x IL21 x B7-H3 Second generation Signal 2 (co-stimulation) andx B7-H3 BoostCD86 x IL21 x First and second Signal 2 (co-stimulation) andSTEAP1 x STEAP1 generation BoostCD86 x IL21 x B7-H3 Second generation Signal 2 (co-stimulation) andx B7-H3 BoostCD80 x CD80 x Second generation Signal 2 (co-stimulation)STEAP1 x STEAP1CD80 x CD80 x B7- Second generation Signal 2 (co-stimulation)H3 x B7-H3CD86 x CD86 x Second generation Signal 2 (co-stimulation)STEAP1 x STEAP1CD86 x CD86 x B7- Second generation Signal 2 (co-stimulation)H3 x B7-H3CD3 xIL21 x STEAP1 Second generation Signal 1 and Boost Tumor targeting even if x B7-H3 negative for one of the TAAs CD80 x CD3 x Second generation Signal 1 and 2 (coTumor targeting even if STEAP1 xB7-H3 stimulation) negative for one of the TAAs CD86 x CD3 x Second generation Signal 1 and 2 (coTumor targeting even if STEAP1 xB7-H3 stimulation) negative for one of the TAAs PD1 xPDl x STEAP1 First and second Prevention of T cell inhibitingx STEAPl generation PD1 signalPD1 x PDl xB7-H3 x Second generation Prevention of T cell inhibitingB7-H3 PD1 signalExample 2: TILsRx Production and Purification
[0282] This example illustrates the production and purification processes of the TILsRx constructs.
[0283] Several TILsRx constructs, each comprising heterodimers formed by two chains joined via the hinge, CH2 and CH3 regions of human IgG, were evaluated for TILsRx production and purification processes. Mutations, as listed in Table 3, were introduced into these regions to promote heterodimerization of the two chains and enhance stability of the TILsRx constructs.
[0284] FIG. 5A illustrates construct A, in which the hCH2 region of chain A is fused to an IL-21 receptor binding domain (the first domain), while the hCH2 region of chain B is fused to a CD28 binding domain of the CD86 molecule (the second domain). This design is intended to enhance anti -turn or T cell activity by binding to the IL-21 receptor, thereby lowering the activation threshold for TILs, and to CD28, providing critical co-stimulatory signals for T cell activation.
[0285] FIG. 5B illustrates construct B, in which both hCH2 regions of chain A and chain B are linked to PD-1 binding domains (the first and second domains), which act as a ligand for PD-L1. This construct is designed to block PD-L1 and PD-L2 molecules on cancer cells, preventing them from inactivating T cells, thereby restoring T cell activity in the tumor microenvironment.
[0286] FIG. 5C illustrates construct C, in which the hCH2 region of chain A is attached to an IL-21 receptor binding domain (the first domain), thereby lowering the threshold for TIL stimulation, while the hCH2 region of chain B is attached to an anti-CD3 antibody (e.g., anti-CD3 scFv) (the second domain), directly stimulating TILs. This dual-function design aims to activate anti -turn or T cell by engaging both the IL-21 receptor and CD3.
[0287] All of the constructs also include cell-targeting domains attached to the hCH3 regions, comprised of an scFv targeting either EpCAM or STEAP1 (the third and fourth domains). These targeting domains enable selective binding to cancer cells. Additionally, one of these cell-targeting domains incorporates a histidine (His) “tag” consisting of six His residues to facilitate purification during the production process. All the constructs are also designed to include a signal sequence (MGWSCIILFLVATATGVHS, SEC ID NO: 64) at the N-terminus of each polypeptide, to facilitate the secretion of the proteins during the production process.
[0288] Table 7 shows the designed sequences of chain A of the constructs, which include the “knob” portion of the knob-in-hole heterodimerization motif on the hCH2-CH3 regions. This includes chain Al: IL-21-Ll-Fv(knob)-L2-aEpCAM; chain A2: PD1-Ll-Fv(knob)-L2-aEpCAM; chain A3: IL-21-Ll-Fv(knob)-L2-aSTEAPl; and chain A4: PD1-Ll-Fv(knob)-L2-aSTEAPl.Table 7. Sequences of Chain A (knob chains) of TILsRx ConstructsChain SequenceChain Al: IL-21- MGWSCIILFLVATATGVHSQGQDRHMIRMRQLIDIVDQLKN Fv(knob)-aEpCAM YVNDLVPEFLPAPEDVETNCEWSAFSCFQKAQLKSANTGNN ERIINVSIKKLKRKPPSTNAGRRQKHRLTCPSCDSYEKKPPKE FLERFKSLLQKMIHQHLSSRTHGSEDSSGGGGSGGGGSGGGG SEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPE VTCVVVDVSHEDPEVI<FNWYVDGVEVHNAI<TI<PREEQYNS TYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA KGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVE WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGN VFSCSVMHEALHNHYTQKSLSLSPGGGGSGGGGSGGGGSQI QLVQSGPELKKPGETVKISCKASGYTFTKYGMNWVKQAPGK CLKWMGWINTYTEEPTYGDDFKGRFAFSLETSASTANLQINN LKSEDTATYFCARFGSAVDYWGQGTSVTVSSGGGGSGGGGS GGGGSDIVMTQAAFSNPVTLGTSGSISCRSSKSLLHSNGITYL YWYLQKPGQSPQLLIYQMSNL ASGVPDRF S S SGSGTDFTLRIS RVEAEDVGVYYCAQNLELPRTFGCGTKLEMKRTVChain A2: PD1- MGWSCIILFLVATATGVHSPGWFLDSPDRPWNPPTFSPALLV Fv(knob)-aEpCAM VTEGDNATFTC SF SNTSESF VLNWYRMSPSNQTDKLAAFPED RSQPGQDCRFRVTQLPNGRDFHMSVVRARRNDSGTYLCGAI SLAPKAQIKESLRAELRVTERRAEVPTAHPSPSPRPAGQFQGG GGSGGGGSGGGGSGGGGSEPKSCDKTHTCPPCPAPELLGGPS VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDG VEVHNAI<TI<PREEQYNSTYRVVSVLTVLHQDWLNGI<EYI<C KVSNKALPAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVS LWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFL YSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGG GGSGGGGSGGGGSGGGGSQIQLVQSGPELKKPGETVKISCKA SGYTFTKYGMNWVKQAPGKCLKWMGWINTYTEEPTYGDD FKGRFAFSLETSASTANLQINNLKSEDTATYFCARFGSAVDY WGQGTSVTVSSGGGGSGGGGSGGGGSDIVMTQAAFSNPVTL GTSGSISCRSSKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSN L ASGVPDRFS S SGSGTDFTLRISRVEAED VGVYYC AQNLELP RTFGCGTKLEMKRTVChain A3: IL-21- MGWSCIILFLVATATGVHSQGQDRHMIRMRQLIDIVDQLKN Fv(knob)-aSTEAP 1 YVNDLVPEFLPAPEDVETNCEWSAFSCFQKAQLKSANTGNN ERIINVSIKKLKRKPPSTNAGRRQKHRLTCPSCDSYEKKPPKE FLERFKSLLQKMIHQHLSSRTHGSEDSSGGGGSGGGGSGGGG SEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPE VTCVVVDVSHEDPEVI<FNWYVDGVEVHNAI<TI<PREEQYNS TYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA KGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVE WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGN VFSCSVMHEALHNHYTQKSLSLSPGGGGSGGGGSGGGGSEV QLVESGGGLVQPGGSLRLSCAVSGYSITSDYAWNWVRQAPG KCLEWVGYISNSGSTSYNPSLKSRFTISRDNSKNTLYLQMNSL RAEDTAVYYCARERNYDYDDYYYAMDYWGQGTLVTVSSG GGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCKSSQS LLYRSNQKNYLAWYQQKPGKAPKLLIYWASTRESGVPSRFS GSGSGTDFTLTISSLQPEDFATYYCQQYYNYPRTFGCGTKVEIKRChain A4: PD1- MGWSCIILFLVATATGVHSPGWFLDSPDRPWNPPTFSPALLV Fv(knob)-aSTEAP 1 VTEGDNATFTC SF SNTSESF VLNWYRMSPSNQTDKLAAFPED RSQPGQDCRFRVTQLPNGRDFHMSVVRARRNDSGTYLCGAI SLAPKAQIKESLRAELRVTERRAEVPTAHPSPSPRPAGQFQGG GGSGGGGSGGGGSGGGGSEPKSCDKTHTCPPCPAPELLGGPS VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDG VEVHNAI<TI<PREEQYNSTYRVVSVLTVLHQDWLNGI<EYI<C KVSNKALPAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVS LWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFL YSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGG GGSGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCA VSGYSITSDYAWNWVRQAPGKCLEWVGYISNSGSTSYNPSL KSRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARERNYDYD DYYYAMDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMT QSPSSLSASVGDRVTITCKSSQSLLYRSNQKNYLAWYQQKPG KAPKLLIYWASTRESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYNYPRTFGCGTKVEIKR
[0289] Table 8 shows the designed sequences of chain B of the constructs, which include the “hole” portion of the knob-in-hole heterodimerization motif. This includes chain Bl: CD86-Ll-Fv(hole)-L2-aEpCAM-His tag; chain B2: PDl-Ll-Fv(hole)-L2-aEpCAM-His tag; chain B3: aCD3-Ll-Fv(hole)-L2-aEpCAM-His tag; chain B4: CD86-Ll-Fv(hole)-L2-aSTEAPl-His tag; chain B5: PDl-Ll-Fv(hole)-L2-aSTEAPl-His tag; and chain B6: aCD3-Ll-Fv(hole)-L2-aSTEAPl-His tag.Table 8. Sequences of Chain B (knob chains) of TILsRx ConstructsChain SequenceChain Bl: MGWSCIILFLVATATGVHSAPLKIQAYFNETADLPCQFAN CD86-Fv(hole)-aEpCAM SQNQSLSELVVFWQDQENLVLNEVYLGKEKFDSVHSKY MGRTSFDSDSWTLRLHNLQIKDKGLYQCIIHHKKPTGMIR IHQMNSELSVLGGGGSGGGGSGGGGSEPKSCDKTHTCPP CPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH EDPEVI<FNWYVDGVEVHNAI<TI<PREEQYNSTYRVVSVL TVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPRE PQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNG QPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFS CSVMHEALHNHYTQKSLSLSPGGGGSGGGGSGGGGSQIQ LVQSGPELKKPGETVKISCKASGYTFTKYGMNWVKQAP GKCLKWMGWINTYTEEPTYGDDFKGRFAFSLETSASTAN LQINNLKSEDTATYFCARFGSAVDYWGQGTSVTVSSGGG GSGGGGSGGGGSDIVMTQAAFSNPVTLGTSGSISCRSSKS LLHSNGITYLYWYLQKPGQSPQLLIYQMSNLASGVPDRFS SSGSGTDFTLRISRVEAEDVGVYYCAQNLELPRTFGCGTKLEMKRTVHHHHHHChain B2: MGWSCIILFLVATATGVHSPGWFLDSPDRPWNPPTFSPAL PD 1 -Fv(hole)-aEpCAM LVVTEGDNATFTCSFSNTSESFVLNWYRMSPSNQTDKLA AFPEDRSQPGQDCRFRVTQLPNGRDFHMSVVRARRNDSG TYLCGAISLAPKAQIKESLRAELRVTERRAEVPTAHPSPSP RPAGQFQGGGGSGGGGSGGGGSGGGGSEPKSCDKTHTC PPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS HEDPEVI<FNWYVDGVEVHNAI<TI<PREEQYNSTYRVVSV LTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPR EPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESN GQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVF SCSVMHEALHNHYTQKSLSLSPGGGGSGGGGSGGGGSG GGGSQIQLVQSGPELKKPGETVKISCKASGYTFTKYGMN WVKQAPGKCLKWMGWINTYTEEPTYGDDFKGRFAFSLE TSASTANLQINNLKSEDTATYFCARFGSAVDYWGQGTSV TVSSGGGGSGGGGSGGGGSDIVMTQAAFSNPVTLGTSGSI SCRSSKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNLAS GVPDRF S S SGSGTDFTLRISRVEAED VGVYYC AQNLELPR TFGCGTKLEMKRTVHHHHHHChain B3: MGWSCIILFLVATATGVHSDIKLQQSGAELARPGASVKM aCD3 -Fv(hole)-aEpCAM SCKTSGYTFTRYTMHWVKQRPGQCLEWIGYINPSRGYTN YNQKFKDKATLTTDKS S STAYMQLS SLTSEDS AVYYC AR YYDDHYCLDYWGQGTTLTVSSVEGGSGGSGGSGGSGGV DDIQLTQ SP AIMS ASPGEK VTMTCRAS S S VS YMNW YQQK SGTSPKRWIYDTSKVASGVPYRFSGSGSGTSYSLTISSME AEDAATYYCQQWSSNPLTFGCGTKLELKGGGGSGGGGS GGGGSEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDT LMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNK ALPAPIEKTISKAKGQPREPQVCTLPPSRDELTKNQVSLSC AVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFL VSKLTVDKSRWQQGNVF SC SVMHEALHNHYTQKSLSLS PGGGGSGGGGSGGGGSQIQLVQSGPELKKPGETVKISCK ASGYTFTKYGMNWVKQAPGKCLKWMGWINTYTEEPTY GDDFKGRFAFSLETSASTANLQINNLKSEDTATYFCARFG SAVDYWGQGTSVTVSSGGGGSGGGGSGGGGSDIVMTQA AFSNPVTLGTSGSISCRSSKSLLHSNGITYLYWYLQKPGQS PQLLIYQMSNL ASGVPDRF S S SGSGTDFTLRISRVEAED V GVYYCAQNLELPRTFGCGTKLEMKRTVHHHHHHChain B4: MGWSCIILFLVATATGVHSAPLKIQAYFNETADLPCQFAN CD86-Fv(hole)- SQNQSLSELVVFWQDQENLVLNEVYLGKEKFDSVHSKY aSTEAPlMGRTSFDSDSWTLRLHNLQIKDKGLYQCIIHHKKPTGMIR IHQMNSELSVLGGGGSGGGGSGGGGSEPKSCDKTHTCPP CPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH EDPEVI<FNWYVDGVEVHNAI<TI<PREEQYNSTYRVVSVL TVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPRE PQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNG QPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFS CSVMHEALHNHYTQKSLSLSPGGGGSGGGGSGGGGSEV QLVESGGGLVQPGGSLRLSCAVSGYSITSDYAWNWVRQAPGKCLEWVGYISNSGSTSYNPSLKSRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARERNYDYDDYYYAMDYWGQ GTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSASVG DRVTITCKSSQSLLYRSNQKNYLAWYQQKPGKAPKLLIY WASTRESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQ QYYNYPRTFGCGTKVEIKRHHHHHHChain B5: MGWSCIILFLVATATGVHSPGWFLDSPDRPWNPPTFSPAL PDl-Fv(hole)-aSTEAPl LVVTEGDNATFTCSFSNTSESFVLNWYRMSPSNQTDKLA AFPEDRSQPGQDCRFRVTQLPNGRDFHMSVVRARRNDSG TYLCGAISLAPKAQIKESLRAELRVTERRAEVPTAHPSPSP RPAGQFQGGGGSGGGGSGGGGSGGGGSEPKSCDKTHTC PPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS HEDPEVI<FNWYVDGVEVHNAI<TI<PREEQYNSTYRVVSV LTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPR EPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESN GQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVF SCSVMHEALHNHYTQKSLSLSPGGGGSGGGGSGGGGSG GGGSEVQLVESGGGLVQPGGSLRLSCAVSGYSITSDYAW NWVRQAPGKCLEWVGYISNSGSTSYNPSLKSRFTISRDNS KNTLYLQMNSLRAEDTAVYYCARERNYDYDDYYYAMD YWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLS ASVGDRVTITCKSSQSLLYRSNQKNYLAWYQQKPGKAP KLLIYWASTRESGVPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQYYNYPRTFGCGTKVEIKRHHHHHHChain B6: MGWSCIILFLVATATGVHSDIKLQQSGAELARPGASVKM aCD3-Fv(hole)- SCKTSGYTFTRYTMHWVKQRPGQCLEWIGYINPSRGYTN aSTEAPlYNQKFKDKATLTTDKS S STAYMQLS SLTSEDS AVYYC AR YYDDHYCLDYWGQGTTLTVSSVEGGSGGSGGSGGSGGV DDIQLTQ SP AIMS ASPGEK VTMTCRAS S S VS YMNW YQQK SGTSPKRWIYDTSKVASGVPYRFSGSGSGTSYSLTISSME AEDAATYYCQQWSSNPLTFGCGTKLELKGGGGSGGGGS GGGGSEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDT LMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNK ALPAPIEKTISKAKGQPREPQVCTLPPSRDELTKNQVSLSC AVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFL VSKLTVDKSRWQQGNVF SC SVMHEALHNHYTQKSLSLS PGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCA VSGYSITSDYAWNWVRQAPGKCLEWVGYISNSGSTSYNP SLKSRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARERN YDYDDYYYAMDYWGQGTLVTVSSGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTITCKSSQSLLYRSNQKNY LAWYQQKPGKAPKLLIYWASTRESGVPSRFSGSGSGTDF TLTISSLQPEDFATYYCQQYYNYPRTFGCGTKVEIKRHHHHHH
[0290] The TILsRx production and purification process includes: 1), gene synthesis; 2), cloning the coding regions into the expression vector (e.g., plasmid pcDNA3.4); 3), transient transfection of Chinese Hamster Ovary (CHO) cells (e.g., ExpiCHO-S cells); 4), purificationof the constructs from the CHO cell supernatant using His tags; and 5), additional purification steps as noted in Table 9.Table 9. Purification process of TILsRx constructs.Nam Sam Purification Buffer Concentr Puri Puri Tot e pie ation ty ty al [mg / ml] SDS SEC [m g] PA HP GE LC[%] [%] A3+ 1 HiTrap MabSelect SuRe, HiTrap SP FF 1ml 20 m M PB, 500mM 0.23 95 90.1 0.0 B4 NaCl, pH 7.2 34 A3+ 2 HiTrap MabSelect SuRe, HiTrap SP FF 1ml 20 m M PB, 500mM 0.13 95 69.2 0.0 B4 NaCl, pH 7.2 9 78 A3+ 3 HiTrap MabSelect SuRe, HiTrap SP FF 1ml (GE, 20mM PB,460mM Nacl 0.31 95 99.1 0.2 B4 Cat.No.17-5054-01) , PH7.2 3 79 A3+ 4 HiTrap MabSelect SuRe, HiTrap SP FF 1ml (GE, 20mM PB,460mM Nacl 0.22 95 63.2 0.0 B4 Cat.No.17-5054-01) , PH7.2 2 77 A4+ 1 HiTrap MabSelect SuRe, Superdex 200 Increase PBS, pH 7.2 0.17 90 93.0 0.0 B5 10 / 300GL 24ml 7 25 A4+ 2 HiTrap MabSelect SuRe, Superdex 200 Increase PBS, pH 7.2 0.09 N / A 86.8 0.1 B5 10 / 300GL 24ml 7 08 A4+ 3 HiTrap MabSelect SuRe, Superdex 200 Increase PBS, pH 7.2 0.71 90 90.1 0.1 B5 10 / 300GL 24ml 2 42 A4+ 4 HiTrap MabSelect SuRe, Superdex 200 Increase PBS, pH 7.2 0.61 85 88.8 0.2 B5 10 / 300GL 24ml 5 44 A3+ 1 HiTrap MabSelect SuRe, Superdex 200 Increase PBS, pH 7.2 0.38 65 86.7 0.2 B6 10 / 300GL 24ml 4 66 A3+ 2 HiTrap MabSelect SuRe, Superdex 200 Increase PBS, pH 7.2 0.28 75 98.9 0.2B6 10 / 300GL 24ml 7 24
[0291] The TILsRx construct A (its diagram shown in FIG. 5A), comprising chain A3 and chain B4, was assessed for production and purification. The purified protein, designated as "A3+B4, sample 3", was obtained through a two-step purification process, as shown in Table 9. The purified protein exhibited a concentration of 0.31 mg / ml and demonstrated high purity, with approximately 95% purity confirmed by SDS-PAGE analysis (FIG. 6A) and 99.13% purity verified through SEC-HPLC (FIG. 7). Further validation of the purified protein was performed using Western blot analysis with anti-His tag antibody (FIG. 6B), anti-human IgG antibody (FIG. 6C), and anti-human IL-21 antibody (FIG. 6D), respectively. These results confirm the efficacy of the production and purification process for generating TILsRx construct A.
[0292] The purified protein “A3+B4, sample 3” was formulated in a buffer consisting of 20 mM phosphate buffer (PB), 460 mM NaCl, at pH 7.2, with a total yield of 279 pg distributed across two tubes, each containing 450 pl. The protein is stored at -80°C to maintain stability and prevent degradation.
[0293] The TILsRx construct B (its diagram shown in FIG. 5B), comprising chain A4 and chain B5, was assessed for production and purification. The purified protein, designated as "A4+B5, sample 3", was obtained through a two-step purification process, as shown in Table 9. The purified protein exhibited a concentration of 0.71 mg / ml and demonstrated high purity, with approximately 90% purity confirmed by SDS-PAGE analysis (FIG. 8A) and 90.12% purity verified through SEC-HPLC (FIG. 9). Further validation of the purified protein was performed using Western blot analysis with anti-His tag antibody (FIG. 8B) and anti-human IgG antibody (FIG. 8C), respectively. These results confirm the efficacy of the production and purification process for generating TILsRx construct B.
[0294] The purified protein “A4+B5, sample 3” was formulated in a 200 pl PBS buffer at pH 7.2, with a total yield of 142 pg in a tube. The protein is stored at -80°C to maintain stability and prevent degradation.
[0295] The TILsRx construct C (its diagram shown in FIG. 5C), comprising chain A3 and chain B6, was assessed for production and purification. The purified protein, designated as "A3+B6, sample 1", was obtained through a two-step purification process, as shown in Table 9. The purified protein exhibited a concentration of 0.38 mg / ml and demonstrated high purity, with approximately 65% purity confirmed by SDS-PAGE analysis (FIG. 10A) and 86.74% purity verified through SEC-HPLC (FIG. 11). Further validation of the purified protein was performed using Western blot analysis with anti-His tag antibody (FIG. 10B) and anti-human IgG antibody (FIG. 10C), respectively. These results confirm the efficacy of the production and purification process for generating TILsRx construct C.
[0296] The purified protein “A3+B6, sample 1” was formulated in a PBS buffer at pH 7.2, with a total yield of 266 pg distributed across two tubes, each containing 350 pl. The protein is stored at -80°C to maintain stability and prevent degradation.Example 3: Cytotoxicity Effects of TILsRx Constructs on Cancer Cells
[0297] This example illustrates cytotoxicity effects of TILsRx constructs on LNCaP clone FGC prostate cancer cells.
[0298] To further assess the ability of TILsRx constructs to activate CD8+ T cells for targeted cytotoxicity against prostate cancer cells, the TILsRx construct C (its diagram shown in FIG. 5C), comprising chain A3 and chain B6, was tested for its efficacy on LNCaP clone FGC prostate cancer cells.
[0299] Target cells (LNCaP clone FGC cells) were seeded in triplicates at 10,000 cells per 100 pl per well in a 96-well plate at least one day before the experiment is initiated. Effector cells (CD8+T cells) were derived from a single donor, diluted in RPMI-1640 medium supplemented with 10% heat-inactivated FBS (without antibiotics), and prepared in serial concentrations. The TILsRx construct A3+B6 or PBS (control) and appropriate volumes of each T cell dilution were carefully added to the target cells to achieve effector-to-target (E / T) ratios of 50:1, 35:1, or 20:1. The cells were incubated at 37°C with 5% CO2 for up to 6 hours, after which cytotoxicity assays were performed.
[0300] Cytotoxicity was measured by detecting lactate dehydrogenase (LDH) release from damaged cells. LDH activity in the medium was assessed by enzymatic conversion of INT (iodotetrazolium chloride) using a detection kit (e.g., Roche, Cat. No. 164-479-3001). LDH activity was quantified by measuring absorbance at 490 or 492 nm and at a reference wavelength of 650 nm (or another wavelength >600 nm) using a microplate reader. The percentage of target cell lysis mediated by the TILsRx construct was calculated using the formula:%(target cell lysis) = 100*[OD(Sample)-OD(E+T)] / [OD(Maximum release)- OD(Minimum release)]
[0301] In this formula:OD (Sample) refers to the optical density (absorbance) at 492 nm minus the optical density at 650 nm;- OD (E+T) refers to the OD of the control sample(s) comprising effector and target cells but lacking the TILsRx construct;OD (Maximum release) refers to the maximal LDH release from target cells following lysis of the cells with Triton XI 00;OD (Minimum release) refers to the spontaneous basal LDH release of the target cells without the presence of effector cells and the TILsRx construct.
[0302] As an exemplary procedure for an experiment addressing the cytotoxic potential of TILsRx constructs, the following principal steps can be considered, exemplified for LNCaP clone FGC cells. 1) Culture target cell line (LNCaP clone FGC) using established conditions.2) Maintain the T cell culture and monitor its cell density every 1-2 days. 3) Once the T cellcounts are expected to be sufficient for the assay, seed LNCaP clone FGC cell in triplicates at 10,000 cells per 100 pl per well in a 96-well plate at least one day before the assay is conducted.4) With the timing of the previous step in mind, prepare PBMCs using LymphoPrep by gradient density centrifugation from human peripheral blood from a healthy donor. 5) Purify CD8+ T cells using a suitable CD8+ binding device as per manufacturer’s instruction (e.g., Miltenyi Biotech). 6) Assess the quality of the isolated cells via flow cytometry using anti-CD8 and anti-CD3 antibodies. 7) Activate and expand effector T cells using a T cell Activation / Expansion Kit per manufacturer’s instructions (Miltenyi Biotech). 8) The day of the assay, count LNCaP clone FGC cells from wells not intended for cytotoxicity assessment then calculate the number of T cells needed based on the LNCaP clone FGC cell counts. 9) Carefully remove the LNCaP clone FGC culture supernatant then add 100 pl / well of the TILsRx contruct(s) (e.g., at 1 pg per 100 pl and well for E / T ratio optimization and, e.g., at 1 pg, 10 pg, 100 pg, 1 ng, 10 ng, 100 ng, and 1 pg per 100 pl and well). Ensure that there are also control (reference) wells to which no TILsRx construct is added. 10) Incubate the 96-well plate for about 30 min at RT. 11) Remove and spin down a suitable aliquot of the T cell culture (optional: wash T cells in plain RPMI-1640 or PBS) then resuspend T cells in Assay Buffer containing IL-2 (no antibiotics), ensuring T cell numbers and IL-2 concentration are as stated in the next step. 12) Carefully and slowly add 100 pl of T cells (T cell numbers according to E / T ratio) for a final reaction volume of 200 pl / well and an IL-2 concentration of 20 U / ml. 13) Incubate the 96-well plate at 37°C with 5% CO2 for a suitable length of time. Consider 6 hours as a starting point for LNCaP clone FGC cells. 14) Conduct an LDH release assay using a cytotoxicity detection kit.
[0303] The data is presented and analyzed via commonly available data analysis software (e.g., GraphPad Prism). As shown in FIG. 12, the TILsRx construct C: A3+B6 activated CD8+ T cells to lyse the STEAP1 -expressing LNCaP clone FGC cells, and optimal conditions included a 6-hour incubation and an E / T ratio of 50:1, which yielded the highest levels of target cell lysis.
[0304] To further evaluate the cytotoxicity of CD8+ T cells activated by the TILsRx construct C: A3+B6, against prostate cancer cells, the assay was performed as described previously under varying concentrations of the TILsRx construct C: A3+B6. As shown in FIG.13, maximal cell lysis was achieved, consistent with the results presented in FIG. 12. The calculated EC50 for the A3+B6 construct was determined to be 15.91 ng / mL, demonstrating its robust activity to stimulate CD8+ T cells in killing LNCaP clone FGC cells. Since the CD8+ T cells used in the experiment were not pre-activated, these results confirm that the A3+B6construct effectively activated the T cells and may have directed them to specifically target the LNCaP cells.Example 4: Cytotoxicity Effects of Second-Generation TILsRx Constructs on Cancer Cells
[0305] This example illustrates cytotoxicity effects of second-generation TILsRx constructs: CD80 x CD3 x STEAP1 and CD3 x IL21 x STEAP1 on LNCaP clone FGC prostate cancer cells.
[0306] We developed second-generation TILsRx constructs targeting STEAP1, specifically: (1) a CD80 x CD3 x STEAP1 construct comprising the amino acid sequences of SEQ ID NOs: 22 and 23, and (2) a CD3 x IL21 x STEAP1 construct comprising the amino acid sequences of SEQ ID NOs: 14 and 15. The second-generation TILsRx constructs each contain C103S, H318R, and Y319F point mutations in the Fc region, with the C103S mutation present on both the “knob” and “hole” chains and the H318R and Y319F mutations only on the “hole” chain (see Table 3), in comparison to the first-generation TILsRx constructs, e.g., the TILsRx construct C: A3+B6 illustrated in Example 3. The two second-generation TILsRx constructs were tested in a dose-response experiment using CD8+ human T cells as effector cells and the LNCaP clone FGC prostate cancer cell line as target cells. The effector-to-target (E:T) cell ratio was maintained at 35:1, as previously established.
[0307] After 6 hours of stimulation, target cell lysis was assessed via lactate dehydrogenase (LDH) release. As a positive control, FIG. 15A demonstrates Raji target cell lysis mediated by an anti-CD20 x CD3 antibody, confirming the assay system’s functionality. FIG. 15B demonstrates sigmoidal target cell lysis for both of the second-generation TILsRc constructs, CD80 x CD3 x STEAP1 and CD3 x IL21 x STEAP1. Both constructs yielded picomolar EC50 values: 922 pM for CD80 x CD3 x STEAP1 and 574 pM for CD3 x IL21 x STEAP1. The maximum % target cell lysis was greater for the CD80 x CD3 x STEAP1 construct (52%) compared to the CD3 x IL21 x STEAP1 construct (21%), as shown in FIG. 15B and Table 10.The HYHEL-10 isotype control antibody served as a negative control. These data further demonstrate that second-generation TILsRx constructs can effectively stimulate CD8+ T cells in killing LNCaP clone FGC cells.Table 10. Bioactivity of the TILsRx constructs CD80 x CD3 x STEAP1 and CD3 x IL21 x STEAP1. Dose-response curve fitting: log(agonist) vs. response — Variable slope (four-parameter).Log (agonist) vs. Response - Variable slopeBest-fit valuesSample ID CD3 x IL21 x STEAP1 CD80 x CD3 x STEAP1 HYHEL-10 Bottom -0.07851 -2.965 NATop 21.89 50.29 NA LogECso -0.2408 -0.03509 NA HillSlope 0.9877 1.187 NAEC50(nM) 0.5744 0.9224 NASpan 21.97 53.25 NAExample 5: Validation of CD80 Mutations That Increase the Binding Affinity for PD-L1
[0308] This example illustrates a systematic computational approach to identifying and prioritizing CD80 mutations that increase binding affinity for PD-L1.
[0309] In short, first, molecular models are built in which the CD80 ECD or IgV domain is bound to PD-L1, CD28, or CTLA-4; second, the CD80 domain is in silico mutated to all 19 alternative standard amino acids (“saturation mutagenesis”) and the effects on target protein (PD-L1, CD28, CTLA-4) binding predicted using software tools such as DDMut-PPI [Zhou et al., 2024] or SSIPe [Huang et al., 2020]; and third, CD80 mutations for which the desired effects on target protein binding are predicted (PD-L1: increased affinity, CD28: decreased affinity, CTLA-4: increased or no change in affinity) are validated by SPR or alternative methods such as BLI or ELISA.
[0310] It is of note that the experimental binding data from the CD80 mutations validated in the aforementioned third step (and from CD80, PD-L1, CD28, or CTLA-4 mutations for which CD80-PD-L1, CD80-CD28, or CD80-CTLA4 binding data are available from elsewhere, e.g., the literature) can be used to gauge the value of the models for realistically predicting the direction of affinity change upon mutagenesis. Such models may include those from the above first step or alternative models. Models with high accuracy and / or other diagnostic parameters indicating reliability for recapitulating the experimentally validated directions of affinity change are favored as tools to search for new CD80 mutations with desired effects.
[0311] To identify mutations increasing the affinity of CD80 for PD-L1, virtual molecular CD80-PDL1 models were built and then subjected to in silico mutagenesis. The effects of these mutations on PD-L1 binding strength were predicted using several software tools, including DDMut-PPI and SSIPe.1. CD80-PDL1 Affinity by Surface Plasmon Resonance (SPR)
[0312] To obtain CD80 mutations not previously shown to affect PD-L1 binding, we queried some of our CD80-PDL1 models generated earlier for predicted affinity increases upon mutagenesis and validated the effects of some of the mutations with expected affinity increases by surface plasmon resonance (SPR) with human PD-L1 as analyte (Tables 11-13, FIGs. 16 and 17).
[0313] The following serves as a general protocol: CD80-Fc fusion proteins were codon-optimized, then the genes synthesized, cloned, and transfected into CHO-S cells. Recombinant proteins were subsequently purified using Protein A affinity chromatography and size exclusion chromatography (SEC). To measure the binding affinity of ligand (CD80V-Fc or CD80ECD-Fc) to analyte (PD-L1) by SPR, ligand was captured on a Series S Sensor Chip Protein A (Cytiva) using a Biacore 8K system (Cytiva). During the association phase, the analyte was injected over the surface of flow cells 1 and 2. For the dissociation phase, running buffer (1 x HBS-EP+ buffer) was injected at a flow rate of 30 pL / min. The assay was conducted at 25 °C. Data processing was performed using Biacore 8K Evaluation Software version 5.0. For resonance unit subtraction, flow cell 1 and blank injections of running buffer in each cycle served as double references.
[0314] Each construct subjected to SPR contained a human IgGl Fc region with the “LALA” (L234A and L235A) mutation [Hale et al., 2024] and a human CD80 domain, either the CD80 IgV domain (CD80V-Fc) or the CD80 ECD domain (CD80ECD-Fc), whereby the ECD contains both the IgV- and IgC domains. The purity of the constructs, as assessed by SDS-PAGE, was normally >95% (Tables 11-13).
[0315] We initially tested a set of five mutations (E10Y, N55D, A71D, A71E, A71Y), expressed both as CD80V-Fc (i.e., without the IgC domain from CD80) and CD80ECD-Fc (ECD; IgV + IgC) constructs. Whereas a binding signal was obtained with the ECD constructs with WT (wild-type) (KD = 29.4 micromolar), E10Y (KD = 11.5 micromolar), A71D (KD = 19.2 micromolar), and A71 Y (KD = 40.0 micromolar) CD80 sequences, only the A71D variant in the CD80V series bound PD-L1 (KD = 93.7 micromolar), suggesting stronger binding of thefull ECD compared to the IgV domain alone. Compared to the WT ECD construct, ECD-E10Y and ECD-A71D bound PD-L1 stronger (lower KD) (Table 11, FIG. 16A). Of note, we did not observe binding of the N55D construct to PD-L1 despite the predicted increase in affinity by the N55D mutation. A possible explanation is that N55 of CD80 is glycosylated (which was not taken into account for the modelling) and that the oligosaccharide chain attached to N55 makes contacts with PD-L1 (Kang-Pettinger et al., 2023; PDB ID: 7TPS), suggesting that loss of the N55 glycosylation by mutation may weaking the strength of the CD80-PDL1 interaction.
[0316] In a second SPR experiment, with ECD constructs, we assessed additional mutations in the CD80 IgV domain and at position 160 in the CD80 IgC domain. As shown in Table 12 and FIG. 16B, relative to the WT, several fold lower KD values (i.e., higher affinity for PD-Ll) were obtained for the CD80 mutations V8W, E10Y, VI IK, D60E, T62W, V68F, V68M, E160C, E160H, E160I, E160L, E160R, E160V, and E160W. In contrast to the first SPR experiment, A71D no longer had a KD value lower than the WT.
[0317] It is of note that at current, there do not seem to be any published reports demonstrating that certain CD80 IgC domain residues directly bind PD-L1 and thereby contribute to the enhanced affinity of the ECD for PD-L1. Rather, the IgC domain is thought to improve CD28 or CTLA-4 binding by optimizing the binding of the IgV domain to CD28 or CTLA-4, for instance by shielding the hydrophobic binding face in the N-terminal IgV domain from solvent [Peach et al., 1995],
[0318] Table 11 summarizes the SPR data for binding of CD80V-Fc (CD80 domain: IgV) and CD80ECD-Fc (CD80 domain: ECD) constructs to human PD-L1. Purity refers to purity by SDS-PAGE under non-reducing condition, Atezolizumab to a positive control (anti-PDLl antibody), and WT to wild-type CD80 sequence.Table 11. Effects of CD80 mutations on CD80-PDL1 affinity in first SPR experiment Mutation CD80 Purity Chi2 ka (1 / Ms) kd (1 / s) KD (mM) Rm ax Domain (RU2) (RU) None (WT) IgV >95% N / A N / A N / A N / A N / A E10Y IgV >95% N / A N / A N / A N / A N / A N55D IgV >95% N / A N / A N / A N / A N / A A71D IgV >90% 3.09E-02 N / A N / A 93.7 948.0 A71E IgV >95% N / A N / A N / A N / A N / AA71Y IgV >95% N / A N / A N / A N / A N / A None (WT) ECD >95% 8.96E-02 N / A N / A 29.4 470.2 E10Y ECD >95% 5.34E-02 N / A N / A 11.5 336.5 N55D ECD >95% N / A N / A N / A N / A N / A A71D ECD >95% 3.13E-01 N / A N / A 19.2 141.3 A71E ECD >95% N / A N / A N / A N / A N / A A71Y ECD >95% 2.31E-02 N / A N / A 40.0 129.1 N / A (Atezolizumab) N / A 6.07E-02 1.77E+05 2.71E-04 0.00153 51.7
[0319] Table 12 summarizes the SPR data for binding of CD80ECD-Fc (CD80 domain: ECD) constructs to human PD-LI . Purity refers to purity by SDS-PAGE under non-reducing condition, Atezolizumab to a positive control (anti-PDLl antibody), and WT to wild-type CD80 sequence.Table 12. Effects of CD80 mutations on CD80-PDL1 affinity in second SPR experiment Mutation Purity Chi2 (RU2) ka (1 / Ms) kd (1 / s) KD (mM) Rmax (RU) None (WT) >95%* 5.89E-02 N / A N / A 32.6 441.5 V8W 95 1.04E-01 N / A N / A 5.04 157.0 E10Y >95%* 9.68E-05 N / A N / A 8.15 217.8 V11K 95 4.99E-02 N / A N / A 6.08 298.2 D60E 90 7.24E-02 N / A N / A 4.50 309.5 T62I 95 N / A N / A N / A N / A N / A T62W 95 3.49E-02 N / A N / A 5.71 111.8 V68F 95 1.38E-02 N / A N / A 2.49 268.9 V68M 95 3.08E-01 N / A N / A 0.627 176.7 V68W 95 N / A N / A N / A N / A N / A A71C 95 N / A N / A N / A N / A N / A A71D >95%* 2.72E-02 N / A N / A 79.8 268.5 A71F 95 N / A N / A N / A N / A N / A A71S 95 N / A N / A N / A N / A N / A A71W 95 N / A N / A N / A N / A N / AL72F 95 N / A N / A N / A N / A N / A L72V 95 2.39E-02 N / A N / A 232 3821.2 L72W 95 N / A N / A N / A N / A N / A L72Y 95 N / A N / A N / A N / A N / A E160C 95 1.20E+00 N / A N / A 5.82 414.9 E160D 95 2.98E-02 N / A N / A 34.3 843.0 E160H 95 1.96E+01 N / A N / A 3.79 360.2 El 601 95 1.99E-01 N / A N / A 8.75 582.6 E160L 95 7.55E+00 N / A N / A 4.03 408.1 E160R 95 2.69E-01 N / A N / A 2.60 359.3 El 60 V 95 9.18E-01 N / A N / A 8.43 491.2 E160W 95 2.08E-02 N / A N / A 4.17 513.7 N / A N / A 4.57E-02 1.60E+05 2.86E-04 0.00180 58.9(Atezolizumab)* For WT, E10Y, and A71D, constructs from the first SPR experiment were used. Indicated purities are those measured for that first experiment (Table 11).
[0320] In a third SPR experiment, we assessed whether combinations of mutations could increase the affinity for PD-L1 more substantially than the corresponding single mutations. As shown in Table 13 and FIGs. 17 and 18, such potential additive or synergistic effects were seen for V68M + E160R and D60E + E160R. Furthermore, whereas the first two SPR experiments demonstrated opposite effects for A71D, this third experiment suggested again that A71D increases the affinity of CD80 for PD-L1.
[0321] Table 13 summarizes the SPR data for binding of CD80ECD-Fc (CD80 domain: ECD) constructs to human PD-L1. Purity refers to purity by SDS-PAGE under non-reducing condition, Atezolizumab to a positive control (anti-PDLl antibody), and WT to wild-type CD80 sequence.Table 13. Effects of CD80 mutations on CD80-PDL1 affinity in third SPR experiment Mutation Purity Chi2 ka (1 / Ms) kd (1 / s) KD (mM) Rmax / Response (RU2) (RU) None (WT) 95 2.27E-04 N / A N / A 60.1 338.0V8W 95 7.71E-02 N / A N / A 5.96 58.6D60E 95 2.07E-02 N / A N / A 9.02 236.0 V68M 95 1.94E-01 N / A N / A 2.35 130.2 A71D 95 1.93E-03 N / A N / A 28.3 69.7 K93D 95 2.44E-03 N / A N / A 33.5 687.2 K93N 95 2.50E-02 N / A N / A 55.1 794.4 E160R 95 2.79E+00 N / A N / A 7.28 259.5 V8W-D60E 95 N / A N / A N / A N / A N / AV8W-E160R 95 3.28E-02 N / A N / A 21.6 340.1 D60E-V68M 95 4.04E-02 N / A N / A 3.73 169.5 D60E-E160R 95 8.29E-02 N / A N / A 1.38 128.1 V68M-E160R 95 7.43E-02 4.58E+05 1.06E-01 0.232 174.5 V8W-V68M 95 3.77E-02 N / A N / A 2.83 103.9 R29Y-Y31R- 95 2.11E-03 N / A N / A 30.2 650.6 Q33KN / A N / A 2.17E-01 2.17E+05 2.73E-04 0.00126 58.2(Atezolizumab)2. Affinity of strong PD-L1 binders for CD28 and CTLA-4 by SPR
[0322] Whereas the CD80-CD28 and CD80-CTLA4 binding interfaces strongly overlap, they are distinct from the binding interface between CD80 and PD-L1 [Maurer et al., 2022], Nevertheless, such spatial separation does not guarantee that CD80 mutations in the interface with PD-L1 do not affect CD80-CD28 or CD80-CTLA4 binding. For example, Maurer et al. demonstrated that the CD80 mutation E35D increases the binding strength of CD80 for PD-L1 even though it is not in the CD80-PDL1 interface (Suppl. Fig. 4; Maurer et al., 2022).
[0323] To assess if and to what extent the CD80 mutations that we showed increase the affinity of CD80 for PD-L1 (FIGs. 16 and 17) affect CD28 and CTLA-4 binding, we subjected corresponding CD80ECD-Fc constructs with single residue mutations to SPR analyses.
[0324] Whereas most mutations did not substantially affect CD28 or CTLA-4 binding, some had a ~2-fold or greater effect (Tables 14 and 15, and FIGs. 19-21). Most notably, D60E selectively increased the affinity for CTLA-4 (lower KD) >4-fold while maintaining wild-type CD28 affinity. Furthermore, whereas the affinity of the V68M construct for CD28 was somewhat higher than for the wild type, the opposite effect occurred for the E160R construct,raising the question of whether these opposing effects would cancel each other out in the V68M-E160R double mutant construct, i.e., of whether such a construct would have no change in the affinity of CD80 for CD28.
[0325] Table 14 summarizes SPR data for binding of CD80ECD-Fc (CD80 domain: ECD) constructs to human CD28. Purity refers to purity by SDS-PAGE under non-reducing conditions and WT to wild-type CD80 sequence.Table 14. Effects of CD80 mutations on CD80-CD28 affinity as part of third SPR experimentMutation Purity Chi2 (RU2) ka (1 / Ms) kd (1 / s) KD (nM) Rmax / Response (RU)None (WT) 95 2.27E-02 N / A N / A 421 262.6V8W 95 2.49E-02 N / A N / A 379 158.6E10Y 95 4.91E-03 N / A N / A 542 153.9V11K 95 2.84E-01 N / A N / A 242 249.1D60E 95 2.30E-02 N / A N / A 416 280.3T62W 95 4.57E-02 N / A N / A 454 185.2V68F 95 6.43E-02 N / A N / A 429 241.3V68M 95 9.86E-02 N / A N / A 302 259.3A71D 95 9.29E-02 N / A N / A 249 221.9 E160C 95 2.79E-02 N / A N / A 517 218.3 E160H 95 8.61E-03 N / A N / A 479 309.9El 601 95 2.03E-02 N / A N / A 415 261.2 E160L 95 8.93E-02 N / A N / A 365 233.5 E160R 95 3.60E-02 N / A N / A 572 328.7El 60 V 95 3.66E-02 N / A N / A 452 297.1 E160W 95 3.88E-03 N / A N / A 648 274.9K93D 95 9.14E-02 N / A N / A 568 338.3K93N 95 1.03E-02 N / A N / A 495 407.4R29Y-Y31R- 95 N / A N / A N / A N / A N / AQ33K
[0326] Table 15 summarizes the SPR data for binding of CD80ECD-Fc (CD80 domain: ECD) constructs to human CTLA-4. Purity refers to purity by SDS-PAGE under non-reducing condition, Ipilimumab to a positive control (anti-CTLA-4 antibody), and WT to wild-type CD80 sequence.Table 15. Effects of CD80 mutations on CD80-CTLA4 affinity as part of third SPR experimentMutation Purity Chi2 (RU2) ka (1 / Ms) kd (1 / s) KD (nM) Rmax / Response (RU)None (WT) 95 3.33E-01 9.33E+05 1.27E-03 1.36 58.2V8W 95 1.83E-01 7.32E+05 6.98E-04 0.954 46.8E10Y 95 3.78E-01 9.01E+05 1.50E-03 1.66 60.2V11K 95 1.72E-01 5.23E+05 2.09E-04 0.399 57.9D60E 95 9.18E-02 6.08E+05 1.62E-04 0.266 43.6T62W 95 4.33E-01 1.75E+06 3.46E-03 1.98 51.1V68F 95 1.68E-01 5.67E+05 5.85E-04 1.03 60.4V68M 95 3.03E-01 4.33E+05 3.24E-04 0.749 69.0A71D 95 4.54E-01 7.18E+05 1.21E-03 1.69 64.0E160C 95 3.17E-01 7.00E+05 1.05E-03 1.50 55.0E160H 95 7.58E-01 8.41E+05 1.44E-03 1.71 71.1El 601 95 7.89E-01 8.67E+05 1.38E-03 1.60 71.8E160L 95 6.01E-01 9.01E+05 1.39E-03 1.54 71.1E160R 95 3.64E-01 1.05E+06 1.52E-03 1.44 53.5El 60 V 95 5.11E-01 9.61E+05 1.50E-03 1.56 65.9E160W 95 4.79E-01 8.14E+05 1.25E-03 1.54 67.1K93D 95 2.43E-01 1.16E+06 9.25E-02 80.1 123.5K93N 95 6.71E-02 2.00E+06 2.18E-02 10.9 42.7R29Y- 95 N / A N / A N / A N / A N / AY31R- Q33KIpilimumab N / A 1.60E-01 1.46E+05 2.04E-03 14.0 93.83. Additional CD80 mutations increasing the affinity for PD-L1
[0327] To potentially obtain additional CD80 mutations increasing the affinity for PD-L1, we conducted in silico saturation mutagenesis screens with models CD80ECD-PDL1-AB (“AB”) and CD80ECD-PDL1-ACCD (“ACCD”). Thereby, CD80ECD-PDL1 interface residues (as determined with mCSM-PPI2 [Rodrigues et al., 2019] and DDMut-PPI) and residues otherwise shown to affect CD80-PDL1 affinity (CD80 residues 35 and 47; Maurer et al., 2022) were virtually mutated to each of the 19 alternative standard residues and effects on CD80ECD-PDL1 affinity predicted using DDMut-PPI.
[0328] Table 16 lists the CD80 mutations experimentally shown or predicted by DDMut-PPI in at least one of the models (“AB” or “ACCD”) (Group 1), or both models (Group 2), to increase the affinity for PD-L1. CD80 mutations predicted to increase PD-L1 binding but shown to decrease affinity by SPR (such as N55D) were excluded. Values shown are DDMut-PPI output values after Z-Score normalization across the 34 experimentally validated mutations followed by subtracting ROC curve-based thresholds. Group 1 lists CD80 mutations predicted in at least one of the models, and / or shown experimentally, to increase CD80-PDL1 affinity. Group 2 lists CD80 mutations predicted to increase CD80-PDL1 affinity in both models. Table 16. CD80 ECD Mutations with Increased Affinity For PD-L1.Binding Strength Group 1 Group 2> 1 modelCD80 ECD Mutation AB ACCD (or positive 2 models experimentaldata)V8A 0.442 -0.266 V8AV8C 0.095 -0.563 V8CV8F 0.202 -0.836 V8FV8I -0.128 -0.751 V8I V8IV8K 1.155 -0.158 V8KV8L 0.128 -0.686 V8LV8M 0.187 -0.493 V8MV8R 0.947 -1.328 V8RV8T 0.251 -0.418 V8TV8W -0.109 -1.121 V8W V8WV8Y 0.684 -0.670 V8YK9R -0.200 -0.784 K9R K9R E10A -0.390 -0.447 E10A E10A EIOC -0.568 -0.590 EIOC EIOC E10D -0.300 -0.610 E10D E10D E1OF -1.375 -0.820 El OF El OF E10G -0.296 0.104 E10GE10H -1.071 -0.878 El OH El OH E1OI -0.288 -0.577 E10I E10I E10K -0.142 -0.746 El OK El OK E1OL -1.047 -1.055 E10L E10L E10M -0.568 -0.555 E10M E10M E10N -0.791 -0.707 El ON E10N E1OQ -0.246 -0.525 E10Q E10Q E10R -0.026 -1.194 El OR E10R EIOS -0.465 -0.427 EIOS EIOS E1OT -0.154 -0.454 E10T E10T E10V -0.261 -0.522 E10V E10V E10W -1.086 -1.698 E10W E10W E10Y -1.038 -0.619 E10Y E10Y V11A 0.241 -0.521 V11AV11C -0.161 -0.691 V11C V11C V11F -0.453 -1.197 VI IF VI IF V11H -0.465 -0.274 VI 1H VI 1H VIII -0.435 -0.830 VIII VIII V11K 0.832 0.000 VI IKV11L -0.264 -0.598 VI IL VI IL V11M -0.209 -0.582 VI IM VI IM V11Q 1.199 -0.116 V11QV11R 0.041 -0.298 VI 1RV11S 0.507 -0.132 V11SIllV11T -0.095 -0.652 V11T V11T V11W -E755 -1.222 VI 1W VI 1W V11Y -0.440 -1.210 V11Y V11Y T13A -0.151 -0.688 T13A T13A T13C -0.259 -0.742 T13C T13C T13D -0.059 -0.365 T13D T13D T13E -0.049 -0.811 T13E T13E T13F -0.342 -0.822 T13F T13F T13G 0.061 -0.499 T13GT13H -0.077 -0.603 T13H T13H T13I -0.344 -0.891 T13I T13I T13K 0.301 -0.502 T13KT13L -0.334 -0.862 T13L T13L T13M -0.215 -0.734 T13M T13M T13N 0.150 -0.590 T13NT13Q -0.079 -0.642 T13Q T13Q T13R 0.262 -0.262 T13RT13S -0.154 -0.668 T13S T13S T13V -0.288 -0.782 T13V T13V T13W -0.298 -0.378 T13W T13W T13Y -0.157 -0.666 T13Y T13Y E35A -0.232 -0.715 E35A E35A E35C -0.236 -0.712 E35C E35C E35D -0.271 -0.748 E35D E35D E35F -0.238 -0.714 E35F E35F E35G -0.223 -0.714 E35G E35G E35H -0.242 -0.728 E35H E35H E35I -0.243 -0.730 E35I E35I E35K -0.195 -0.690 E35K E35K E35L -0.210 -0.695 E35L E35LE35M -0.262 -0.739 E35M E35M E35N -0.259 -0.739 E35N E35N E35P -0.065 -0.557 E35P E35P E35Q -0.279 -0.758 E35Q E35Q E35R -0.216 -0.702 E35R E35R E35S -0.252 -0.738 E35S E35S E35T -0.257 -0.744 E35T E35T E35V -0.206 -0.695 E35V E35V E35W -0.215 -0.696 E35W E35W E35Y -0.246 -0.731 E35Y E35Y M47A -0.090 -0.439 M47A M47A M47C -0.228 -0.579 M47C M47C M47E 0.198 -0.053 M47EM47F -0.174 -0.583 M47F M47F M47G 0.068 -0.205 M47GM47H -0.088 -0.534 M47H M47H M47I -0.276 -0.578 M47I M47I M47L -0.334 -0.760 M47L M47L M47N 0.081 -0.188 M47NM47Q -0.028 -0.357 M47Q M47Q M47R 0.163 -0.013 M47RM47S 0.065 -0.274 M47SM47T -0.046 -0.358 M47T M47T M47V -0.236 -0.519 M47V M47V M47W -1.527 -1.690 M47W M47W M47Y -0.119 -0.415 M47Y M47Y K54A -0.234 -0.707 K54A K54A K54C -0.383 -0.794 K54C K54C K54D -0.501 -0.903 K54D K54D K54E -0.493 -0.787 K54E K54EK54F -0.705 -0.955 K54F K54F K54G -0.160 -0.722 K54G K54G K54H -0.425 -0.646 K54H K54H K54I -0.481 -0.968 K54I K54I K54L -0.867 -1.069 K54L K54L K54M -0.408 -0.846 K54M K54M K54N -0.365 -0.690 K54N K54N K54P 0.950 -0.756 K54PK54Q -0.375 -0.712 K54Q K54Q K54R -0.197 -0.692 K54R K54R K54S -0.379 -0.723 K54S K54S K54T -0.269 -0.790 K54T K54T K54V -0.392 -0.912 K54V K54V K54W -0.626 -0.862 K54W K54W K54Y -0.561 -0.866 K54Y K54Y N55A -0.170 -0.831 N55A N55A N55C -0.301 -0.944 N55C N55C N55E -0.184 -1.217 N55E N55E N55F -0.556 -1.024 N55F N55F N55G -0.049 -0.643 N55G N55G N55H -0.241 -0.770 N55H N55H N55I -0.576 -1.381 N55I N55I N55K -0.338 -1.008 N55K N55K N55L -0.508 -1.201 N55L N55L N55M -0.398 -1.260 N55M N55M N55P -0.020 -0.878 N55P N55P N55Q -0.282 -0.912 N55Q N55Q N55R -0.506 -0.854 N55R N55R N55S -0.156 -0.680 N55S N55S N55T -0.148 -0.812 N55T N55TN55V -0.367 -1.048 N55V N55V N55W -0.341 -1.178 N55W N55W N55Y -0.452 -0.851 N55Y N55Y R56K 0.326 -0.173 R56KT57A -0.073 -0.494 T57A T57A T57C -0.184 -0.618 T57C T57C T57D 0.343 -0.180 T57DT57E 0.305 -0.237 T57ET57F -0.454 -1.020 T57F T57F T57G 0.273 -0.144 T57GT57H -0.067 -0.533 T57H T57H T57I -0.191 -0.674 T57I T57I T57K 0.230 -0.297 T57KT57L -0.288 -0.711 T57L T57L T57M -0.239 -0.680 T57M T57M T57N 0.188 -0.297 T57NT57Q 0.072 -0.434 T57QT57R 0.273 -0.083 T57RT57S -0.058 -0.567 T57S T57S T57V -0.216 -0.646 T57V T57V T57W -0.800 -1.687 T57W T57W T57Y 0.014 -0.630 T57YI58C -0.081 -0.663 I58C I58C 158F -0.710 -0.716 158F 158F 158L -0.617 -1.017 158L 158L 158M -0.673 -0.855 158M 158M I58Q 0.178 -0.364 I58Q158R 0.525 -0.003 158RI58T 0.379 -0.165 I58TI58V -0.309 -0.907 158 V I58V158 W -E216 -0.519 158 W 158 W I58Y -0.632 -0.655 158 Y I58Y D60A 0.959 -0.361 D60AD60C 0.466 -0.505 D60CD60E 0.000 -0.908 D60ED60F 0.452 -0.788 D60FD60G E320 -0.228 D60GD60H 0.632 -0.494 D60HD60I E080 -0.641 D60ID60K E083 -0.461 D60KD60L E088 -0.534 D60LD60M 0.671 -0.615 D60MD60N 0.221 -0.683 D60ND60Q 0.644 -0.509 D60QD60R 0.891 -0.690 D60RD60S 0.844 -0.348 D60SD60T 0.818 -0.361 D60TD60V 1.184 -0.514 D60VD60W 1.083 -0.652 D60WD60Y 0.283 -0.756 D60YT62A -0.210 -0.722 T62A T62A T62C -0.223 -0.726 T62C T62C T62D -0.297 -0.779 T62D T62D T62E -0.289 -0.787 T62E T62E T62F -0.237 -0.740 T62F T62F T62G -0.232 -0.734 T62G T62G T62H -0.257 -0.751 T62H T62H T62K -0.266 -0.763 T62K T62K T62L -0.219 -0.726 T62L T62L T62M -0.238 -0.750 T62M T62MT62N -0.248 -0.739 T62N T62N T62P -0.198 -0.690 T62P T62P T62Q -0.248 -0.744 T62Q T62Q T62R -0.219 -0.744 T62R T62R T62S -0.225 -0.722 T62S T62S T62V -0.212 -0.714 T62V T62V T62W -0.292 -0.800 T62W T62W T62Y -0.232 -0.738 T62Y T62Y N63A -0.268 -1.092 N63A N63A N63C -0.341 -1.051 N63C N63C N63D -0.348 -1.458 N63D N63D N63E -0.643 -1.806 N63E N63E N63F -0.373 -1.209 N63F N63F N63G -0.182 -0.936 N63G N63G N63H -0.145 -0.935 N63H N63H N63I -0.614 -1.297 N63I N63I N63K 0.014 -0.678 N63KN63L -0.580 -1.390 N63L N63L N63M -0.622 -1.159 N63M N63M N63P 0.280 -0.127 N63PN63Q -0.206 -0.984 N63Q N63Q N63R 0.215 -0.551 N63RN63S -0.364 -0.848 N63S N63S N63T -0.056 -0.771 N63T N63T N63V -0.378 -1.217 N63V N63V N63W -0.434 -2.458 N63W N63W N63Y -0.865 -1.252 N63Y N63Y V68A 0.105 -0.381 V68AV68C -0.207 -0.716 V68C V68C V68D 1.192 -0.169 V68DV68F -0.520 -1.357 V68F V68F V68I -0.360 -0.835 V68I V68I V68L -0.346 -0.846 V68L V68L V68M -0.305 -0.634 V68M V68M V68N 0.581 -0.250 V68NV68Q 0.310 -0.252 V68QV68S 0.141 -0.256 V68SV68T -0.120 -0.571 V68T V68T V68Y -0.332 -1.065 V68Y V68Y L70C 0.200 -0.198 L70CL70F 0.032 -0.563 L70FL70M 0.188 -0.410 L70ML70Y 0.562 -0.083 L70YA71D -0.712 -2.212 A71D A71D A71G 0.165 -0.293 A71GA71I -0.104 -0.277 A71I A71I A71L -0.800 -0.671 A71L A71L A71M -0.101 -0.535 A71M A71M A71N 0.309 -0.406 A71NA71Q 1.004 -0.099 A71QA71T 0.323 -0.244 A71TA71V -0.037 -0.578 A71V A71V L72C 0.116 -0.136 L72CL72M -0.038 -0.281 L72M L72M DI 07 A -0.186 -0.798 DI 07 A DI 07 A D107C -0.212 -0.924 D107C D107C D107E -0.259 -0.682 D107E D107E D107F -0.191 -0.854 D107F D107F D107G -0.164 -0.614 D107G D107G D107H -0.183 -0.563 D107H D107HDI 071 -0.143 -0.767 DI 071 DI 071 D107K -0.145 -0.663 D107K D107K D107L -0.128 -0.875 D107L D107L D107M -0.150 -0.800 D107M D107M D107N -0.256 -0.732 D107N D107N D107P -0.009 0.104 D107PD107Q -0.198 -0.649 D107Q D107Q D107R -0.122 -0.722 D107R D107R D107S -0.205 -0.743 D107S D107S D107T -0.193 -0.702 D107T D107T DI 07 V -0.165 -0.716 DI 07 V DI 07 V D107W -0.186 -0.783 D107W D107W D107Y -0.148 -0.838 D107Y D107Y D158A 0.933 -0.216 D158AD158C 0.635 -0.446 D158CD158E 0.616 -0.365 D158ED158F 0.838 -0.380 D158FD158G 1.077 -0.065 D158GD158H 0.840 -0.543 D158HD158I 0.658 -0.274 D158ID158K 0.778 -0.406 D158KD158L 0.759 -0.459 D158LD158M 0.730 -0.337 D158MD158N 0.415 -0.425 D158ND158Q 0.618 -0.305 D158QD158R 0.824 -0.655 D158RD158S 0.717 -0.366 D158SD158T 0.763 -0.330 D158TD158V 0.849 -0.286 D158VD158W 0.760 -0.285 D158WD158Y 1.016 -0.541 D158YP159A -0.232 -0.756 P159A P159A P159C -0.337 -0.882 P159C P159C P159D 0.072 -0.336 P159DP159E 0.018 -0.345 P159EP159F -0.351 -0.870 P159F P159F P159G -0.201 -0.670 P159G P159G P159H -0.069 -0.663 P159H P159H P159I -0.394 -1.035 P159I P159I P159K -0.056 -0.631 P159K P159K P159L -0.326 -1.119 P159L P159L P159M -0.161 -0.947 P159M P159M P159N -0.128 -0.759 P159N P159N P159Q -0.147 -0.559 P159Q P159Q P159R 0.129 -0.663 P159RP159S -0.224 -0.706 P159S P159S P159T -0.173 -0.625 P159T P159T P159V -0.330 -0.932 P159V P159V P159W -0.438 -1.084 P159W P159W P159Y -0.447 -0.955 P159Y P159Y El 60 A -0.064 -0.188 E160A E160A E160C -0.303 -0.242 E160C E160C E160F -0.456 -0.368 E160F E160F E160G -0.014 -0.008 E160G E160G E160H -0.154 -0.152 E160H E160H El 601 -0.229 -0.172 E160I El 601 E160K -0.074 -0.060 E160K E160K E160L -0.539 -0.269 E160L E160L E160M -0.246 -0.237 E160M E160M E160N -0.341 -0.096 E160N E160NE160Q -0.164 -0.097 E160Q E160Q E160R -0.233 -0.148 E160R E160RE160S -0.109 -0.214 E160S E160SE160T -0.041 -0.273 E160T E160TEl 60 V -0.137 -0.169 E160V El 60 VE160W -0.566 -0.333 E160W E160WE160Y -0.547 -0.437 E160Y E160YT161A 0.552 -0.358 T161AT161C 0.238 -0.553 T161CT161D 0.333 -0.883 T161DT161E 0.631 -0.502 T161ET161F 0.563 -0.368 T161FT161G 1.020 -0.029 T161GT161H 0.625 -0.185 T161HT161I 0.374 -0.338 T161IT161K 0.379 -0.503 T161KT161L 0.168 -0.574 T161LT161M 0.355 -0.494 T161MT161N 0.502 -0.663 T161NT161P 1.591 -0.138 T161PT161Q 0.504 -0.301 T161QT161S 0.128 -0.394 T161ST161V 0.275 -0.419 T161VT161Y 0.837 -0.188 T161YExample 6: CD80 ECD Variants That Affect Binding Affinity for CD28 and / or CTLA4
[0329] This example illustrates a systematic computational approach to identifying and prioritizing CD80 mutations that decrease binding affinity for CD28, while maintaining or increasing affinity for CTLA-4.
[0330] To minimize effector cell overstimulation, we aimed at reducing the affinity of CD80 for CD28 through additional mutations. Since the PD-L1 and CD28 (or CTLA-4) binding interfaces on CD80 are distinct [Maurer et al., 2022], we concluded that the CD80 mutations predicted to increase the affinity for PD-L1 (Table 16) do not necessarily affect CD28 and CTLA-4 binding. Therefore, CD28 and CTLA-4 binding can be assessed separately from PD-L1 binding.
[0331] As with PD-L1, CD80ECD-CD28 and CD80ECD-CTLA4 models were built and screened using prediction tools to identify novel CD80 mutations that reduce affinity for CD28 while ideally maintaining wild-type (WT) or higher affinity for CTLA-4. However, unlike the PD-L1 models, DDMut-PPI yielded less reliable results than SSIPe for the CD28 and CTLA-4 models [based on W50A [Fargeas et al., 1995], K93D and K93N (FIG. 9), for which experimental data on CD80-CD28 binding are available] (data not shown). Therefore, SSIPe was chosen as the prediction tool for the selection of CD80 mutations potentially reducing the affinity for CD28.
[0332] Since only a few CD80 mutations with experimentally validated effects on CD28 or CTLA-4 binding were found in the public domain or in our own data set (FIG. 19), a “diagnostic” correction of the predicted tool output values (as was done for the CD80-PDL1 models) was not feasible. However, to minimize the risk of incorrectly identifying a mutation as CD28 affinity-reducing, we used the lowest SSIPe output DDG value among W50A, K93D, and K93N for CD28 as the cutoff (marked in Bold in Table 17), since these mutations are known to reduce CD28 binding (Fargeas et al., 1995, FIG. 19).
[0333] Furthermore, as increases of the CD80-CTLA4 affinity were considered beneficial, we ranked the mutations based on their predicted differential effects between CD28- and CTLA-4 binding, with those having larger differences potentially reducing the CD28 affinity more substantially than the CTLA-4 affinity or even reducing CD28 affinity while having no effect on the affinity for CTLA-4. CD80 residues W50 and E88 consistently display substantial predicted differential effects on CD28 vs. CTLA-4 binding (Table 17).
[0334] While no clear structural explanation for a differential effect on CD28 versus CTLA-4 binding upon mutagenesis of residue W50 was observed in iCn3D [Wang et al., 2020], residue E88 interacts with K54 of CD28 but does not appear to bond with CTLA-4. This suggests that mutating E88 would primarily affect the E88-K54 interaction and thus CD80-CD28 affinity.
[0335] Table 17 summarizes CD80 mutations predicted to have differential effects on CD28 vs. CTLA-4 binding. Mutations were assessed by SSIPe using the models CD80ECD-CD28-AC and CD80ECD-CTLA4-AC, representing CD80-CD28 and CD80-CTLA4 interface residues determined with DDMut-PPI. The table shows SSIPe DDG (AAG) output values and corresponding differences (last column) used for ranking. Experimentally, W50A (Fargeas et al., 1995), K93D, and K93N (FIG. 19) have also been shown to reduce CD80-CD28 affinity. Only mutations with CD28 DDG values no smaller (i.e., with the same or lower predicted affinity) than the lowest CD28 DDG value among W50A, K93D, and K93N (i.e., K93D) are listed to minimize the risk of incorrectly identifying a mutation as CD28 affinity-reducing. Table 17. CD80 ECD Mutations with Reduced Affinity for CD80Difference CD80ECD-CD28- CD80ECD-CTLA4- CD80 ECD (CD28- AC ACMutation CTLA4)DDG DDG ADDGW50P 3.185 0.215 2.970E88P 2.243 0.000 2.243 W50K 2.449 0.215 2.234 W50Q 2.449 0.215 2.234 W50D 2.286 0.215 2.071 W50N 2.286 0.215 2.071 W50S 2.286 0.215 2.071A91R 3.064 1.104 1.960 W50E 2.129 0.215 1.914 W50R 2.129 0.215 1.914 W50A 1.980 0.215 1.765 W50G 1.980 0.215 1.765 W50H 1.980 0.215 1.765E88K 1.517 0.000 1.517 W50C 1.697 0.215 1.482 W50I 1.697 0.215 1.482E88N 1.357 0.000 1.357 E88S 1.354 0.000 1.354 W50T 1.564 0.215 1.349 W50V 1.564 0.215 1.349 E88D 1.340 0.000 1.340 W50M 1.421 0.215 1.206 Y31W 1.363 0.242 1.121 W50F 1.310 0.212 1.098 M38W 1.521 0.492 1.029 Y31F 1.570 0.607 0.963 R29V 1.612 0.701 0.911 R29H 2.058 1.209 0.849 R29E 2.253 1.416 0.837 R29F 1.372 0.536 0.836 R29Q 2.572 1.760 0.812 R29T 1.636 0.830 0.806 R29S 2.354 1.552 0.802 R29G 2.045 1.243 0.802 R29N 2.358 1.559 0.799 R29A 2.045 1.246 0.799 R29C 1.749 0.960 0.789 R29D 2.365 1.576 0.789 R29P 3.240 2.452 0.788 F92R 1.400 0.633 0.767 Q33D 1.772 1.011 0.761 R29K 2.316 1.562 0.754 L85R 2.754 2.031 0.723 R29I 1.657 0.943 0.714 R29M 1.306 0.599 0.707 K93N 1.317 0.636 0.681 A91K 2.033 1.402 0.631Q33R 1.496 0.872 0.624 Q33N 1.765 1.172 0.593 V83K 2.273 1.681 0.592 Q33E 1.411 0.828 0.583 Y31E 2.580 2.014 0.566 Q33P 2.596 2.041 0.555 V83R 2.254 1.699 0.555 Q33S 1.727 1.175 0.552 V83C 1.614 1.062 0.552 Q33A 1.394 0.842 0.552 Q33K 1.795 1.243 0.552 K93P 2.142 1.590 0.552 Q33G 1.408 0.866 0.542 V83T 1.439 0.898 0.541 M38R 2.338 1.800 0.538 V83E 2.019 1.481 0.538 V83G 2.145 1.617 0.528 V83H 1.671 1.143 0.528 V83A 2.019 1.498 0.521 V83S 2.349 1.828 0.521 V83P 3.146 2.635 0.511 V83N 2.287 1.777 0.510 V83Q 2.304 1.803 0.501 L97M 1.463 0.968 0.495 V83D 2.253 1.770 0.483 Y31I 1.837 1.363 0.474 Y31V 1.874 1.424 0.450 K93D 1.304 0.858 0.446 L97F 1.461 1.021 0.440 Y31H 2.331 1.901 0.430 Y31T 1.946 1.519 0.427R94P 2.960 2.548 0.412 L97I 1.838 1.428 0.410 L97H 2.205 1.799 0.406 L97C 1.903 1.520 0.383 Y31M 1.431 1.050 0.381 L97V 1.803 1.424 0.379 L97E 2.366 1.997 0.369 L97T 1.851 1.489 0.362 L97N 2.576 2.215 0.361 Y31C 2.035 1.677 0.358 Y31P 3.577 3.219 0.358 L97D 2.569 2.215 0.354 L97P 3.455 3.104 0.351 L97A 2.240 1.892 0.348 L97G 2.243 1.895 0.348 L97S 2.556 2.208 0.348 Y31A 2.379 2.034 0.345 R94H 1.376 1.032 0.344 M38K 2.258 1.918 0.340 Y31D 2.760 2.436 0.324 Y31G 2.399 2.079 0.320 Y31S 2.702 2.391 0.311 Y31N 2.715 2.405 0.310 Y31Q 2.851 2.551 0.300 L97R 2.205 1.908 0.297 L97Q 2.545 2.248 0.297 L85H 1.854 1.577 0.277 F92S 1.792 1.553 0.239 L97K 2.470 2.241 0.229 Y31K 2.456 2.248 0.208 M38H 2.042 1.834 0.208M38T E568 1.367 0.201 F92G E626 1.428 0.198 M38Q 2.354 2.160 0.194 M381 E364 1.174 0.190 A91N E539 1.359 0.180 L85K 2.425 2.252 0.173 M38E 2.130 1.977 0.153 M38C 1.578 1.450 0.128 M38D 2.365 2.250 0.115 M38 A 1.950 1.838 0.112 M38P 3.060 2.951 0.109 M38S 2.290 2.181 0.109 M38G 1.960 1.855 0.105 M38N 2.327 2.236 0.091 L85D 2.535 2.453 0.082 L85V 1.585 1.510 0.075 L85C 1.790 1.742 0.048 L85T 1.626 1.581 0.045 L85G 2.202 2.161 0.041 F92A 1.394 1.356 0.038 E81P 1.734 1.706 0.028 L85E 2.307 2.280 0.027 L85N 2.481 2.460 0.021 L85A 2.140 2.123 0.017 L85S 2.477 2.460 0.017 L85P 3.315 3.309 0.006 F92E 1.537 1.537 0.000 Y31R 2.181 2.211 -0.030 R94D 1.603 1.642 -0.039 L85I 1.370 1.418 -0.048 F92N 1.359 1.434 -0.075F92D 1.666 1.809 -0.143F92P 2.333 2.483 -0.150F92Q 1.498 1.696 -0.198 K36P 1.734 1.952 -0.218 R94S 1.402 1.652 -0.250 A91P 1.846 2.234 -0.388 A91Q 1.348 1.774 -0.426 D90P 1.921 2.354 -0.433L85Q 1.813 2.381 -0.568Example 7: Bioassays as Proxy for T cell Activation by CD80 ECD-Containing Multi-specific binding proteins
[0336] TILsRx multi-specific binding proteins. Three sets of TILsRx constructs were generated and assessed for bioactivity. Two sets were targeted to STEAP1 and one to B7-H3 using an scFv we developed [SEQ ID NO. 104 in WO2025245264A1 (PCT / US2025 / 030429)]. Each set consists of three TILsRx constructs with identical targeting domains (anti-STEAPl or anti-B7-H3) but differing in the effector domains (neg. control scFv, WT CD80 ECD, CD80 ECD with V68M / E160R double mutation. Furthermore, whereas one of the STEAP1 sets has an identical domain orientation as the B7-H3 set, the other STEAP1 set has a unique domain orientation (FIG. 22).
[0337] Principle of bioassay. CHO-K1 cells engineered to express both PD-L1 and an agonistic CD3 antibody in scFv format are cocultured with Jurkat-derived reporter cells expressing human PD-1 protein and NFAT-RE-induced luciferase [WO2025098364A1] (GS-J2B / PD-1). Binding of PD-L1 to PD-1 on the GS-J2B / PD-1 reporter cells, in the absence of treatment, reduces the luciferase signal. In contrast, treatment with an immune checkpoint inhibitor such as an anti-PDl antibody increases the luciferase signal. Similarly, transient transfection of the engineered CHO-K1 cells with an expression plasmid encoding a tumor-associated antigen (TAA) (such as B7-H3) and treatment with a TAA-targeted “TILsRx” multispecific binding protein carrying CD80 extracellular domains also blocks the PD-LEPD-l interaction and consequently increases the luciferase signal (FIG. 23).
[0338] Establishing bioassay conditions. To establish suitable experimental conditions (especially TILsRx concentrations), CHO-K1 cells engineered to express both PD-L1 and an agonistic CD3 antibody in scFv format were transfected with a human B7-H3 expression plasmid then co-cultured with PD-1 -expressing reporter cells (GS-J2B / PD-1). Cell mixtures were treated with a negative control antibody (HYHEL-10), a positive control antibody (Keytruda Biosimilar), a B7-H3 -targeted TILsRx construct with two CD80 wild-type ECDs (Complex 8), or a B7-H3 -targeted TILsRx construct with two CD80 ECDs, each with a V68MZE160R double mutation (Complex 9). As shown in FIG. 24, both Complex 8 and 9 induced luciferase activity, however, the induction was stronger with Complex 9, suggesting that the CD80 ECD with the V68MZE160R double mutation is a stronger inhibitor of PD-1 signaling than the wild-type CD80 ECD.
[0339] Bioassay with establishe...
Claims
WHAT IS CLAIMED IS:
1. A multi-specific binding protein comprising:(a) a first polypeptide comprising a first Fc region that is linked to a first domain at the N-terminus and a second domain at the C-terminus; and(b) a second polypeptide comprising a second Fc region that is linked to a third domain at the N-terminus and a fourth domain at the C-terminus;wherein each of the first, second, third, and fourth domains independently comprises a tumor-associated antigen (TAA) binding domain (TAA-BD) or an immune modulatory domain (IMD);wherein the multi-specific binding protein comprises at least one TAA-BD and at least one IMD; andwherein the first Fc region and the second Fc region form an Fc dimer.
2. The multi-specific binding protein of claim 1, wherein each domain comprises an active domain (AD) capable of binding to a cell surface protein.
3. The multi-specific binding protein of claim 2, wherein each AD comprises an antibody, a cytokine, a receptor, a ligand for a receptor, or any derivative, fragment or fusion thereof.
4. The multi-specific binding protein of claim 3, wherein the antibody comprises a single-chain variable fragment (scFv).
5. The multi-specific binding protein of any one of claims 2-4, wherein each AD of the one or more TAA-BDs binds to a cancer cell surface protein.
6. The multi-specific binding protein of claim 5, wherein the cancer cell surface protein is selected from the group consisting of STEAP1, B7-H3, EpCAM, ABCC4, AN07, CEACAM1, F0LH1, 0R51E1, OR51E2, PSCA, SLC30A4, SLC45A3, SPON2, STEAP2, TARP, TMEFF2, TMPR8, TMPRSS2, VEGF, CD274 (PD-L1), CD273 (PD-L2), CTLA4, and V domain immunoglobulin suppressor of T-cell activation (VISTA, VSIR), HER2 (ERBB2), HER3, Trop2 (TACSTD2), B7-H4 (VTCN1), MUC1, EGFRvIII, BCMA, CD19, CD20, CD22, CD33, CD123, CD138, CD171, PSMA, Ig-kappa, LeY, R0R1, FAP, FR, Glypican-3, IL13Ralpha2, mesothelin, and an NKG2D ligand.
7. The multi-specific binding protein of claim 5, wherein the cancer cell surface protein comprises STEAP1, B7-H3, EpCAM, or any derivative, fragment or fusion thereof.
8. The multi-specific binding protein of claim 7, wherein each AD of the one or more TAA-BDs comprises an anti-STEAPl antibody, an anti-B7-H3 antibody, and / or an anti-EpCAM antibody.
9. The multi-specific binding protein of claim 8, wherein the anti-STEAPl antibody comprises a VH amino acid sequence having at least 80% identity to SEQ ID NO: 6 and a VL amino acid sequence having at least 80% identity to SEQ ID NO: 7.
10. The multi-specific binding protein of claim 8, wherein the anti-B7-H3 antibody comprises a VH amino acid sequence having at least 80% identity to SEQ ID NO: 4 and a VL amino acid sequence having at least 80% identity to SEQ ID NO: 5.
11. The multi-specific binding protein of claim 8, wherein the anti-EpCAM antibody comprises a VH amino acid sequence having at least 80% identity to SEQ ID NO: 109 or 111 and a VL amino acid sequence having at least 80% identity to SEQ ID NO: 110 or 112.
12. The multi-specific binding protein of any one of claims 2-11, wherein each AD of the one or more IMDs binds to an immune cell surface protein.
13. The multi-specific binding protein of claim 12, wherein the immune cell surface protein is selected from the group consisting of CD3y (CD3 gamma chain), CD36 (CD3 delta chain), CD3s (CD3 epsilon chain), CD3(^ (CD3 zeta chain, CD247), CD2, CD27, CD28, CD69, ICOS, IL-2RB, PTPRC (CD45), CD48, SELL, CD137 (4-1BB, TNFRSF9), CD134 (0X40, TNFRSF4), IL-7R, IL-15R, IL-21R, CTLA4, PD-L1, PD-L2, PD-1 (PDCD-1, CD279), TIGIT, and HAVCR2 (TIM3).
14. The multi-specific binding protein of claim 12, wherein the immune cell surface protein comprises CD3, IL-21R, IL-2R, CD28, PD-L1, PD-L2, PD-1, or any derivative, fragment or fusion thereof.
15. The multi-specific binding protein of claim 14, wherein each AD of the one or more IMDs comprises an anti-CD3 antibody, an anti-PD-Ll antibody, an anti-PD-L2antibody, IL-21, IL-2, an CD80 extracellular domain (ECD), CD86 ECD, PD-1 ECD, PD-L1 ECD, PD-L2 ECD, and / or any derivative, fragment or fusion thereof.
16. The multi-specific binding protein of claim 15, wherein the anti-CD3 antibody comprises a VH amino acid sequence having at least 80% identity to SEQ ID NO: 8 and a VL amino acid sequence having at least 80% identity to SEQ ID NO: 9.
17. The multi-specific binding protein of claim 15, wherein the PD-L1 ECD or a fragment thereof comprises an amino acid sequence having at least 80% identity to SEQ ID NO: 117.
18. The multi-specific binding protein of claim 15, wherein the IL-21 or a fragment thereof comprises an amino acid sequence having at least 80% identity to SEQ ID NO: 1.
19. The multi-specific binding protein of claim 15, wherein the CD80 ECD or a fragment thereof comprises an amino acid sequence having at least 80% identity to SEQ ID NO: 2.
20. The multi-specific binding protein of claim 19, wherein the CD80 ECD or a fragment thereof is a CD80 ECD variant with increased binding affinity for PD-L1, wherein the CD80 ECD variant comprises one or more substitutions at amino acid positions 8, 9, 10, 11, 13, 35, 47, 54, 55, 56, 57, 58, 60, 62, 63, 68, 70, 71, 107, 158, 159, 160, and 161, and wherein the substitutions and the positions are determined with reference to SEQ ID NO: 2, optionally wherein the one or more substitutions are selected from Table 16.
21. The multi-specific binding protein of claim 19 or 20, wherein the CD80 ECD or a fragment thereof is a CD80 ECD variant with reduced binding affinity for CD28, wherein the CD80 ECD variant comprises one or more substitutions at amino acid positions 29, 31, 33, 36, 38, 50, 81, 83, 85, 88, 90, 91, 92, 93, 94, and 97, and wherein the substitutions and the positions are determined with reference to SEQ ID NO: 2, optionally wherein the one or more substitutions are selected from Table 17.
22. The multi-specific binding protein of claim 15, wherein the CD86 ECD or a fragment thereof comprises an amino acid sequence having at least 80% identity to SEQ ID NO: 3.
23. The multi-specific binding protein of claim 15, wherein the PD-1 ECD or a fragment thereof comprises an amino acid sequence having at least 80% identity to SEQ ID NO: 116.
24. The multi-specific binding protein of any one of claims 2-23, wherein one or more ADs each binds to an inhibitory domain (ID) that prevents the AD from binding to the cell surface protein.
25. The multi-specific binding protein of claim 24, wherein the ID comprises an IL- lb pro-peptide, PAS peptide, and / or any derivative, fragment or fusion thereof.
26. The multi-specific binding protein of claim 25, wherein the IL- lb propeptide comprises an amino acid sequence having at least 80% identity to SEQ ID NO: 12.
27. The multi-specific binding protein of claim 25, wherein the PAS peptide comprises an amino acid sequence having at least 80% identity to SEQ ID NO: 13.
28. The multi-specific binding protein of any one of claims 24-27, wherein the ID is linked to the AD through a domain linker.
29. The multi-specific binding protein of claim 28, wherein the domain linker comprises an amino acid sequence selected from the group consisting of (GS)n, (GGS)n, (GGGS)n and (GGGGS)n, where n is an integer from 1 to 10.
30. The multi-specific binding protein of claim 28 or 29, wherein the domain linker comprises an amino acid sequence having at least 80% identity to any one of SEQ IDNOs: 65-71.
31. The multi-specific binding protein of any one of claims 28-30, wherein the domain linker comprises a protease cleavage site (PCS), and wherein cleavage at the PCS by a protease releases the ID from the AD, thereby allowing the AD to bind to the cell surface protein.
32. The multi-specific binding protein of claim 31, wherein the protease is selected from the group consisting of matrix metalloprotease 1 (MMP-1), MMP-2, MMP-3, MMP-8, MMP-9, MMP-13, MMP-14, plasmin, prostate-specific antigen (PSA), prostate-specific membrane antigen (PSMA), cathepsin D, cathepsin K, cathepsin S, a disintegrin and metalloprotease 10 (ADAM10), ADAM12, ADAM17 (TACE), ADAM with Thrombospondin motifs (AD AMTS), caspase-1, caspase-2, caspase-3, caspase-4, caspase-5, caspase-6, caspase-7, caspase-8, caspase-9, caspase-10, caspase-11, caspase-12, caspase-13, caspase-14, tissue plasminogen activator (tPA), and urokinase plasminogen activator (uPA).
33. The multi-specific binding protein of claim 31 or 32, wherein the PCS comprises an amino acid sequence having at least 80% identity to any one of SEQ ID NOs: 73-87.
34. The multi-specific binding protein of any one of claims 1-33, wherein the first and / or second Fc regions are from IgG, IgM, IgA, IgD, and / or IgE.
35. The multi-specific binding protein of any one of claims 1-34, wherein the first and second Fc regions each comprises a hinge region, and wherein the Fc dimer is formed via one or more disulfide bonds in the hinge regions of the first and second Fc regions.
36. The multi-specific binding protein of any one of claims 1-35, wherein the first and / or second Fc regions comprise one or more mutations to promote heterodimerization.
37. The multi-specific binding protein of claim 36, wherein the first Fc region comprises a knob mutation and the second Fc region comprises a hole mutation.
38. The multi-specific binding protein of claim 37, wherein the first Fc region comprises an amino acid sequence having at least 80% identity to SEQ ID NO: 10.
39. The multi-specific binding protein of claim 37 or 38, wherein the second Fc region comprises an amino acid sequence having at least 80% identity to SEQ ID NO: 11.
40. The multi-specific binding protein of any one of claims 1-39, further comprising one or more regional linkers between the first and / or second Fc regions and the domains.
41. The multi-specific binding protein of claim 40, wherein each of the one or more regional linkers comprises an amino acid sequence selected from the group consisting of (GS)n, (GGS)n, (GGGS)n, and (GGGGS)n, where n is an integer from 1 to 10.
42. The multi-specific binding protein of claim 40 or 41, wherein each of the one or more regional linkers comprises an amino acid sequence selected from any one of SEQ IDNOs: 65-71.
43. The multi-specific binding protein of any one of claim 40-42, wherein one or more of the regional linkers are cleavable linkers comprising one or more protease cleavage sites (PCSs), and wherein cleavage at the PCS by a protease releases the domain from the first or second Fc region.
44. The multi-specific binding protein of claim 43, wherein the protease is selected from the group consisting of matrix metalloprotease 1 (MMP-1), MMP-2, MMP-3, MMP-8, MMP-9, MMP-13, MMP-14, plasmin, prostate-specific antigen (PSA), prostatespecific membrane antigen (PSMA), cathepsin D, cathepsin K, cathepsin S, a disintegrin and metalloprotease 10 (ADAM10), ADAM12, ADAM17 (TACE), ADAM with Thrombospondin motifs (AD AMTS), caspase-1, caspase-2, caspase-3, caspase-4, caspase-5, caspase-6, caspase-7, caspase-8, caspase-9, caspase-10, caspase-11, caspase-12, caspase-13, caspase-14, tissue plasminogen activator (tPA), and urokinase plasminogen activator (uPA).
45. The multi-specific binding protein of claim 43 or 44, wherein each of the one or more PCSs comprises an amino acid sequence having at least 80% identity to any one of SEQ ID NOs: 73-87.
46. The multi-specific binding protein of any one of claim 43-45, wherein the one or more cleavable regional linkers comprise an amino acid sequence having at least 80% identity to any one of SEQ ID NOs: 88-108.
47. The multi-specific binding protein of any one of claims 1-46, wherein the first polypeptide, in either N- to C- terminal direction or C- to N-terminal direction, comprises a first TAA-BD, the first Fc region, and a first IMD.
48. The multi-specific binding protein of claim 47, wherein the second polypeptide, in either N- to C- terminal direction or C- to N-terminal direction, comprises a second TAA-BD, the second Fc region, and a second IMD.
49. The multi-specific binding protein of claim 47, wherein the second polypeptide, in either N- to C- terminal direction or C- to N-terminal direction, comprises a second IMD, the second Fc region, and a third IMD.
50. The multi-specific binding protein of claim 47, wherein the second polypeptide, in either N- to C- terminal direction or C- to N-terminal direction, comprises a second TAA-BD, the second Fc region, and a third TAA-BD.
51. The multi-specific binding protein of any one of claims 48-50, wherein the first, second, and third TAA-BDs and / or the first second, and third IMDs are the same.
52. The multi-specific binding protein of any one of claims 48-50, wherein the first, second, and third TAA-BDs and / or the first second, and third IMDs are different.
53. The multi-specific binding protein of any one of claims 47-52, wherein the first Fc region comprises a knob mutation and the second Fc region comprises a hole mutation.
54. The multi-specific binding protein of any one of claims 1-53, wherein the first polypeptide comprises an amino acid sequence having at least 80% identity to any one of SEQ ID NOs: 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, and 62.
55. The multi-specific binding protein of any one of claim 1-54, wherein the second polypeptide comprises an amino acid sequence having at least 80% identity to any one of SEQ ID NOs: 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, and 63.
56. The multi-specific binding protein of any one of claims 1-55, wherein the multi-specific binding protein binds to the cancer cell surface protein STEAP1 and the immune cell surface proteins CD3 and IL-21R.
57. The multi-specific binding protein of claim 56, wherein the first domain comprises an anti-STEAPl antibody, the second domain comprises IL-21, the third domain comprises an anti-CD3 antibody, and the fourth domain comprises an anti-STEAPl antibody, IL-21, or an anti-CD3 antibody.
58. The multi-specific binding protein of claim 57, wherein the IL-21 is linked to the first or second Fc region through a cleavable regional linker comprising one or more PCSs, and wherein cleavage at the one or more PCSs by a protease releases the IL-21 from the first or second Fc region.
59. The multi-specific binding protein of any one of claims 56-58, wherein the first polypeptide comprises an amino acid sequence having at least 80% identity to SEQ ID NOs: 14 or 18, and wherein the second polypeptide comprises an amino acid sequence having at least 80% identity to SEQ ID NO: 15 or 19.
60. The multi-specific binding protein of any one of claims 1-55, wherein the multi-specific binding protein binds to the cancer cell surface protein B7-H3 and the immune cell surface proteins CD3 and IL-21R.
61. The multi-specific binding protein of claim 60, wherein the first domain comprises an anti-B7-H3 antibody, the second domain comprises IL-21, the third domain comprises an anti-CD3 antibody, and the fourth domain comprises an anti-B7-H3 antibody, IL-21, or an anti-CD3 antibody.
62. The multi-specific binding protein of claim 61, wherein the IL-21 is linked to the first or second Fc region through a cleavable regional linker comprising one or more PCSs, and wherein cleavage at the one or more PCSs by a protease releases the IL-21 from the first or second Fc region.
63. The multi-specific binding protein of any one of claims 60-62, wherein the first polypeptide comprises an amino acid sequence having at least 80% identity to SEQ ID NOs: 16 or 20, and wherein the second polypeptide comprises an amino acid sequence having at least 80% identity to SEQ ID NO: 17 or 21.
64. The multi-specific binding protein of any one of claims 1-55, wherein the multi-specific binding protein binds to the cancer cell surface protein STEAP1 and the immune cell surface proteins CD3 and CD28.
65. The multi-specific binding protein of claim 64, wherein the first domain comprises an anti-STEAPl antibody, the second domain comprises an anti-CD3 antibody, thethird domain comprises CD80 or CD86, and the fourth domain comprises an anti-STEAPl antibody, CD80, CD86, or an anti-CD3 antibody.
66. The multi-specific binding protein of claim 65, wherein the anti-CD3 antibody binds to an inhibitory domain (ID), thereby inhibiting the anti-CD3 antibody from binding to CD3 present on an immune cell.
67. The multi-specific binding protein of claim 66, wherein the ID is linked to the anti-CD3 antibody through a cleavable domain linker comprising one or more PCSs, and wherein cleavage at the one or more PCSs by a protease releases the ID from the anti-CD3 antibody, thereby allowing the anti-CD3 antibody to bind to the CD3 present on the immune cell.
68. The multi-specific binding protein of claim 66 or 67, wherein the ID comprises an IL- lb pro-peptide fragment comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 12 or a PAS fragment comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 13.
69. The multi-specific binding protein of any one of claims 64-68, wherein the first polypeptide comprises an amino acid sequence having at least 80% identity to any one of SEQ ID NOs: 22, 26, 30 and 34, and wherein the second polypeptide comprises an amino acid sequence having at least 80% identity to any one of SEQ ID NO: 23, 27, 31, and 35.
70. The multi-specific binding protein of any one of claims 1-55, wherein the multi-specific binding protein binds to the cancer cell surface protein B7-H3 and the immune cell surface proteins CD3 and CD28.
71. The multi-specific binding protein of claim 70, wherein the first domain comprises an anti-B7-H3 antibody, the second domain comprises an anti-CD3 antibody, the third domain comprises CD80 or CD86, and the fourth domain comprises an anti-B7-H3 antibody, CD80, CD86, or an anti-CD3 antibody.
72. The multi-specific binding protein of any one of claims 70-71, wherein the first polypeptide comprises an amino acid sequence having at least 80% identity to any one of SEQ ID NOs: 24, 28, 32 and 36, and wherein the second polypeptide comprises an amino acid sequence having at least 80% identity to any one of SEQ ID NO: 25, 29, 33, and 37.
73. The multi-specific binding protein of any one of claims 1-55, wherein the multi-specific binding protein binds to the cancer cell surface protein STEAP1 and the immune cell surface proteins CD28 and IL-21R.
74. The multi-specific binding protein of claim 73, wherein the first domain comprises an anti-STEAPl antibody, the second domain comprises IL-21, the third domain comprises CD80 or CD86, and the fourth domain comprises an anti-STEAPl antibody, IL-21, CD80, or CD86.
75. The multi-specific binding protein of any one of claims 73-74, wherein the first polypeptide comprises an amino acid sequence having at least 80% identity to SEQ ID NOs: 38 or 42, and wherein the second polypeptide comprises an amino acid sequence having at least 80% identity to SEQ ID NO: 39 or 43.
76. The multi-specific binding protein of any one of claims 1-55, wherein the multi-specific binding protein binds to the cancer cell surface protein B7-H3 and the immune cell surface proteins CD28 and IL-21R.
77. The multi-specific binding protein of claim 76, wherein the first domain comprises an anti-B7-H3 antibody, the second domain comprises IL-21, the third domain comprises CD80 or CD86, and the fourth domain comprises an anti-B7-H3 antibody, IL-21, CD80, or CD86.
78. The multi-specific binding protein of any one of claims 76-77, wherein the first polypeptide comprises an amino acid sequence having at least 80% identity to SEQ ID NOs: 40 or 44, and wherein the second polypeptide comprises an amino acid sequence having at least 80% identity to SEQ ID NO: 41 or 45.
79. The multi-specific binding protein of any one of claims 1-55, wherein the multi-specific binding protein binds to the cancer cell surface protein STEAP1 and the immune cell surface protein CD28.
80. The multi-specific binding protein of claim 79, wherein the first and third domains each comprises an anti-STEAPl antibody, and the second and fourth domains each comprises CD80 or CD86.
81. The multi-specific binding protein of any one of claims 79-80, wherein the first polypeptide comprises an amino acid sequence having at least 80% identity to SEQ ID NOs: 46 or 50, and wherein the second polypeptide comprises an amino acid sequence having at least 80% identity to SEQ ID NO: 47 or 51.
82. The multi-specific binding protein of any one of claims 1-55, wherein the multi-specific binding protein binds to the cancer cell surface protein B7-H3 and the immune cell surface protein CD28.
83. The multi-specific binding protein of claim 82, wherein the first and third domains each comprises an anti-B7-H3 antibody, and the second and fourth domains each comprises CD80 or CD86.
84. The multi-specific binding protein of any one of claims 82-83, wherein the first polypeptide comprises an amino acid sequence having at least 80% identity to SEQ ID NOs: 48 or 52, and wherein the second polypeptide comprises an amino acid sequence having at least 80% identity to SEQ ID NO: 49 or 53.
85. The multi-specific binding protein of any one of claims 1-55, wherein the multi-specific binding protein binds to the cancer cell surface proteins STEAP1 and B7-H3, and the immune cell surface proteins CD3 and IL-21R.
86. The multi-specific binding protein of claim 85, wherein the first domain comprises an anti-STEAPl antibody, the second domain comprises IL-21, the third domain comprises an anti-B7-H3 antibody, and the fourth domain comprises an anti-CD3 antibody.
87. The multi-specific binding protein of any one of claims 85-86, wherein the first polypeptide comprises an amino acid sequence having at least 80% identity to SEQ ID NOs: 54, and wherein the second polypeptide comprises an amino acid sequence having at least 80% identity to SEQ ID NO: 55.
88. The multi-specific binding protein of any one of claims 1-55, wherein the multi-specific binding protein binds to the cancer cell surface proteins STEAP1 and B7-H3, and the immune cell surface proteins CD3 and CD28.
89. The multi-specific binding protein of claim 88, wherein the first domain comprises an anti-STEAPl antibody, the second domain comprises an anti-CD3 antibody, the third domain comprises an anti-B7-H3 antibody, and the fourth domain comprises a CD80 or CD86.
90. The multi-specific binding protein of any one of claims 88-89, wherein the first polypeptide comprises an amino acid sequence having at least 80% identity to SEQ ID NO: 56 or 58, and wherein the second polypeptide comprises an amino acid sequence having at least 80% identity to SEQ ID NO: 57 or 59.
91. The multi-specific binding protein of any one of claims 1-55, wherein the multi-specific binding protein binds to the cancer cell surface protein STEAP1 and the immune cell surface protein PD-L1.
92. The multi-specific binding protein of claim 91, wherein the first and third domains each comprises an anti-STEAPl antibody, the second and fourth domains each comprises PD-1.
93. The multi-specific binding protein of any one of claims 91-92, wherein the first polypeptide comprises an amino acid sequence having at least 80% identity to SEQ ID NOs: 60, and wherein the second polypeptide comprises an amino acid sequence having at least 80% identity to SEQ ID NO: 61.
94. The multi-specific binding protein of any one of claims 1-55, wherein the multi-specific binding protein binds to the cancer cell surface protein B7-H3 and the immune cell surface protein PD-L1.
95. The multi-specific binding protein of claim 94, wherein the first and third domains each comprises an anti-B7-H3 antibody, the second and fourth domains each comprises PD-1.
96. The multi-specific binding protein of any one of claims 94-95, wherein the first polypeptide comprises an amino acid sequence having at least 80% identity to SEQ ID NOs: 62, and wherein the second polypeptide comprises an amino acid sequence having at least 80% identity to SEQ ID NO: 63.
97. The multi-specific binding protein of any one of claims 1-96, wherein the first and / or second polypeptides further comprise a signal sequence at the N-terminus.
98. The multi-specific binding protein of claim 97, wherein the signal sequence comprises an amino acid sequence having at least 80% identity to SEQ ID NO: 64.
99. The multi-specific binding protein of any one of claims 1-98, wherein the first and / or second polypeptides further comprise a 6x His tag at the C-terminus.
100. A nucleic acid encoding the first or second polypeptide of the multispecific binding protein of any one of claims 1-99.
101. A vector comprising the nucleic acid of claim 100.
102. The vector of claim 101, wherein the nucleic acid is operably linked to a promoter.
103. A host cell comprising the nucleic acid of claim 100 or the vector of claim 101 or 102.
104. A method for producing a multi-specific binding protein, comprising: culturing the host cell of claim 103 under conditions suitable for the expression of the multi-specific binding protein; andrecovering the produced multi-specific binding protein from the host cell or from the culture.
105. A composition comprising one or more of the multi-specific binding proteins of any one of claims 1-99.
106. The composition of claim 105, further comprising a chemical compound and / or biological protein capable of providing an activation signal for T cells and / or blocking an inactivation signal for T cells.
107. A pharmaceutical composition comprising the composition of claim 105 or 106, and a pharmaceutically acceptable excipient.
108. A method for treating a subject in need thereof, comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 107 to the subject.
109. The method of claim 108, wherein the subject has cancer.
110. The method of claim 109, wherein the subj ect has epithelial or glandular cancer, prostate cancer, or Ewing sarcoma.
111. A kit comprising one or more of the multi-specific binding proteins of any one of claims 1-99, the nucleic acid of claim 100, the vector of claim 101 or 102, the host cell of claim 103, the composition of claim 105 or 106, or the pharmaceutical composition of claim 107.
